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A BST R A C T 
In silico and molecular validation of identified putative genes and functional analysis 
of a NKG2D ligand as a breast cancer biomarker 
H.A. Bankole 
PhD, Thesis, Department of Biotechnology, University of the Western Cape. 
The current diagnostic, prognostic, predictive and therapeutic monitoring methods 
used for breast cancer are limited. Thus, research into more specific, sensitive and 
effective strategies is required. Breast cancer is the most prevalent form of cancer in 
women worldwide and accounts for the most common cause of death in women every 
year. Cancer development is characterized by a wide spread of genetic abnormalities 
of gene sequences that can be used in detecting and monitoring treatment of the 
disease as a result of altered gene expression patterns which leave a trail of 
biomarkers. Seven candidate genes (Gene 1-7) were identified from a previous in 
silico study and their gene products (BRG 1-7) were annotated to be good candidate 
breast cancer biomarkers. Differential gene expression analysis using quantitative 
real-time PCR (qRT-PCR) validated the over-expression of Gene 3, Gene 4 and Gene 
7 in a breast cancer cell line (MCF7), of which Gene 7, annotated as a Natural killer 
group 2, member D (NKG2D) ligand, was observed to be the most over-expressed 
gene.  
7KHLQQDWHLPPXQHV\VWHPLVWKHILUVWOLQHRIWKHERG\¶VSKysiological defense against 
diseases and the natural killer (NK) cells, are central to mediating this type of 
immunity. NK cells are activated when a specific surface receptor such as the NKG2D 
receptor binds its ligands expressed by tumor cells. To evade being detected by the 
immune system, cancer cells are reported to shed off the NKG2D ligands and are 
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expected to be present in the bodily fluids of cancer patients. Also, chemotherapeutics 
have been reported to suppress the natural anti-tumour immune response, thus should 
be taken into account when designing optimal therapy for cancer patients. The aim of 
this research was to validate these candidate genes as effective breast cancer 
biomarkers using several in silico methods as well as molecular techniques and study 
the effect of Gene 7 on modulating the effect of several pro-apoptotic compounds. 
The in silico part of the study investigated the functional, protein interaction, 
pathways, and tissue expression specificity of the candidate biomarkers using 
computational software such as DAVID, STRING, KEGG, Genecards and GEA. Also 
an in silico validation of the prognostic/predictive values of the genes was analysed 
using SurvExpress, KMplot, and GOBO. Protein expression of selected genes was 
analysed by Western blot, and immunofluorescence analysis. BRG 7 gene was cloned 
into pcDNA3.1 vector using recombinant DNA technology while commercial shRNA 
construct was used to ³knock-down´ Gene 7 expression. The two constructs were used 
to transfect MCF-7 and MCF-12A cells. Over-H[SUHVVLRQDQG³NQRFNGRZQ´RI%5* 
7 in transfected cells was confirmed using western blot analysis. Stably transfected 
cells were then treated with three pro-apoptotic compounds (Camptothecin, 
Doxorubicin and DMSO) for 24 hours. The apoptotic cells were stained with 3, 4, 5, 
6-tetrachloro-¶¶¶¶-tetraiodofluorescein (TCTF) and then analysed using flow 
cytometry.  
Functional analysis linked Gene 1, Gene 2, Gene 4, Gene 6 and Gene 7 to different 
cancer related processes. The pathway analysis showed Gene 1, Gene 2, Gene 4 and 
Gene 7 were involved in pathways that can be linked to cancer modulation. The 
protein-protein interaction analysis showed only BRG 2 was directly linked to two 
major hallmarks of cancer (Apoptosis and Autophagy). Breast cancer associated 
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Transcription factors were shown to regulate these genes. Gene 1 and Gene 5 as well 
as the three genes observed to be highly expressed in the qRT-PCR study were 
validated to differentially express in breast cancer. An additional protein (BRG 8) was 
identified and postulated to be a good biomarker candidate for breast cancer based on 
its direct interaction with BRG 7 and estrogen receptor protein (ESR).  
The prognostic value of the candidate genes were monitored in two datasets (DATA1 
and DATA2) in SurvExpress. DATA1 showed that Gene 6 and Gene 8 while DATA2 
showed that Gene 3, Gene 6 and Gene 7 were valuable candidate genes in breast 
cancer prognosis. The survival curves from the two datasets showed the combined 
genes could predict the outcome of breast cancer patients undergoing treatments. A 
plot box output from SurvExpress showed most of the genes were differentially 
expressed comparing two risk groups. The Kaplan Meier plotter confirmed, Gene 1, 
Gene 3, Gene 4 and Gene 7 have a significant P-value in predicting the survival 
outcome based on gene differential expression value. GOBO analysis showed the 
genes may accurately predict the survival outcome of estrogen positive subtype, 
ERBB2 subtype of estrogen receptor negative and lymph node negative subtype of 
ER- tumours, but not all subtype of ER- tumours. 
Western blot analysis showed BRG 7 may be highly expressed in MCF-7 as compared 
to MCF-12A, BRG 8 was found to be expressed in all cancer cell types analyzed 
except for MCF-7 and HT29. BRG 2 was found to be expressed in all cancer types 
analyzed. Immunofluorescence analysis showed BRG 3, BRG 4 and BRG 7 are 
differentially expressed in breast cancer cell line and are more localized on the cell 
membrane when compared to the breast non-cancer cell line.    
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Over-expression and gene knock down in cells were successfully confirmed with 
Western blot analysis. Stably transfected MCF-12A cell for over-expression of BRG7 
protein, resulted in cell senescent and the cell stopped growing while stably 
transfected MCF-7 over-expressing BRG7 did not show any morphological changes. 
Apoptosis was enhanced in cells treated with camptothecin, doxorubicin and DMSO 
overexpressing BRG7. Apoptosis was reduced in camptothecin and DMSO treated 
gene ³knock-down´ cells but not doxoruELFLQWUHDWHG%5*JHQH³NQRFN-GRZQ´LQ
transfected cells showed varying response to all three pro-apoptotic compounds.  
From this study Gene 3, 5, 7 and 8 and their protein levels were confirmed to be 
differentially expressed in breast cancer cells and could serve as putative biomarkers 
for breast cancer. However the variance in the effectiveness of individual genes 
suggests that the set of genes would perform better than individual gene. The 
modulating role of BRG7 in drug induced apoptosis, suggest it could probably play 
an important role in personalised medicine and could serve as a biomarker to monitor 
the prognosis and/or therapeutic outcome of pro-apoptotic drugs in breast cancer 
patients. These findings will be further investigated in human breast tissues to validate 
these data. 
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Chapter 1: L iterature Review 
1.1 Cancer 
Cancer is a disease that occurs as a result of a series of molecular events that 
fundamentally alter the normal properties of cells. It develops due to extensive genetic 
abnormalities and aberrations in gene expression patterns (Allinen et al., 2004). In 
cancer, there is a loss of balance between cell division and cell death and cells that 
should have died, did not receive the signals to do so (Wong, 2011). Cancer has 
become the leading cause of death worldwide, according to the World Health 
Organization (WHO), it is projected that death resulting from cancer will rise above 
13.1 million by 2030 (Mathers and Bonita, 2009). According to the Cancer 
Association RI6RXWK$IULFD¶VHVWLPDWH, there are one in six male and one in seven 
female cancer patients in South Africa (Jemal et al., 2011). 
Two major factors that contribute to the development or progression of cancers are 
either environmental (external) or hereditary (internal) (Czene et al., 2002). External 
factors includes tobacco, chemicals, radiation, infectious organisms etc., while 
internal factors that play a role include hormones, inherited mutations, immune 
conditions and mutations that result from metabolism (Amir et al, 2010). The 
combination of both these factors gives rise to genetic abnormalities, which can occur 
WKURXJKRXWWKHSHUVRQ¶VOLIHWLPH$PLUet al, 2010). The abnormalities in cancer cells 
usually result from mutations in protein-encoding genes that regulate cell division, 
and over time more genes could become mutated.  
1.2 Genetics of cancer 
The etiology of cancer is multifactorial, with both genetic and environmental factors 
interacting to produce a given malignancy. However, knowledge of cancer genetics is 
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rapidly improving the understanding of cancer biology, helping to identify individuals 
at risk, improving the ability to characterize malignancies, establishing treatment 
tailored to the molecular fingerprint of the disease, helping to identify suitable 
biomarkers for easy diagnosis, prognosis and also leading to the development of new 
therapeutic modalities. This expanding knowledge base thus has implications for all 
aspects of cancer management, including prevention, screening, and treatment (Lindor 
et al., 2008). 
Cancer is generally recognized as a multistage disease involving accumulation of a 
critical number of mutations within a stem cell (Loeb and Loeb, 2000). Alterations in 
a gene can be associated with cancer in different ways. These malfunctioning genes 
can be broadly classified into three groups. The first group, called proto-oncogenes; 
produces protein products that normally enhance cell division or inhibit normal cell 
death. The mutated forms of these genes are called oncogenes. The second group, 
called tumour suppressors, makes proteins that normally prevents cell division or 
cause cell death. The third group is genes involve in DNA repair, which help prevent 
mutations that lead to cancer. The discovery of oncogenes, tumour suppressor, DNA 
repair and cancer susceptibility genes has led to the concept that carcinogenesis is a 
pure endogenous genetic process (Hahn and Weinberg, 2002; Hoyer et al., 2002), but 
LW¶VEHHQVKRZQWKDWPRVWWLPHVWKHVHJHQHVDUHPRGXODWHGE\YDULRXVHQYLURnmental 
factors (Mucci et al., 2001).  
Human cancers occur as a consequence of genetic alterations that promote 
uncontrolled cell proliferation. Mutations in oncogenes and tumour suppressor genes 
influence various cellular processes, such as signal transduction and gene expression. 
In normal cells, proto-oncogenes code for the proteins that send a signal to the nucleus 
to stimulate cell division. These signaling proteins act in a series of steps called signal 
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transduction cascades or pathways. An oncogene is a modified proto-oncogene that 
promotes unregulated proliferation of cells, increasing the chance that a normal cell 
develops into a tumour cell, possibly resulting in cancer (Rigel et al., 2011).  
As the pro-oncogene stimulates cell division, the tumour suppressor genes are meant 
to keep the proliferation of cells in check to bring about homeostasis. Tumour 
suppressor genes are normal genes that slow down cell division, repair DNA mistakes, 
or instruct cells when to die (a process known as Apoptosis or Programmed Cell 
Death). When tumour suppressor genes functions are inadequate, cells can grow out 
of control, which can lead to the onset and progression of cancer (López-Otín, and 
Matrisian, 2007). 
Tumour suppressor proteins retinoblastoma (RB protein) and TP53 are two well-
known tumour suppressor gene products that play a central role in governing the 
decision for cells to proliferate or alternatively, activate senescence (Hanahan and 
Weinberg, 2011). Defects in these genes enable cells to proliferate uncontrollably 
rendering the cells insensitive to growth signals and resistant to apoptosis. Familial 
cancers are believed to be due to the inheritance of a mutated tumour suppressor gene 
and that a second mutation event, involving the wild type allele of that gene, leads to 
malignancy (Knudson, 1985). In addition to these genetic alterations as a result of 
mutation, changes in DNA methylation, an epigenetic modification that occur in 
mammalian cells, is another hallmark of human cancer (Herman, 1999; Sharma et al., 
2010).  
1.3 Cell signaling and cancer 
Cells are known to respond to specific chemicals that signal them to divide.  While 
there are countless pathways utilized by cells, they all display the same fundamental 
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FKDUDFWHULVWLFV  $OO ³VLJQDO SDWKZD\V´ LQvolve a chemical messenger, a protein 
receptor, and a cellular response (Hunter, 2000).  
Cellular signaling pathways are interconnected to form complex signaling networks. 
Cells receive information from many different growth factor receptors and from cell-
matrix and cell-cell contacts (Figure 1.1). They then integrate this information to 
regulate diverse processes, such as protein synthesis, cell growth, motility, cell 
architecture and polarity, differentiation, and programmed cell death (Martin, 2003). 
Cell proliferation, motility, and survival are regulated by multiple pathways, and the 
changes that occur in cancer cells are the result of multiple alterations in the cellular 
signaling machinery (Greenhough et al., 2009).  
Cancer cells are genetically unstable, undergo multiple genetic and epigenetic 
changes, and continuously evolve in response to selective pressures. They even evade 
inhibition of mutational activated pathways by activating alternate pathways to block 
the action of the inhibitor, though early stage malignancy may respond to a single 
inhibitor (Martin, 2003). The complex architecture of signaling networks and the 
consequences of this complexity are now been looked at for cancer diagnostics and 
therapeutics. 
Normal cells require mitogenic growth signals (GS) before they can move from a 
quiescent state into an active proliferative state. These signals are transmitted into the 
cell by transmembrane receptors that bind distinctive signaling molecules: diffusible 
growth factors, extracellular matrix components, and cell-to-cell to extracellular 
superstructures adhesion/interaction molecules. Many of the oncogenes in the cancer 
catalog, act by mimicking normal growth signaling in one way or another. Three 
common molecular strategies tumour cells use to achieve GS autonomy involves 
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alteration of extracellular growth signals, alteration of trans-cellular transducers of 
those signals, or the alteration of intracellular circuits that translate those signals into 
action (Hanahan and Weinberg, 2000). 
 
 
F igure 1.1: Cellular signaling pathways involved in cancer (Pattabiraman and 
Weinberg, 2014) 
While most soluble mitogenic growth factors (GFs) are made by one cell type in order 
to stimulate proliferation of another, a process known as heterotypic signaling, many 
cancer cells acquire the ability to synthesize GFs to which they are responsive, 
creating a positive feedback signaling loop often termed autocrine stimulation (Fedi 
et al., 1997; Avraham et al., 2011). Clearly, the manufacture of a GF by a cancer cell 
obviates dependence on GFs from other cells within the tissue. The production of 
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PDGF (platelet-derived growth factor) and tumour JURZWK IDFWRU Į 7*)Į) by 
glioblastomas and sarcomas, respectively, are two illustrative examples (Fedi et al., 
1997; Hanahan and Weinberg, 2000). 
1.4 Hallmarks of cancer 
Research over the years has revealed common molecular, biochemical and cellular 
traits shared by most and perhaps all cancer types (Hanahan and Weinberg, 2000). 
Tumour cells are more than clustered masses of proliferated cells; they are complex 
tissues interacting with one another (Hanahan and Weinberg, 2011). The progression 
of normal cells to a neoplastic state is due to certain capabilities that are unique to 
cancer cells as compared to normal cells. 
Advances in cancer research have generated a rich and complex body of knowledge, 
suggesting that cancer is a disease involving dynamic changes in the genome. 
Different cancer phenotypes have been shown to be as a result of mutation(s), which 
generates oncogenes with dominant gain of function and tumour suppressor genes 
with recessive loss of function (Bishop and Weinberg, 1996). Hanahan and Weinberg 
(2011) suggested that there are six hallmarks linked to all cancer types. These are: (1) 
cancer cells being self-sufficient, (2) insensitivity to anti-growth signals, (3) sustained 
angiogenesis, (4) tissue invasion and metastasis, (5) limitless replicative capacity, and 
(6) evading apoptosis (Figure 1.2). Understanding these hallmarks has brought 
perspective into how this unified theory can be used to identify cancer biomarkers and 
provide possible ways by which the disease can be managed (Abbott et al, 2006). 
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F igure 1.2: Six hallmarks associated with all cancer types (Hanahan and Weinberg, 
2011) 
 
1.4.1 Self-sufficiency in growth signalling 
Normal tissues are known to carefully manage and control the release of growth 
signals through the cell cycle. During this cycle, cells are programmed to undergo 
self-death (apoptosis) at a later stage of the cycle. Also if there are defects in the 
genome of the cell, a signal will be sent for apoptosis to occur. Likewise, signals are 
send for cell repair or growth, through signalling pathways in the cell cycle. However, 
 
 
 
 
   8     
     
cancer cells facilitate their growth by either producing growth factor ligands 
themselves to which they can respond to by the expression of cognate receptors, 
resulting in autocrine proliferative stimulation or by sending signals to manipulate 
normal cells into supplying them with growth signals (Cheng et al., 2008; Bhowmick 
et al., 2004). Also they can deregulate receptor signaling by elevating the levels of 
receptor proteins displayed on the cancer cell surface, making the cell hyper-
responsive to otherwise limited growth factor signals (Hanahan and Weinberg 2011). 
1.4.2 Evading growth suppressors 
Cancer cells in addition to sustaining growth by activating positive growth signals, 
also circumvent programs that negatively regulate cell proliferation which most times 
depend on the actions of tumour suppressor genes. The activities of these tumour 
suppressor genes in limiting cell growth and proliferation, was discovered through 
their inactivation in one or another form of cancer by loss or gain of function. Two 
typical genes of the tumour suppressor genes encode the retinoblastoma (RB) and the 
TP53 proteins. These proteins operate as central control nodes within two key 
complementary cellular regulatory circuits that govern the decisions of cells to 
proliferate or, alternatively, activate senescence and apoptotic programs (Hanahan and 
Weinberg, 2011).  
The RB protein receives different signals from both extracellular and intracellular 
sources, integrates them and decides if a cell should proceed through the growth cycle 
(Burkhart and Sage, 2008; Deshpande et al., 2005; Sherr and McCormick, 2002). 
Cells with defects in the RB pathway, misses the services of a critical gatekeeper of 
cell-cycle progression and whose absence permits persistent cell proliferation. The RB 
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protein transduces growth-inhibitory signals that originate largely outside of the cell 
(Hanahan and Weinberg, 2011).  
The tumour suppressor gene TP53 on the other hand encodes a transcription factor 
(protein) which is activated in response to several forms of cellular stress and exerts 
multiple, anti-proliferative functions (Vogelstein et al., 2000). Somatic TP53 gene 
alterations are frequent in most human cancers and germline TP53 mutations are 
linked to a wide spectrum of early-onset cancers (Hainaut and Hollstein, 2000). 
Although these two suppressor genes have prominence in regulating cell proliferation, 
various lines of evidence have shown that they operate in a network that may bring 
about functional redundancy. For example, clusters of RB null cells in rats, expected 
to cause neoplasms was found to participate in relatively normal tissue morphogenesis 
throughout the body (Lipinski and Jacks, 1999). Likewise, TP53 null mice that 
developed leukemia and sarcomas later in life, largely showed proper cell and tissue 
homeostasis, and developed normally for the major part of their lives (Ghebranious 
and Donehower, 1998; Vuong et al., 2012). 
1.4.3 Sustained angiogenesis 
In order to sustain growth, tumour cells require means of getting nutrients like oxygen 
as well as possess the ability to take out metabolic waste and carbon dioxide. Normal 
cells get oxygen and nutrients supplies by vasculature, which necessitates virtually all 
cells in a tissue to reside within 100 µm of a capillary blood vessel (Hanahan and 
Weinberg, 2000). Malignant cells form functional micro-vascular networks with red 
blood cell perfusions (Neovasculature) through the process of angiogenesis to address 
their nutrient supply and metabolic waste excretion needs. Development of 
vasculature normally occurs during embryogenesis (Hanahan and Folkman, 1996).  
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Embryogenesis involves the birth of new endothelial cells and their assembly into 
tubes (vasculogenesis) as well as sprouting (angiogenesis) of new vessels from 
existing ones. Following this, the normal vasculature becomes dormant until it is 
required in adulthood for normal physiologic processes such as wound healing and 
female reproductive cycling, where angiogenesis is transiently turn on. In contrast, 
during tumour progression, an angiogenic process is always activated and remains on, 
allowing normal vasculature to continually sprout new vessels that help sustain 
expanding neoplastic growths (Hanahan and Weinberg, 2011). 
This angiogenic switch is control by regulators, some of which are signaling proteins 
that bind to stimulatory or inhibitory cell surface receptors displayed by vascular 
endothelial cells. Two examples of these angiogenesis inducers and inhibitors are 
vascular endothelial growth factor-A (VEGFA) and thrombospondin-1 (TSP1), 
respectively (Hanahan and Weinberg, 2011).  
The VEGFA gene encodes ligands that stimulate growth of new blood vessels during 
embryogenic and postnatal development, for maintaining homeostasis for the survival 
of endothelial cells, as well as being required in maintaining normal physiological and 
pathological situation in adults (Ferrara, 2010). The VEGFA gene expression is 
regulated at multiple levels through three tyrosine kinase receptors (VEGFR-1-3), but 
the up-regulation of the VEGF can be as a result of both hypoxia and oncogene 
signaling (Ferrara, 2010; Mac Gabhann and Popel, 2008; Carmeliet, 2005). VEGF 
ligands can be released into the extracellular matrix in an inactive form and later 
activated by extracellular matrix-degrading proteases such as the matrix 
metalloproteinase-9 (MMP9) (Kessenbrock et al., 2010). Some pro-angiogenic 
compounds such as the fibroblast growth factor (FGF) family members have also been 
shown to be up-regulated in the sustenance of tumour angiogenesis (Baeriswyl and 
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Christofori, 2009). The anti-angiogenic signal TSP1, in maintaining homeostasis of 
the angiogenic switch, also binds trans-membrane receptors on the endothelial cells, 
to evoke suppressive signals that counteract pro-angiogenic stimuli (Kazerounian et 
al., 2008). 
1.4.4 T issue invasion and metastasis 
As most human cancer types develops, primary tumour tissue produce cells that have 
the ability to invade adjacent tissues and hence may travel to a distant site where they 
may succeed in forming new colonies. This spread is referred to as metastasis and the 
new cancer formed is called metastases, which are reported to be the cause of about 
90 % of all human cancer deaths (Sporn, 1996; Chaffer and Weinberg, 2011). The 
ability of cancer cells to leave the primary tumour tissue and invade other tissues to 
form metastases, provides these cells at least an initial unlimited amount of nutrients 
and space (Chaffer and Weinberg, 2011).  
Cancer cells associated with carcinomas arising from epithelial tissues are altered in 
shape as well as in their attachment to other cells and the extracellular matrix (ECM) 
as the carcinomas progresses to higher pathological grades of malignancy (Thompson 
and Newgreen, 2005).  
A well-known alteration is the loss of a key cell-to-cell adhesion protein known as E-
cadherin. This protein normally helps to assemble epithelial cell sheets by forming 
adherence junctions with adjacent epithelial cells and keeps the cells in an inactive 
state within the sheet (Park et al., 2008). Alteration in the expression of E-cadherin is 
well established as a modulator of cancer metastasis. The increase expression served 
as an antagonist of invasion and metastasis. Thus, the down regulation of the gene or 
its inactivation as a result of mutation, as found in human carcinomas, is a strong 
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indicator that E-cadherin serve as a key suppressor of metastasis (Berx and van Roy, 
2009; Cavallaro and Christofori, 2004).  
Alterations in the expression of genes encoding other cell-to-cell or cell-to-ECM 
molecules have also been shown to be involved in highly aggressive carcinomas 
(Cavallaro and Christofori, 2004). The process of invasion and metastasis begins with 
local invasion, then intravasation by the cancer cells into nearby blood and lymphatic 
vessels. The cancer cells then transit through the lymphatic and blood systems, 
followed by the release of cancer cells from the lumina of the vessels into the 
parenchyma of distant tissues (extravasation). The cancer cells then form small 
nodules (micrometastases), which then finally grows to macroscopic tumours 
(Talmadge and Fidler, 2010; Fidler, 2003). 
1.4.5 L imitless replicative potential 
All mammalian cells appear to possess an intrinsic autonomous program independent 
of the cell-to-cell signaling pathways that limit their multiplication. Unlike normal 
mammalian cells, which are known to have finite growth-and-division cycles, cancer 
cells acquire unlimited replicative ability to form macroscopic tumours (Hanahan and 
Weinberg, 2000). As normal cells replicates, it either gets to a stage of senescence, 
which is an irreversible, but non-proliferative state or experiences cell death as a result 
RIVRPH³FULVLV´Hanahan and Weinberg, 2011; Hanahan and Weinberg, 2000).  
The telomeres, which are regions of repetitive nucleotide sequences of a chromosome 
that protect the chromosome from deterioration, are highly implicated in infinite 
growth of tumour cells (Blasco, 2005; Shay and Wright, 2000). Thus, the length of 
the telomeric DNA will determine the number of successive cell generations. The 
telomerase; a DNA polymerase that adds telomere to the end of telomeric DNA, is 
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reported to be highly expressed in the majority of immortalized cells, including cancer 
cells but found to be almost absent in non-immortalized cells (Hanahan and Weinberg, 
2011).  
The telomerase helps to counter progressive erosion of telomeric DNA by extending 
telomeric DNA and its active presence (either in spontaneous immortalized cells or 
cells engineered to express the protein), is correlated with resistance to induction of 
both senescence and apoptosis. Whereas the suppression of telomerase activity leads 
to the shortening of the telomere and eventually the activation of either senescence or 
cell death (Shay et al., 2001). 
1.4.6 Evading apoptosis 
The programmed cell death (apoptosis) mechanism is triggered in response to various 
physiologic stresses, most of which cancer cells experiences from the effect of the 
body¶V immune defenses, as a result of anticancer therapy or during the course of 
tumourigenesis itself (Adams and Cory, 2007; Lowe et al., 2004: Evan and 
Littlewood, 1998). There is profound evidence from both animal studies and cultured 
cell lines as well as from descriptive analysis of different stages of human 
carcinogenesis, which showed that cancer cells acquired various means of resisting 
apoptosis (Fernald and Kurokawa, 2013). For example, genetic inactivation of the 
Bcl-2 antagonist/killer (BH3) protein or a caspase in mouse genetic models does not 
only inhibit pro-apoptotic stimuli but also stimulate tumour formation in mice (Hubner 
et al., 2008; Bean et al., 2013; Parsons et al., 2013). Likewise, other studies showed 
that disruption of the apoptotic pathways were present in tumours that succeeded in 
processing high-grade malignancy and those that resist therapy (Adams and Cory, 
2007; Lowe et al., 2004). 
 
 
 
 
   14     
     
1.5 Apoptosis and cancer 
Organisms have naturally developed a cellular suicidal program to eliminate 
unhealthy or unnecessary cells from the body in their course of development or 
following cellular stress. Apoptosis involves a series of cellular events that culminate 
in the activation of caspases (cysteine proteases) that are generally grouped as 
µLQLWLDWRU¶FDVSDVHVFDVSDVH-DQGDQGWKHµH[HFXWLRQHU¶FDVSDVHVFDVSDVH- 
3 and 7) (Denault, and Salvesen, 2002).  
The initiator caspases are activated by the apoptotic stimuli and in turn they activate 
WKH ]\PRJHQLF µH[HFXWLRQHU¶ caspases, which subsequently cleaves some specific 
cellular substrates, and the effect leads to cell death (Fernald and Kurokawa, 2013). 
Thus the apoptotic machinery is said to be composed of both the upstream regulators 
and the downstream effector components (Adams and Cory, 2007).  
The regulators are further divided into those receiving and processing extracellular 
death signals known as the extrinsic apoptotic program. Their actions culminate in the 
activation of caspase-8 and 10 through the formation of the death-inducing signal 
complex (DISC) when extracellular ligands such as Fas, tumour necrosis factor (TNF) 
bind their cell surface receptors (Fulda and Debatin, 2006). The other regulator is 
responsible for sensing and integrating intracellular death signals and eventually 
activates the intrinsic apoptotic program through the mitochondrial outer membrane 
permeabilization (MOMP) mechanism (Hanahan and Weinberg, 2011).  
MOMP triggers the release of pro-apoptotic proteins, including Cytochrome c and 
second mitochondria-derived activator of caspases (SMAC), into the cytoplasm from 
the mitochondrial inter-membrane space. Cytochrome c binds to the apoptotic 
protease-activating factor 1 (APAF-1) to form an apoptosome; a caspase-9-activating 
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complex, which then initiates a cascade of proteolysis by activating the effector 
caspases responsible for the execution phase of apoptosis by disassembling the cancer, 
cells which are then consumed by phagocytic cells (Tait and Green, 2010). SMAC 
augments Cytochrome c-induced caspase activation by binding and neutralizing X-
linked inhibitor of apoptosis protein (XIAP), an inhibitor of caspase-3, -7, and -9 
(Hanahan and Weinberg, 2011; Fernald and Kurokawa, 2013).  
1.5.1 Inhibition of Apoptosis in cancer  
Inhibition of apoptosis is strongly believed to be critical to cancer cells survival as 
well as tumour development. The B cell lymphoma 2 (Bcl-2) family proteins plays an 
important role in regulating apoptosis, serving as a pro- or anti-apoptotic signals, 
depending on the member of the protein family that is controlling MOMP (Tait, and 
Green, 2010).   
The BH3-only proteins e.g., Bcl-2-interacting mediator of cell death (BIM), BH3-
interacting domain death agonist (BID), and Bcl-2-associated agonist of cell death 
(BAD) and multi-BH domain proteins e.g., Bcl-2-associated protein X (BAX) and 
Bcl-2 antagonist/killer (BAK) promotes MOMP as shown in figure 1.3. Thus the Bcl-
2 protein family are mostly pro-apoptotic (Youle, and Strasser, 2008). The BH3-only 
proteins initiate oligomerization of BAX (or BAK) following cytotoxic or genotoxic 
stress and this results in MOMP (Figure 1.3). However the pro-survival members of 
the protein family for example, the Bcl-2, B cell lymphoma extra-large (Bcl-xL), and 
induced myeloid leukemia cell differentiation protein (MCL-1), inhibits the activities 
of pro-apoptotic substances (Martinou and Youle, 2011; Stresser et al., 2011). 
As a result of several extrinsic factors including oncogenic factors, genomic 
instability, and cellular hypoxia, cancer cells are constantly under physiological stress, 
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which stimulate apoptosis, and in response to such stimuli, the intrinsic pathway of 
apoptosis would normally be activated. However, cancer cells will often avoid this 
cellular response by disabling the apoptotic pathways (Fernald and Kurokawa, 2013). 
Though forced expression of anti-apoptotic Bcl-2 family proteins can significantly aid 
tumour development induced by an oncogene, the over-expression of the anti-
apoptotic protein alone may not result in tumour formation similar to that seen with 
an oncogene alone (Lowe and Lin 2000; Fernald and Kurokawa, 2013). 
 
F igure 1.3: Apoptosis as it is been triggered in response to internal or external stimuli 
(Fernald and Kurokawa, 2013).  
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1.6 Cancer and the immune system 
Another important mechanism by which cancer progresses, is by evading the immune 
surveillance machinery. An immune-surveillance hypothesis of an immunological 
response to tumours was first proposed as early as the 1950s with no evidence until 
the last two decades when tumour specific antigens and immune modulation leading 
to tumour regression were identified (Waldner et al., 2006).  
The long-standing theory of immune surveillance proposes that cells and tissues are 
constantly monitored by the immune system, and that such immune surveillance is 
responsible for recognizing and eliminating the vast majority of incipient cancer cells 
and thus nascent tumours (Hanahan and Weinberg, 2011). The activation of the host 
immune system by tumour cells is a complex cascade that involves both the innate 
and adaptive immune systems. Several research evidence have shown that both cell-
mediated innate and adaptive immunity are essential in preventing primary tumour 
outgrowth and rejecting transplanted tissues (Dunn et al., 2004; Pardoll, 2003). 
Tumour-associated macrophages (TAMs) and T cells are the most commonly found 
cells within the tumour microenvironment. High levels of TAM have been correlated 
with poor cancer prognosis (Murdoch et al., 2008), and it is known to promote 
angiogenesis, invasion and metastasis (Condeelis and Pollard, 2006). Mature T cells 
are majorly of two types based on the receptors they expressed. They are either gamma 
GHOWDJGȖįRU DOSKDEHWDDEĮȕ7FHOOV, which are further classified based on their 
effector functions as CD8+ cytotoxic T cells (CTLs), and CD4+ helper T cells (Th) 
(which include Th1, Th2, Th17 and T regulatory (Treg) cells, as well as natural killer 
T (NK) cells). Based on their effector function, T cells can exert both tumour-
suppressive as well as tumour-promoting effects (DeNardo et al., 2009; Langowski et 
al., 2007; Smyth et al., 2006).  
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Actions of tumour promoting T cells are mediated by cytokines, whereas both 
cytokines and cytotoxic processes mediate the anti-tumourigenic effects of T 
lymphocytes. However, the NK cells are the only immune surveillance cells that lacks 
a pro-tumourigenic effect (Grivennikov et al., 2010). 
The CTL and NK cells recognize and kill virus-infected or transformed cells through 
three main pathways. CTLs use ligands of the tumour necrosis factor super family on 
their cell surface to bind and eliminate target cells expressing the corresponding 
receptors (Cullen et al., 2010). The CTL/NK cells can also target cells using the 
granule exocytosis pathway by delivering cytotoxic granules to the surface of target 
cells. A third process is the perforin/Granzyme B pathway by which apoptosis is 
initiated in cells as shown in figure 1.4 (Fadeel and Orrenius, 2005; Lawen, 2003). 
 Membrane-disrupting toxins in the cytoplasm known as perforin as well as a family 
of proteins, which are structurally similar to the serine proteases, (the granzymes) with 
substrate specificity, are secreted by exocytosis to induce apoptosis on the target cells 
(Trapani and Smyth, 2002).  Perforin, promotes granzyme delivery into the cytosol of 
target cells and these proteases (granzymes) cleave their cohort of substrates to 
promote rapid and efficient cell death (Cullen et al., 2010). The major constituents of 
cytotoxic granules are perforin and granzymes. The granzymes are contained in the 
granules preventing them from damaging the host cells. When CTL/NK cell 
recognizes a tumour cell, cytotoxic granules move along microtubules and polarize at 
the plasma membrane, adjacent to the target cell, where they are then secreted into the 
immunological synapse between the two cells (Cullen and Martin, 2008). 
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F igure 1.4: Pathways of granzyme B-mediated cell death (Cullen et al., 2010). 
Cancers are made up of different cell types, which include the fibroblasts and 
epithelial cells, as well as the innate and adaptive immune cells, and specialized 
mesenchymal cell types that are unique to each tissue microenvironment. Based on 
the site of cancer origin, there are different types and subtypes of cancer, named by 
the tissue they primarily originate from (Visvader, 2011). The main function of the 
mammalian immune system is to maintain tissue homeostasis, prevent invading or 
infectious pathogens and eliminate damaged cells (de Visser, et al., 2006). The innate 
and adaptive immune systems are involved in preventing cancer originating from any 
tissue of the body in humans (Vesely, et al., 2011). Expression patterns of 
lymphocytes (T cells, T regulatory cells, NK cells) and their cytokine have been 
implicated in preventing breast cancer and its recurrence (Standish, et al., 2008) 
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1.7 Breast cancer 
Breast cancer refers to a malignant tumour that has developed from cells in the breast. 
Usually the malignancy either begins in the cells of the milk-producing glands known 
as the lobules, or the ducts, which is the passages that drain milk from the lobules to 
the nipple (Kanagathara and kavitha, 2014). Breast cancer can also start in the stromal 
tissues, which include the fatty and fibrous connective tissues of the breast, although 
this is rare (Devadoss et al., 2013).  
The cancer cells can invade nearby breast tissue with time and make their way into 
the small organs that filter out foreign substances in the body known as the lymph 
nodes. The lymph nodes then serve as a pathway for these cancer cells into other parts 
of the body (Devadoss et al., 2013). The metastasized cancer cells may attach to other 
tissues and grow to form new tumours of those tissues. For breast cancer, the most 
common sites for metastatic tumours are the bones, liver, lungs, and the brain (DuPrie, 
2010). Breast cancer is the most frequent cancer among women with a global 
estimation of about 23 % of newly diagnosed cases in 2008 of all cancers, and also 
the most common cause of cancer deaths in women in both developing and developed 
countries (Kartal et al., 2014).  
Epidemiologic studies have shown a marked geographic variation in the breast cancer 
burden worldwide. Northern Europe, Australia, and New Zealand average 95±100 
cases for 100,000 persons. Surprisingly, the incidence rate in Western Africa and 
Eastern Asia is approximately 20 per 100,000. Also there is a substantial variation in 
breast cancer incidence and mortality rates among regions within the continent of 
Africa. An estimated age-standardized incidence rate per 100,000 women are 20.2 in 
Eastern Africa, 13.5 in Middle Africa, 24.8 in Western Africa, and 31.8 in Southern 
Africa (Fregene and Newman, 2005; Ferlay et al., 2010).  
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Significant problems exists for accurate estimation of breast cancer incidences in 
developing countries (Ferlay et al., 2010). Challenges such as, countries not having 
cancer registries that can provide incidence rates covering intervals of 15 years and 
above or fail in obtaining accurate incidence rates (Fregene and Newman, 2005). Few 
countries have cancer registries that can provide accurate information whilst several 
of the most mature registries cover relatively small populations. Also, difficulty in 
estimating population denominators further creates an additional barrier to the 
calculation of incidence and mortality rates (Fregene and Newman, 2005).  
South Africa is one of the few African countries that collates population-based cancer 
data, through the National Cancer Registry. However, it is suspected that the registry 
may underestimate actual cancer burden because it relies on information submitted by 
pathology laboratories and cases of a 1arge population group do not always get to the 
pathologist (Vorobiof et al., 2001). A comparison between populations subsets in 
South Africa reveal progressively decreasing lifetime risk of breast cancer for white 
South Africans (1 in 13) versus mixed ethnicity South Africans (1 in 63) versus black 
South Africans (1in 81). However, it is believed these figures are not accurate 
(Vorobiof et al., 2001). 
1.7.1 Types of breast cancer 
Normally the mammary glands are located at the level of the III to VII ribs separated 
by a deepening called the cavity (sinus mammarum) and surrounded by fatty tissue  
except for the nipples and the areola (Reece et al., 2009). In average it is 10-12 cm in 
diameter when it is not lactating, 2-3 cm in thickness and weighs between 150-200 g 
(300-900 g during lactation) (Sahoo et al. 2015). Each segment of the mammary gland 
is divided into the lobules (lobuli mammae), separated from each other by connective 
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tissue and consisting of alveoli and the adipose tissue.  The adipose tissue carries all 
lobular lymph nodes in space.  The lymph nodes are small, bean-shaped collections 
of immune system cells that are connected by lymphatic vessels (Sahoo et al. 2015).  
Based on the location of the malignancy, breast cancer is classified majorly into two 
forms, either ductal or lobular. Furthermore, the ductal or lobular carcinoma can 
further be classified based on pathological distinction as in-situ or invasive, indicating 
if the cancer remain within the ducts or lobules (localised) or if it has spread to 
surrounding tissues (metastasize) (Hammer et al, 2008). Ductal carcinoma in-situ of 
the breast is sometimes referred to as non-invasive or pre-invasive breast cancer 
because it might develop into an invasive breast cancer if left untreated. When cancer 
cells are confined to the lobules it is called lobular carcinoma in-situ (Allred et al., 
2001).   
The Invasive Ductal Carcinoma (IDC), which is the most common type of breast 
cancer, starts in the milk ducts of the breast, breaks through the wall of the duct, and 
grows into the fatty tissue of the breast. While the Invasive Lobular Carcinoma (ILC), 
starts from the milk producing glands (lobules). Like IDC, it can spread (metastasize) 
to other parts of the body too (Sahoo et al., 2015).  
DNA microarray expression profile analysis indicates five distinct and reproducible 
groups of invasive breast cancinomas which are: luminal A, luminal B, HER2-
enriched, +/estrogen receptor (ER), basal-like, and normal breast-like (Rakha et al., 
2008). The basal-like subtype has been shown to have the highest proliferation rates 
and poor clinical outcomes (Rakha et al., 2008). They are typically ER and HER2 
receptor negative and are described in association with BRCA1 modulated carcinomas 
showing some characteristics of breast myoepithelial cells, but little is known with 
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regard to their development and prevention (Livasy et al., 2006). Triple-negative 
breast cancer is used to describe breast cancers (usually invasive ductal carcinomas) 
whose cells lack estrogen receptors and progesterone receptors, and do not have an 
excess of the HER2 protein on their surfaces (Sahoo et al., 2015). 
The luminal (glandular) cells, basal/myoepithelial cells, and stem cells are the three 
types of epithelial cell component of a normal breast duct. The cytokeratin expression 
pattern of the epithelial cells distinguishes the myoepithelial cells from the luminal 
epithelia cells. Myoepithelial cells are known to express cytokeratin 5/6 and 
cytokeratin 17, while luminal epithelial cells expresses cytokeratins 8 and 18 (Böcker 
et al., 2002). Immunohistochemical staining for these cytokeratins are helpful in 
subtyping invasive breast carcinomas into distinct biological subtypes, although the 
staining patterns for cytokeratins 5/6 and 17 is not absolute (Livasy et al., 2006).  
An adenocarcinoma is a type of cancer that starts from tissue that makes and secretes 
substances, like glandular tissue for example. The ducts and lobules of the breast are 
glandular tissues because they produce and secrete the breast milk, so cancers starting 
in these areas are often referred to as adenocarcinomas (Sahoo et al. 2015). 
Inflammatory breast cancer (IBC) is an uncommon type of invasive breast cancer that 
is found in about 1 to 6 % of all breast cancers (Yang et al., 2008). The affected breast 
may become larger or firmer, tender, or itchy. Usually this type of cancer does not 
present any lump or tumour and it might not be detected by a mammogram (Sahoo et 
al. 2015). This cancer makes the skin on the breast look red and feels warm. It may 
also make the breast skin appear thick and pitted in appearance (the breast looks a lot 
like an orange peel). These changes in appearance are as a result of cancer cells 
blocking lymph vessels of the skin. Inflammatory breast cancer is often mistaken for 
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an infection of the breast (called mastitis) in its early stages and treated with 
antibiotics, but in most cases biopsy will reveal cancer when there is no improvement 
in treatment. This type of breast cancer tends to have a higher chance of spreading and 
a worse outlook (prognosis) than typical invasive ductal or lobular cancer (Sahoo et 
al. 2015; Yang et al., 2008; Bertucci et al., 2005). 
Paget disease of the nipple and phyllodes are two rare breast cancer types that occur 
in about 1 % of breast cancer cases (Sahoo et al. 2015). Paget disease of the nipple 
normally starts in the breast ducts and then spreads to the skin of the nipple, the areola 
and then finally the dark circle around the nipple (Rosen 2001). The skin of the nipple 
and areola often appears crusted, scaly, and red, with areas of bleeding or oozing. The 
woman may notice burning or itching. It is most times always associated with either 
ductal carcinoma in-situ (DCIS) or infiltrating ductal carcinoma (Fu et al., 2001). The 
prognosis of this disease is excellent if it is associated with DCIS, but the prognosis is 
not too good if it leads to invasive cancer and the cancer will need to be staged and 
treated like any other invasive cancer (Sahoo et al., 2015).  
The phyllodes tumour on the other hand is a very rare breast tumour that develops in 
the stroma (connective tissue) of the breast, in contrast to carcinomas, which develop 
in the ducts or lobules (Lee, 2008). Other names for these tumours include phyllodes 
tumour and cystosarcoma phyllodes. They are usually benign but on rare occasions 
may be malignant. The benign phyllodes tumours are usually removed along with a 
margin of normal breast tissue, while a malignant type is treated by removing it along 
with a wider margin of normal tissue, or by mastectomy (Hunt et al., 2012; Sahoo et 
al. 2015).  
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Another rare type of breast cancer is Angiosarcoma. This form of cancer rarely occurs 
in the breasts and when it does it usually starts in cells that line blood vessels or lymph 
vessels resulting from complication of previous radiation used as treatment (Hunt et 
al., 2012). It is an extremely rare complication of breast radiation therapy that can 
develop about 5 to 10 years after radiation. It is also found in the arms of women who 
develop lymphedema as a result of lymph node surgery or radiation therapy to treat 
breast cancer (Sahoo et al., 2015). 
1.7.2 Breast cancer risk factors and diagnosis 
The knowledge of breast cancer risks and the risks and benefits of the intervention, 
greatly assist in choosing an appropriate strategy in managing the disease. It is central 
to making accurate decisions regarding the level of prevention for individual risk 
assessment. Women who are at high risk of breast cancer can be offered more 
intensive surveillance or prophylactic measures, such as surgery or chemoprevention. 
Generally, the population quoted for breast cancer diagnosis, is estimated to be a 
lifetime risk of one in eight to one in twelve (Amir et al., 2010). Genetic and familial 
factors can substantially increase the lifetime risk of developing breast cancer and are 
associated with the development of cancer at a young age. Other risk factors, such as 
endocrine factors, and host factors including breast density and history of benign 
proliferative breast disorders, can substantially modify the risk of developing breast 
cancer (Amir et al., 2010).  
Risk assessments are grouped into two categories namely the risk of carrying a 
mutation in a high-penetrance gene such as BRCA1 or BRCA2 and the risk of 
developing breast cancer with or without such a mutation (Amir et al., 2010). Other 
germline mutations that are associated with familial breast cancer have been identified 
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in other genes and they include TP53, PTEN, ATM, CHEK2, NBS1, RAD50, BRIP, 
and PALB2 (Walsh and King, 2007). It is important to assess as many factors as 
possible accurately over time before concluding if there is a risk of breast cancer 
development or not. A number of risk factors for breast cancer have been identified 
and quantified. Some of these risk factors are: 
1.7.2.1 Family history of breast cancer 
Apart from age, the most important risk factor associated with the development of 
breast cancer is the presence of a substantial family history of breast cancer.  
Consequently, a family history evaluation is necessary to assess the likelihood of 
predisposing genes for breast cancer in a family (Amir et al., 2010).  
Normally two-pronged approaches are used to assess familial breast cancer risk in an 
individual. Firstly, those patients who are at risk of carrying a germline mutation are 
identified and offered formal genetic testing. Secondly, for those who do not meet the 
criteria for genetic testing or who test negative for germline mutations, there is a need 
to quantify the risk of developing cancer over a specified length of time. With the 
resulting information, surveillance, lifestyle, pharmacological, or surgical 
interventions can be instituted to improve patients risk (Amir et al., 2010).  
The age of the patient at onset of breast cancer, family history of whether there are 
multiple cases or not on both the maternal or paternal side, cases of unilateral versus 
bilateral disease, the degree of relationship (first or greater), cases of other related 
tumours with early-onset (e.g., ovary, sarcoma), and the number of members of a 
family that are unaffected are some of the parameters considered (Kolonel et al., 
2004). Women with one affected first-degree relative have twice the risk of breast 
cancer, those with two first-degree relatives have thrice the risk, and those with three 
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or more first-degree relatives have quadruple the risk when compared with women 
with no affected relatives. Breast cancer diagnosed at a younger age in a family 
member is associated with an increased risk of breast cancer in a first-degree relative 
(Kolonel, et al., 2004; Amir et al., 2010).  
1.7.2.2 Hormonal and reproductive r isk factors 
Hormonal and reproductive factors have long been recognized to be important in the 
development of breast cancer. Certain established factors, such as postmenopausal 
obesity, age at menarche, and use of exogenous hormones, have been shown to 
contribute to breast cancer risk by increasing systemic exposure to hormones 
(Schneider et al., 2008). Early age at menarche is associated with a 4 % per-year 
increase in the relative risk of breast cancer, whereas late menopause is associated 
with a 3 % per-year increase (Amir et al., 2010).  
There is a risk of diagnosing breast cancer in women taking contraceptives, but no 
significant increased risk of having breast cancer ten or more years following the 
cessation of the oral contraceptive agent. Cancers diagnosed in women taking the oral 
contraceptive may not likely be in a clinically advanced state when compared to those 
diagnosed in women who have never used oral contraceptives (Sestak et al., 2012). A 
meta-analysis based study showed a 1-2 % per year increase risk of breast cancer in 
women taking hormone replacement therapy but disappeared within 5 years of 
stopping treatment. There is a higher risk associated with estrogen and progestin 
combined hormone replacement therapy as compared to estrogen only whose risk may 
be negligible (Lacey, et al., 2006). Another meta-analysis study suggested an 
increased risk of about 24 % of breast cancer diagnoses during current use of the 
combined oral contraceptive and 10 years after discontinuation (Amir et al., 2010). 
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1.7.2.3 Proliferative benign breast disease 
Some types of benign breast disease present a higher risk of breast cancer compared 
to others. For example, lobular carcinoma in-situ is associated with a 10-fold increase 
in breast cancer risk when compared to ductal carcinoma in-situ (Amir et al., 2010). 
There is a four to five times higher risk of developing breast cancer in women with 
severe atypical epithelial hyperplasia as compared to women who do not have any 
proliferative changes in their breast and the risk increase nine fold in women with a 
family history of breast cancer (first degree relative) (Mcpherson et al., 2000).  
1.7.2.4 Mammographic density 
The breast density can rapidly be determined using a mammogram, thus, the 
mammographic data can present reliable risk prediction data (Amir et al., 2010). 
Mammographic density is generally looked at as the proportion of the breast tissue 
that appears dense on the mammogram. It is the most assessable important risk factor 
and its presentation has a substantial heritable component.  The presentation has some 
geographical distribution link; approximately 5 % of the white female population 
worldwide has mammographic density covering more than 75 % of the breast (Boyd 
et al., 2007).  
The increase in relative risk for women with 50±75 % mammographic breast density 
is approximately twice that of women with mammographic breast density of less than 
10 %, and these women comprise approximately 14 % of white women. This white 
female population have an increased risk of about fivefold when compared with 
women with mammographic breast density of less than 10 %. (Boyd et al., 2007). 
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1.7.2.5 Other risk factors 
The risk of breast cancer observed in teenage girls exposed to radiation during the 
Second World War doubled (Mcpherson et al., 2006). It was also observed that 
ionisation radiation during breast formation increase the risk later in life. Obesity in 
post-menopausal women showed an increase risk of breast cancer whereas a reduced 
incidence is associated with premenopausal women (Mcpherson et al., 2006). There 
is an inconsistent report of alcohol and smoking as risk factors of breast cancer. Some 
studies show a link between alcohol consumption and an increase in incidence rate, 
but the relationship was inconsistent and it was concluded that the association might 
be influence by other dietary factors other than alcohol (Mcpherson et al., 2000). 
1.8 Breast cancer screening methods 
Breast cancer screening is reported to be an effective tool for reducing breast cancer 
mortality in most recent publications (Kartal et al., 2014). Breast cancer is a 
progressive disease, and small tumours when detected early could be treated 
successfully, and present a much better prognosis. So the main benefit of breast cancer 
screening is that it allows for the detection of breast cancers before it become palpable 
(Smith et al., 2003).  
Although it is true that breast screening is associated with reduced morbidity and 
mortality, most women who participate in screening do not develop breast cancer in 
their lifetime. Also, screening do not benefit all women diagnosed as having breast 
cancer, since it can harm women who undergo biopsy for abnormalities that are not 
breast cancer as well as women that are over-treated for lumps like ductal carcinoma 
in-situ (DCIS) that may not progress to breast cancer (Smith et al., 2003).  
 
 
 
 
   30     
     
There is a smaller benefit associated with screening in younger women probably as a 
result of lower incidence, more rapidly growing tumours, and greater radiographic 
density of breast tissue in women less than 50 years of age. However, screening is 
most times offered to women with a genetic predisposition to breast cancer that are 
under the age of 50 years (Pissano et al., 2005).  
Various screening methods, such as mammography (sensitivity 71±96 %, specificity 
94±97 %), clinical breast examination (CBE; sensitivity 40±69 %, specificity 86±99 
%), and self-breast examination (SBE; sensitivity 12±14 %), have a big role in 
detecting breast cancer (Ma et al., 2012). Self-breast examination and clinical breast 
examination as diagnostic techniques for breast cancer remain controversial with 
recommendations ranging from those advocating for SBE/CBE to others stating there 
is insufficient evidence for their efficacy or a lack of utility in performing these 
examinations (Ma et al., 2012).  
The American Cancer Society (ACS) guidelines for breast cancer screening 
recommended that women should begin annual screening at age 40 noting that there 
was no chronological age at which screening should stop, and further stated that a 
woman in good health would most likely benefit from breast cancer screening (Saslow 
et al., 2007). Also annual CBE was recommended for women 40 and above scheduled 
close to the time of, and before, their annual mammograms (Smith et al., 2003).  
Mammographic screening of women who are between 50 and 70 years of age have 
been demonstrated to reduce mortality from breast cancer, however, there is no 
consensus about the value of mammographic screening among women who are 40 to 
49 years old. One of the reasons for the lack of agreement is the difficulty in detecting 
tumours by mammographic screening in younger women, who have denser breasts 
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than postmenopausal women (Kriege et al., 2004). There is a reduction in sensitivity 
in mammography as compared to clinical breast examination in detecting tumours in 
women less than 50 years, especially in carriers of a BRCA mutation. The reason 
could be typical changes seen on screening mammograms and specific 
histopathological characteristics seen in carriers of BRCA mutations, as compared 
with non-carriers of the same age (Kriege et al., 2004).  
Although CBE and SBE could be effective in screening for palpable breast cancer, 
these methods could be very subjective and inadequate. The magnetic resonance 
imaging (MRI) is a sensitive method in a diagnostic setting generally and breast 
imaging in particular (Saslow et al., 2007). Comparing MRI screening in women with 
a familial or genetic predisposition to breast cancer revealed that MRI appears to be 
more sensitive than mammography in detecting tumours in women with an inherited 
susceptibility to breast cancer, however it is highly influenced by breast density 
making the specificity variable and also the technologies cost are high (Kriege et al., 
2004). Despite the availability and recommended use of mammography, MRI, SBE 
and CBE as routine screening methods for screening breast cancer in women, their 
effectiveness in reducing overall population mortality from breast cancer is still a big 
issue. Currently, tumour markers are being investigated for use in breast cancer 
detection (Li et al., 2002). 
1.9 Biomarkers 
The National Institutes of Health define biomarkers as a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to therapeutic intervention (Coccia, 
2012).  Generally, cancer biomarkers are defined as any measurable cellular, 
 
 
 
 
   32     
     
subcellular, or humoral factors that indicate the presence or absence of malignance, 
its potential, or predict tumour behaviour, prognosis, or response to treatment. These 
indicators could be nucleic acids, proteins, carbohydrates, lipids, small metabolites, 
whole cells or biophysical characteristics of tissue (Bahr et al., 2013).  
Breast cancer lack early symptoms in most cases and breast cancer detected at an early 
stage is treatable, but presently there is no Food and Drug Administration-approved 
tests for early detection of the disease, by the time the cancer is finally diagnosed, it 
is often in an advance stage of progression and untreatable. Thus, there is a need for 
reliable breast cancer biomarkers, which can indicate the potential, or presence of the 
disease (Kirmiz et al., 2007). 
Cancer cells display a large range of genetic alterations that include gene 
rearrangements, point mutations, and gene amplifications, which may lead to change 
in molecular pathways regulating cell growth, survival, as well as leading to 
metastasis. Such changes in a specific type of tumour in the majority of patients can 
serve as biomarkers for diagnosis, prognosis and predicting response to treatment 
(Karley et al., 2011). Identification of biomarkers for cancer processes required 
pathway related studies, which include those responsible for proper regulation of 
various cell functions, whilst paying attention to specific component of the pathway. 
Study of a single component might not be an easy task because there are lots of 
components involved in the regulation, thus most times a comparative study of two or 
more components in the process of carcinogenesis is employed to identify biomarkers 
which can track the event at an early stage as depicted in the figure below (Karley et 
al., 2011). 
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F igure 1.5: The process of carcinogenesis, showing opportunities of identifying 
biomarker (Karley et al., 2011). 
1.9.1 Biomarkers of disease 
Every cell type has a unique molecular signature, which are distinguishable 
characteristics such as, levels of activities of some genes, proteins or other molecular 
features, and are referred to as biomarkers. Biomarkers are subject to dynamic 
modulation, and are expected to serve as an indicator of drug metabolism, drug action, 
efficacy, and safety. They can also facilitate molecular definition of diseases, provide 
information about the course of disease and predict response to therapies (Bhatt et al., 
2010).  
The advent of various technologies such as the mRNA (cDNA) microarrays in recent 
years has helped in generating significant amount of data pertaining to the diagnosis 
of human diseases. These new techniques have helped in identifying new disease 
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subtypes that would not have been possible using conventional techniques, which had 
led to new molecular based classifications of some types of cancers (Kulasingam, and 
Diamandis, 2008). In most diseases, proteins are subjected to various changes 
including proteolytic cleavage and/or post-translation modification. Also there is 
differential expression of some proteins, which result in over-expression or under-
expression in disease conditions (Karley et al., 2011).  
In cancers, there are alterations in the expression of proteins involved in the process 
of signal transduction. There are many instances where the protein products of proto-
oncogenes modulate the signal transduction process and alteration in these genes may 
lead to uncontrolled cellular signalling (Alaiya et al., 2000). Messenger-RNA 
(mRNA) expression profiling normally carried out with the aid of microarray analysis 
present a first line of investigation in the search for disease biomarker, however, they 
fall short of presenting absolute biomarkers for disease diagnosis. This is because the 
microarray that provides information on differential expression of genes will not 
provide information on post-translational modification of the protein products. For 
example, alternative splicing of the mRNA can produce different forms of proteins, 
also in some cases there is no correlation between the level of mRNA and protein 
concentration (Karley et al., 2011). 
1.9.2 Tumour and cancer biomarkers 
Biomarkers that will guide physicians at every stage of cancer onset, progression and 
its management are ideal for the future of cancer management. The cancer biomarker 
will be useful for accurate evaluation of a disease stage and can be used for predicting 
several outcomes during the course of disease including: early detection, outcome 
prediction and detection of disease recurrence (Chatterjee and Zetter, 2005). 
 
 
 
 
   35     
     
Effective tumour markers have the potential to reduce cancer mortality rates by either 
facilitating early cancer diagnosis or helping to individualize treatments, thus they are 
in great demand. They are endogenous molecules (nucleic acids, proteins, metabolites, 
etc.) whose amounts or modifications can serve as indicators of the presence or 
absence of a tumour, the state of the tumour, progression, characteristics, or response 
to therapies, which could be present in the tumour tissues or body fluids (Karley et 
al., 2011).  
Serum biomarkers are molecules or antigens produced by body organs or tumours on 
cell surfaces detected in blood and could be suggestive of tumour activities. Most can 
be produced by normal organs and thus may be non-specific for cancer. An example 
is the prostate cancer antigen (PSA) produced by normal prostate cells but whose 
increase in production is in high positive correlation with prostate cancer. 
Nevertheless, it is probably the only serum biomarker currently used consistently in 
primary care (Adam et al., 2002). However, cancer antigen 125 (CA-125) should be 
a biomarker for risk of ovarian cancer (OC) or an indicator of the malignancy, but iW¶V
also found to be present in high concentration in pancreatitis, kidney or liver diseased 
patients and so cannot be a specific biomarker for OC (Cho, 2007).  CA-125 can 
however be used to monitor progress of treatment, or predict treatment failure if the 
levels rises after treatment.  
Some biomarkers are affected by environmental factors, for example, 
carcinoembryonic antigen (CEA) is a biomarker elevated in colorectal, breast, lung, 
or pancreatic cancer patients, but which smoking can elevate. This biomarker could 
be used to determine the adequacy of post-operative therapy in colon cancer patients 
(Karley et al., 2011). However, a combination of several tumour markers is used for 
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diagnosis, prognosis, or risk predictors for someone whose family history for the 
disease is quite high (Cho, 2007). 
1.9.3 C lasses of cancer biomarkers 
Tumour markers can be used for specific purposes such as screening the general 
population, for differential diagnosis in symptomatic patients, and for clinical staging 
of cancer. They can also be used to estimate tumour volume, to evaluate response to 
treatment, to assess disease recurrence through monitoring, or as prognostic indicators 
of disease progression (Kulasingam and Diamandis, 2008). Based on these cancer 
biomarkers are generally classified as: 
1.9.3.1 Diagnostic biomarkers 
A diagnostic marker is used to detect and identify a given type of cancer in an 
individual. This class of biomarkers play an important role in early detection of cancer 
disease so they are expected to be specific and sensitive (Kulasingam and Diamandis, 
2008). Current clinical and pathological markers poorly predict early disease 
development and response to treatment. Standard diagnostic methods, including tissue 
histopathology are now shifting rapidly toward molecular diagnosis due to the rapid 
progress in facilities for proteomic studies. This powerful technology can identify all 
proteins and their posttranslational modifications in disease conditions, and hence will 
greatly accelerate progress toward novel diagnostic and predictive tools to track early 
disease and tailor made treatments to specific patients (Simpson et al., 2008).  
The advent of various new technologies in biomarker research should bring about 
development of novel markers that will detect cancer early enough, as well as predict 
the risk of tumours by screening for invasive cancer. However, the major challenge in 
utilizing circulating molecular markers to detect cancer is that very small tumours, 
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which are to be detected and removed before they metastasized to other organs, may 
not produce enough of the marker that can be easily detected in bodily fluids. To 
overcome the challenge, it is necessary to first develop new ultrasensitive methods for 
detecting very low circulating levels of the analytes (Chatterjee and Zetter, 2005).    
1.9.3.2 Prognostics biomarkers 
These are markers used once the disease status has been established. These biomarkers 
are used to predict the recurrence and probable course of the disease before it is 
treated, and are therefore important in determining the aggressiveness of therapy. For 
example, in testicular teratoma, Human Chorionic Gonadotropin (HCG) and alpha-
fetoprotein levels can discriminate two groups with different survival rates (Simpson 
et al., 2008). Tumour classification, staging and sometimes grade are normally used 
to assess prognosis. However staging could incorporate other parameters that improve 
prognosis bringing about additional cost. Biomarker expression often replaces or 
complements tumour classification, stage and grade when biologically targeted 
therapeutics is under consideration, but addition of markers could similarly fragment 
the staging process, thereby limiting LW¶V utility (Ludwig and Weinstein, 2005). 
1.9.3.3 Predictive (Stratification) biomarkers 
These are biomarkers used to predict the response of a patient to a drug before starting 
treatment. It classifies individuals as likely responders or non-responders to a 
particular treatment. These biomarkers mainly arise from array-type experiments that 
make is possible to predict clinical outcome from the molecular characteristics of the 
SDWLHQW¶VWXPRXU.XODVLQJDPDQG'LDPDQGLV 
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1.10 Breast Cancer Biomarkers; Uses and L imitation 
Breast cancer markers currently in use includes the cancer antigen 15-3 (CA 15-3) and 
carcinoembryonic antigen (CEA). The BR27.29 marker (also known as CA27.29) 
detects the same antigen i.e. MUC-1 protein just like the CA 15-3 in the serum, and 
they provide similar clinical information, however, the CA 15-3 has been more 
investigated (Harris et al., 2007). The serum levels of CA 15-3 and CEA are related 
to tumour size and nodal involvement and have been recommended by the American 
Society of Clinical Oncology (ASCO) to be used in conjunction with diagnostic 
imaging, history and physical examination in monitoring patients with metastatic 
disease during active therapy (Harris et al., 2007). These markers are not sensitive 
enough for screening and early diagnosis of primary breast cancer, but serum cancer 
levels reflect tumour burden (Kulasingam and Diamandis, 2008).  
Humoral response against many tumour associated proteins such as c-erbB-
2/HER2/neu, RS/DJ-1, and mucin-related antigens have been detected in breast cancer 
(LópezǦÁrias et al., 2012). The proto-oncogene c-erbB-2/HER2/neu, which encodes 
a growth factor receptor, was found to be over-expressed in about 30 % of patient with 
breast cancer. Also the autoantibodies to this oncogene have been observed in 11 % 
of breast cancer cases and this figure correlates with the amount of protein over-
expressed in tumour tissues. In addition, elevated amount of c-erbB-2/HER2/neu 
protein was found in the serum of 29 % of patients with breast carcinoma associated 
with poor prognosis (Yi et al., 2009).  
The non-serological markers like the hormone receptors estrogen and progesterone 
are used in the clinic as breast cancer tissue-based markers. The estrogen receptors is 
regarded as a weak prognostic marker, it is also used for predicting response to 
hormone therapy in conjunction with progesterone receptor in both early and 
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advanced breast cancer treatment (Reis-Filho and Pusztai, 2011).  A meta-analysis 
study, showed that ER-positive patients were 7-times less likely to develop recurrent 
disease than ER-negative patients after 5 years of adjuvant treatment with an estrogen 
receptor antagonist, tamoxifen. Her-2/neu is another tissue-based marker used in the 
clinic for breast cancer prognosis and it is most useful in node-positive patients 
(Duffy, 2001). For the node-negative patients, there are conflicting reports on 
prognosis markers (McShane et al., 2005). The levels of Her-2 in tissue are also used 
for determining patients with either early or metastatic breast cancer for treatment with 
Trastuzumab (Herceptin) (Kulasingam and Diamandis, 2008).  BRCA1 and BRCA2 
are two genetic markers used to identify individuals who are at high risk of developing 
breast or ovarian cancer in high-risk families (Kulasingam and Diamandis, 2008).  
Although many candidate biomarkers for breast cancer disease have been identified 
and evaluated, efforts are still very intensive for the discovery of novel biomarkers. 
Some major problems in biomarker research are that biomarker detection assays may 
not be sufficiently sensitive or specific enough to be reliable for early diagnosis, or 
prognosis. Presently, great efforts are being made toward the discovery of better 
biomarkers for the early diagnosis and prognosis of disease (Yi et al., 2009). For this 
purpose, bioinformatics is one of the new powerful techniques that could be exploited 
to identify new biomarkers from various data generated from different biological 
samples and powerful technological platforms. 
1.11 Bioinformatics and biomarkers 
The availability of the complete human genome has paved the way for the systematic 
understanding of human diseases. Recent technological advances in functional 
genomics and proteomics using microarray and mass spectrometry, coupled with 
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improved bioinformatics and statistical tools, have fuelled the interest in identifying 
biomarkers for complex diseases such as the neurodegenerative diseases and cancer 
(Karley et al., 2011). Functional genomics involves the use of large-scale data 
produced by high throughput (HTP) technologies to analyse the expression pattern of 
large number of genes in diseased and normal tissue, and to understand the function 
of such genes and other parts of the genome. Also, much effort is directed towards the 
development of strategies for quantitative protein profiling using different biological 
samples (Karley et al., 2011).  
The increasing size and complexity of the data generated by HTP methods and the 
microarray technology provide challenges for researchers to extract the biologically 
relevant information. Bioinformatics serve to link scientific data with clinical 
information. This is particularly important in relation to the recent development of 
powerful bioinformatics algorithms, which can interpret multiple parameters much 
more efficiently than most traditional approaches (Kulasingam and Diamandis, 2008).  
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F igure 1.6: A proposed approach to cancer gene discovery from the CGAP database. 
Both novel and known ESTs are identified using multiple data-mining tools from this 
database (Narayanan, 2007).  
Genomics provides the blueprint for the discovery of possible gene products that can 
serve as biomarkers. Although there are about 30,000 genes in the human genome 
(http://www.ncbi.nlm.nih.gov/genome/guide/human/), the protein complement of 
these genes (the proteome) of a cell or tissue is larger and more dynamic in nature. 
This as a result of different modification processes like alternative splicing of 
transcripts, which leads to different isoforms of a protein, glycosylation, 
phosphorylation, myristylation etc. that leads to different active proteins per gene 
(Packer et al., 2007).   
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The genomics and transcriptomics approach to biomarker discovery provide powerful 
tools for identifying candidate markers, but an important shortcoming of these 
approaches is that there are no correlation between the changes in expression of 
mRNA and level of protein. Thus many technologies are being developed and 
exploited to collect information about proteins (Patterson and Aebersold 2003). Most 
of the proteomics studies begin with isolation of total proteins from test samples and 
another from a control group. Analysis of these proteins is then carried out by mass 
spectrometry (MS) or 2-D gel electrophoresis. The data generated is then subjected to 
data mining (Bioinformatics) to recognize a complex pattern and identify proteins 
involved, which could serve as biomarkers (Patterson and Aebersold 2003). 
 
F igure 1.7:   Current status of proteomic technologies in biomarker discovery 
(Patterson and Aebersold 2003). 
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F igure 1.8: Schematic representation of the proteomics process in biomarker 
discovery (Verma, 2007). 
With increasing availability of public data, there is a need for rigorous comparisons 
of data, pre-processing and data mining in the course of searching for biomarkers. 
Bioinformatics approaches appear to be very critical for effective analyses and mining 
of data in providing insights into disease biology that provides good candidate markers 
(Moore, 2010). Many algorithms exist to mine large datasets, but no specific approach 
is ideal or applicable to all study designs, different approaches are normally used in 
parallel before arriving at a final algorithm. Finally, it is anticipated that existing and 
emerging computational data mining approaches along with rigorous and systematic 
evaluation, will help to unleash the full biological potential of proteomic profiling 
(Sugimoto et al., 2012). 
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1.13 A im and Objectives 
1.13.1 A im	  
The aims of this research was to validate several candidate genes identified from a 
previous study as effective breast cancer biomarkers using several in silico methods as 
well as molecular techniques and to study the modulating effect on pro-apoptotic 
compounds of one of these genes in particular (Gene 7). 
1.13.2 Objectives 
x Functional characterization of the identified candidate biomarkers using a 
bioinformatics (in silico) approach. 
x Prognostic and predictive validation of the candidate biomarkers using a 
bioinformatics approach 
x Protein expression analysis of the candidate biomarkers in cancer cell lines 
x &RQVWUXFWLRQRI³Nnock-down´ and over-expression vectors of Gene 7 in breast 
cell lines 
x Effect of *HQH³knock-down´ and over-expression in a breast cancer cell line 
on Apoptosis using different apoptotic inducers. 
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Chapter 2; Functional characterisation of identified genes using in silico 
approach 
2.1.1 Introduction 
The field of bioinformatics has grown in recent years with a concurrent increase in 
genomic and proteomic data (Li et al., 2010). Data intensive research has spurred the 
development of computational methods to ease analysis of databases, especially those 
of a cross-disciplinary nature, which serve as resources for data collection and 
integration (Ramakrishnan et al., 2005). Databases come in all forms, and some 
examples are protein interaction databases and pathway databases to mention only a 
few. These are valuable tools that allow for genes and proteins to be organised within 
their larger biological context, making it possible for inferences to be made regarding 
their role in disease pathways (Draghici et al., 2007).  
The widespread use of DNA microarray technology to perform experiments on 
thousands of gene fragments at the same time has generated lots of expression data. 
In handling these huge datasets, whose interrelationships is well understood, 
exploratory and visualization techniques are necessary (Gibbons and Roths, 2002). 
Different bioinformatics techniques such as placing members of a set of genes to one 
of a much smaller number of classes (Clustering) are exploited in inferring gene 
function(s) (Aittokallio and Schwikowski, 2006). Gene clustering encompasses many 
techniques, such as hierarchical clustering (which encompassing single-, complete-, 
and average linkage variants), k-means clustering, and self-organized maps (SOM), 
used to assign genes into similar and relevant biological groups (Gibbons and Roths, 
2002). 
The identification of candidate genes or proteins that may be involved in cancer 
disease is important in expanding our knowledge of the disease process which may 
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help in early diagnosis, prognosis and therapeutics. Investigating the role of identified 
genes and other proteins they interact with could provide clues of their molecular 
function and regulation within a disease process such as cancer (Baylin and Jones, 
2011). Also identifying associated cellular pathways could reveal the functional 
environment of a candidate gene (Hartman et al., 2001). Various databases made up 
of experimentally verified genes from published literature as well as data of predicted 
genes, based on trends from the genome wide sequence, could provide a framework 
for further experiments and studies using bioinformatics platforms. 
The advances in technology and the advent of high-throughput genomic, proteomic 
combined with bioinformatics techniques, allows investigators to simultaneously 
examine the changes, expression level or pattern and regulation of genome-wide genes 
under certain biological conditions, unlike the traditional biological approaches that 
typically study one gene at a time (Huang et al., 2009). The output of these high-
WKURXJKSXW WHFKQLTXHV DUH ODUJH µLQWHUHVWLQJ¶ JHQH OLVWV WKDW QHHGs to be further 
analysed with the aim of achieving a smaller sized gene list that can be validated using 
traditional biological techniques. However interpreting the biological functions and 
relevance of the genes in such a list is still a challenging and daunting task. This is 
because of the size of the generated gene list, but with the aid of bioinformatics 
methods, the biological knowledge discovered or predicted and stored in public 
databases could help to sieve out and assemble a summary of the most enriched and 
pertinent candidate gene(s) (Huang et al., 2009). 
2.1.2 Previous study 
An in silico approach was used to identify cell surface genes implicated in the 
development or progression of breast cancer through mining of biological databases 
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such as ONCOMINE and Gene Expression Atlas (GEA). ONCOMINE 
(www.oncomine.org) is a popular cancer micro-array database, while the GEA 
(www.ebi.ac.uk) is a general micro-array database. A set criterion that searched for 
upregulated, cell surface genes in breast cancer was used, which resulted in extraction 
of several gene lists from these databases. The resulting lists were harmonized, refined 
and the final output was ranked based on the intersection of the data types. Candidate 
genes were selected based on their ranking and subjected to Gene Ontology (GO) 
analysis for functional characterization to determine their cellular localization. 
Twenty-three genes whose protein products are categorized as cell surface proteins 
were selected based on the GO analysis. Cell surface proteins were of particular 
interest as it is anticipated that their protein products will be shed into human bodily 
fluids and could easily be assessed for early diagnosis of breast cancer. A literature 
search on these candidate genes was done and fourteen were found to be 
experimentally linked to breast cancer, one was in the process of clinical validation as 
a biomarker, one had FDA approval as breast cancer biomarker whilst seven were not 
inferred or proven as breast cancer biomarkers.  
The expression of these 7 genes were subsequently analyzed in breast cancer cell lines 
as well as other types of cancers, using semi-quantitative PCR and qRT-PCR. Gene 
expression analyses performed on a breast cancer cell line and a non-cancerous breast 
cell line, revealed differential expression of some of these genes between the cancer 
and the non-cancerous cells. In addition, a differential expression analysis comparing 
the expression level of these genes in breast cancer cell line with several other cancer 
types revealed that some of these putative genes were also over-expressed in the other 
cancer types, whilst three of the genes were found to be differentially expressed in the 
breast cancer cell line (MFC-7) (Ngcoza, 2012).  
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2.1.3 A im  
The aim of this chapter was to functionally characterize the seven identified genes as 
putative breast cancer biomarkers using several in silico approaches. 
 
2.1.4 Objectives 
x Gene clustering analysis of the candidate genes 
x Gene pathway analysis of the candidate genes 
x Protein interaction analysis of the candidate genes 
x Transcription factor binding analysis of the candidate genes 
x Tissue expression anlysis of the candidate genes 
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2.2.0 Gene clustering (Gene Ontology)  
The Gene Ontology (GO) is an annotation tool set to present consistent descriptions 
of gene products across databases. The project was founded in 1998 by the GO 
consortium (GOC), incorporating many databases, including several major 
repositories for plant, animal and microbial genomes (Lee and Sonnhammer, 2003).  
The Gene Ontology Consortium (GOC) provides a structured language that is applied 
to the distribution of differentially expressed genes and proteins in all organisms into 
functional categories (Rhee et al., 2008). GO is structured into three main categories 
namely: Biological Process, Molecular Function, and Cellular Component. Biological 
Process includes broad biological processes, which are accomplished by ordered 
assemblies of molecular functions for example, the purine metabolism process. 
Molecular Function annotate genes based on the tasks performed by their individual 
gene products; examples are transcription factor activity and DNA Helicase activity. 
The Cellular Component annotations include classification of genes into sub-cellular 
structures, locations, and macromolecular complexes; examples include nucleus, 
telomere, and origin recognition complex (Coulibaly and Page, 2008). 
2.2.1 Database for annotation, visualization, and integrated discovery (D A V ID) 
Various tools have been GHYHORSHGWRDVVHVVWKHVWDWLVWLFDOVLJQL¿FDQFHRIDVVRFLDWLRQ
of a list of genes with GO annotations terms over the years. Most of these tools provide 
exceptional depth and coverage of the functional data available for a given gene, but 
are not designed to effectively explore the biological knowledge associated with 
hundreds or thousands of genes in parallel (Dennis et al., 2003).  
The Database for Annotation, Visualization, and Integrated Discovery (DAVID) 
provides a set of data-mining tools that describe the functions of genes in a set of data 
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and systematically combine the functionally descriptive data with graphical displays. 
DAVID provides exploratory visualization tools that promote discovery through 
functional classification, biochemical pathway maps, and conserved protein domain 
architectures, while simultaneously remaining linked to rich sources of biological 
annotation (Huang et al., 2008).  
The DAVID Gene Functional Classification Tool (http://david.ncifcrf.gov) annotate 
and combine a gene list of similar properties of associated biological terms into groups 
based on reported or predicted functions. These classes of related genes are referred 
to as biological modules and are accomplished by mining the biological co-
occurrences found in different sources of functional annotation (Huang et al., 2008). 
2.2.2 Pathway analysis 
The advents of high-throughput techniques for gene sequences and gene/protein 
profiling have transformed biological research by providing an effective means of 
monitoring a biological system. These high-throughput techniques usually present a 
list of differentially expressed genes after analysis, indicating genes that may play a 
role in a given phenomenon or phenotype. However, these lists most times often do 
not provide insight into the underlying biological condition being studied (Khatri et 
al., 2012).  
A major application of identified regulatory networks or the identification of clusters 
of functionally related genes is to associate the genes and their interconnections with 
known metabolic pathways (Barabási et al., 2011). Biochemists summarized the 
sequence of enzymes that catalyzed metabolic reactions between biomolecules into 
network of interactions that results from the conversion of one organic substance 
(substrate) to another (product). These biochemical networks represent the potential 
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link that exists EHWZHHQ JHQHV DQG JHQH SURGXFWV LQYROYHG LQ VSHFL¿F biological 
processes (Coulibaly and Page, 2008).  
There are lots of specialized databases available with large amount of information on 
metabolic reactions and one of such is the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG), used for this study.  
2.2.3 K yoto encyclopaedia of genes and genomes (K E G G) 
The Kyoto Encyclopaedia of Genes and Genomes (KEGG) is a database resource of 
the Japanese GenomeNet service (http://www.genome.ad.jp/) use in understanding 
WKHIXQFWLRQVRIFHOOVRUWKHRUJDQLVPV¶EDVHRQWKHLUJHQRPLFLQIRUPDWLRQRashidi 
and Buehler, 1999).  
KEGG consists of a database of pathways (PATHWAY database) for analysing 
molecular interaction and networks, the database of genes (GENES database) for 
accessing information about genes and their protein products which are generated by 
genome sequencing projects, and the database with information about chemical 
compounds and chemical reactions that are relevant to cellular processes (LIGAND 
database) (Kanehisa et al., 2002). The KEGG pathway maps are widely used for 
biological interpretation of genome sequences and other high-throughput data. The 
database is a reference database for pathways developed by capturing and organizing 
experimental results from published literature, which initially focused on metabolic 
pathways but later incorporated other cellular processes (Kanehisa et al., 2014). 
2.2.4 Search tool for the retrieval of interacting genes/proteins (ST RIN G) 
STRING is a database and web resource dedicated to protein±protein interactions, 
including both physical and functional interactions (Jensen et al., 2009). Proteins 
interact with one another not only by physical binding, but also indirectly by sharing 
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an intermediary substrate in a metabolic pathway, by regulating the transcription of 
each other either through feedback or co-expression, or by participating in larger 
multi-protein assemblies (Von Mering et al., 2005). 
These various interactions which may be transient and as well functional pathways, 
are context dependent and requires various experimental techniques which are not 
similar, and thus, not easily elucidated and understood (Ben-Hur and Noble, 2005). 
Nevertheless, protein±protein interaction networks or functional association networks 
are crucial in understanding the cellular machineries in organisms (Barabasi and 
Oltvai, 2004). Furthermore, protein networks can help fulfill other practical purposes 
such as filtering and assessing high-throughput functional genomics data, and 
providing intuitive visual scaffolds for annotating the structural, functional and 
evolutionary properties of proteins (Jensen et al., 2009). STRING present an 
aggregate of available information on protein±protein associations, scores and weights 
them, and also augments the list with predicted interactions, as well as results from 
automatic literature-mining searches (Jensen et al., 2009).  
2.2.5 GeneCards® Version 3: the human gene integrator 
GeneCards (www.genecards.org) is a comprehensive, authoritative compendium of 
list of annotated information of human genes. Its content are automatically mined and 
collated from over 80 data sources of genome, transcriptome, proteome and disease 
data. These databases includes large public databases like ENSEMBL, UniprotKB, 
National Centre for Biotechnology Information (NCBI) and HUGO Gene 
Nomenclature committee (HGCN) among others (Safran et al., 2010).  
The database was established by the Weizmann Institute of Science in collaboration 
with the Life Map Sciences Incorporated with the aim to integrate various data 
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generated by the human genome project and different specialized databases derived 
from this project and other expression analysis resources (Crusio and Gerlai, 1999). 
GeneCards version 3 contains more than 73 000 entries, which includes cards for 
known and predicted protein coding genes as well as pseudo-genes and RNA genes 
(Safran et al., 2010).  
The GeneCards® database also provide multifaceted tools for gene characterisation 
from a nucleotide sequence starting point, to the analysis of gene expression and 
protein modification, including protein involvement in cellular and disease pathways, 
listing transcription factors associated with protein of interest and providing 
information on molecular tools to aid research (Safran et al., 2010). 
2.2.6 T factS®: (T ranscription Factor activity database)  
TfactS® is a database designed to predict regulation, inhibition or the activation of 
transcription factors (TFs) in a biological system based on gene lists of upregulated 
and down regulated genes generated in microarray experiments (Essaghir and 
Demoulin, 2012). List of up- and/or down-regulated genes are submitted for TF query 
to the TfactS® input dialogue boxes, the list is compared with a catalogue of annotated 
target genes, and returns three lists of transcription factors whose annotated target 
genes show a significant overlap with the query genes. One of the list shows the 
regulated Transcription Factors (TF), another list consist of activated TF while the 
third shows a list of repressed TF. Both the activated and repressed lists are produced 
using the Sign-Sensitive catalogue whilst the Sign-Less catalogue does not provide 
this information (i.e., up-/down-regulated TF) (Essaghir et al., 2010). 
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2.2.7 Gene Expression A tlas 
Gene Expression Atlas (GEA) is a general micro-array database that makes use of 
information obtained from experiments carried out using both tissues and cell line 
samples in various disease states from humans (Lein, et al., 2007). GEA integrates 
data from 5.372 human samples representing 369 different cell and tissue types. It 
makes use of over 9000 raw data files generated on the human gene expression array 
Affymetrix U133A from public databases, Gene Expression Omnibus and Array 
Express. GEA thus integrates all micro-array studies pertaining to a disease and allows 
the user to search for a gene of interest as well as to define conditions, and provides 
an overall output extracted from all the information collected in the database regarding 
gene expression in that disease condition. (Kapushesky et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   55     
     
2.3 Materials and methods 
2.3.1 Functional annotation 
The seven genes identified as putative breast cancer biomarkers (Ngcoza, 2012) were 
classified based on annotated roles in cancer disease using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) v6.7 (Niaid, 2006). The 
functional annotation tool was selected from the home page of the software 
(http://david.abcc.ncifcrf.gov/). The HGCN gene symbols of the 7 genes were typed 
LQWR³SDVWHOLVW´ER[³official gene symbol´ was selected as the unique identifier, and 
³gene list´ZDVVHOHFWHGDVOLVWW\SHDIWHUZKLFK the ³submit list´ button was selected. 
Functional annotation clustering was selected from the output and different processes 
implicated in cancer were selected from the different clusters. These biochemical 
processes were tabulated against the annotated genes. 
2.3.2 Pathway analysis.  
Each of the seven genes was submitted to the KEGG pathways database 
(http://www.genome.jp/kegg/pathway.html) after selecting Homo sapiens as the 
organism and the output were tabulated against annotated pathways. The default 
setting was used for the pathway analysis. 
2.3.3 Protein-protein interaction analysis 
 The interactions of the protein products of the putative gene, with proteins known to 
be involved in apoptosis and those involve in autophagy where monitored using the 
STRING protein database version 9.1 (http://string-db.org/). The protein symbols for 
each gene was pasted in the ³list of SURWHLQ´ER[DIWHUVHOHFWLQJ multiple names as 
input option for the database, Homo sapiens was selected as organism and ³go´ button 
was clicked for interaction search. Also Gene 7, observed to be the most differentially 
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expressed from the qRT-PCR analysis (Ngcoza, 2012), was also separately analyzed 
by inputting the gene symbol into the search box DIWHUVHOHFWLQJWKH³VHDUFKE\QDPH´
option. The default confidence score of 0.400 was changed to 0.700 in order to restrict 
the result to interactions with a high confidence level. 
2.3.4 Validating expression of candidate genes in breast cancer 
The Gene Expression Atlas database was accessed at http://www.ebi.ac.uk/gxa and 
the seven genes were queried by inserting the gene names (HGCN) into the gene box, 
the ³up/down expression´RSWLRQ in Homo sapiens was selected under organism and 
³cancer, cancerous´ were selected under condition. The result was viewed in a heat 
map format showing the genes, the number of studies done, and their expression level 
in different cancer types. The number of times a gene was reported to be over-, under-
, or not reportedly (not determined) expressed in breast, colon, lung and prostate 
cancer types was recorded by assigning 2, 1 and 0 to over-, under- or not reported 
expression respectively. The experimental outcome in different cancer cell lines and 
tissue for each of the cancer types was then plotted against the genes using the Graph 
pad prism version 5.00 statistical tool GraphPad Software (San Diego, California 
USA). 
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2.4 Result and Discussion 
2.4.1 Functional annotation 
Identifying specific gene expression signatures of biological relevance from the 
genome-wide expression or microarray generated data would further our 
understanding of central tumour forming biological processes. Their controlling 
factors and might also help to delineate therapeutic, diagnostics or prognostic 
considerations for cancer care, as well as play an important role in the development 
of novel targeted therapies (Fredlund et al., 2012).  
The aim of this chapter was to validate seven genes identified in an earlier study 
(Ngcoza, 2012) as potential breast cancer biomarkers using additional in silico 
approaches to functionally characterize these candidate genes. The involvement of 
these genes and their protein products were analysed to identify their functional 
relationship and links with other genes and protein products already implicated in 
cancer in general and breast cancer in particular.  
Figure 2.1 shows the genes were clustered into several functional groups using the 
DAVID database. The result showed that several of the identified genes are involved 
in processes that have been implicated in cancer pathways (Figure 2.1). Three of the 
seven genes were present in the list of genes annotated as secreted proteins. These 
genes included Gene 7, which showed high differential expression between the non-
cancerous breast cell line, (MCF-12A) and the breast cancer cell line (MCF-7), as well 
as Gene 1 and Gene 2, that did not show differential expressession amongst the cell 
lines analysed based on the qRT-PCR analysis (Ngcoza, 2012).  
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F igure 2.1: Functional annotation clustering of the seven putative breast cancer 
genes using GO analysis.  
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A number of gene families of secreted and trans-membrane proteins related by 
homology have been identified and classified into groups known to have key roles in 
important biological processes such as morphogenesis, cellular differentiation, 
angiogenesis, apoptosis, and modulation of the immune response, as well as disease 
processes such as cancer progression. These genes are members of diverse gene 
families, which include tumour necrosis factors, growth factors, cytokines, 
chemokines, interferons, and angiopoietin-related protein families, as well as the 
protein families of their receptors and other receptors such as the Toll-like receptors, 
integrins, and disintegrins (Clark et al., 2003). This result suggests that the protein 
products of these putative genes shown to be secreted, might be present in bodily 
fluids of breast cancer patients, and may easily be accessible if they are to be used as 
a biological indicator of breast cancer in a point of care device.   
Apart from serving as markers for cancer discovery and monitoring, secreted protein 
could play a key role in cancer therapeutics and prognosis. They also play an integral 
role at a specific state of a disease or the biological pathway leading to disease, and 
their identification and characterization may lead to understanding the disease 
paradigm. Based on their location on the cell they possess good properties of 
therapeutic agents or targets, since they are accessible to various drug delivery 
mechanisms (Rangiah et al., 2009). Rituxan and Herceptin are two therapeutic 
antibodies that target B lymphocyte-specific CD20 protein and HER2 receptor protein 
for the treatment of non-+RGJNLQ¶VO\PSKRPDDQGEUHDVWFDQFHUUHVSHFWLYHO\DQd are 
considered as markers for these diseases (Clark et al., 2003). 
Some of these genes were also found to be involved in processes that are hallmarks of 
cancer like angiogenesis (Gene 6), apoptosis, cell cycle and regulation of cell 
differentiation (Gene 2). Angiogenesis is the development of new vessels from 
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existing vasculature, a process necessary in tumour growth, survival, and progression. 
Angiogenesis is regulated at the molecular level by pro and anti-angiogenic cytokines. 
The cytokines that majorly control angiogenesis is the relatively small family of 
vascular endothelial growth factors (VEGFs) (Wehland et al., 2013). VEGF was 
among the twenty-three genes identified in the earlier in silico approach to identifying 
breast cancer biomarkers (Ngcoza, 2012).  
Several angiogenic particles have been studied as prospective predictive biomarkers 
for different breast cancer types, but not all breast cancer patient have a good 
prognostic outcome for anti-angiogenic therapy. Thus, so far no pattern has been 
established to select biomarkers that will serve this purpose (Wehland et al., 2013). 
Although none of the three highly differentially expressed genes based on qRT-PCR 
analysis (Ngoza, 2012) were shown to be involve in angiogenesis, the functional 
annotaion analysis showed one of the seven genes (Gene 6) to be involved in this 
biochemical process (Figure 2.1). This suggests that the expression pattern of the 
protein product of Gene 6, could potentially serve a prognostic biomarker role in anti-
angiogenic therapy in breast cancer following extensive molecular validation.  
Figure 2.1 also showed one of the seven candidate genes (Gene 2) to be involved in 
regulating apoptosis. Deregulation of apoptosis is a known characteristic of human 
carcinogenesis and molecules involved in this process are expected to be good 
candidate markers. Several apoptotic markers like Bcl-2, caspase-3, P53, Survivin etc. 
have been suggested as prognostic markers for different cancer types (Karam et al., 
2007). Also Gene 2 is the only gene out of the seven candidate genes associated with 
other cancer causing processes like; cell cycle, negative regulation of cell 
proliferation, and post-transcriptional regulation of gene expression (Figure 2.1).  
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Interestingly, Gene 2 was not shown to be differentially expressed in the qRT-PCR 
analysis (Ngcoza, 2012), but could be considered a good candidate biomarker based 
on its recurring presence in most cancer related processes based on the in silico 
functional annotation analysis thus far. The expression level of this gene could 
potentially be repress under breast cancer conditions. Gene repression can also serve 
as a good indicator of disease onset or progression (Frank and Hargreaves, 2003), 
which could be an additional basis for Gene 2 being a potential biomarker for breast 
cancer. Post transcriptional regulation of gene expression play a key role in human 
disease states. MicroRNAs (miRNAs), a class of small non-coding RNAs is known to 
modulate post-transcriptional outcomes of gene expression by targeting mRNAs and 
triggering either translational repression or RNA degradation (Iorio et al., 2005). Also, 
Gene 2 was the only gene out of the seven candidate genes linked with cell cycle, 
regulation of apoptosis and negative regulation of cell proliferation and not classified 
as an anti-apoptotic molecule from the annotation analyses (Figure 2.1), which suggest 
other possible reasons why it could be repressed by an oncogene to enhanced cancer 
proliferation.   
2.4.2 Pathway analysis 
Grouping and/or assigning genes, proteins, and/or other biological molecules to the 
pathways they are involved in, helps to minimise the number of pathways that needs 
to be dealt with when characterizing candidate biomarkers on a molecular level. Also 
identifying distinct active pathways between candidate genes under different 
conditions can have more validating power than a simple list of differentially 
expressed genes or protein. Thus, pathway analysis has become the first choice for 
gaining insight into the underlying biology of differentially expressed genes and 
protein (Khatri et al., 2012).  
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From the pathway analysis result using KEGG (table 2.1), the seven genes showed no 
known direct and specific link to breast cancer. However, some of the genes are shown 
to be involved in pathways that may enhanced, inhibit or regulate macromolecule 
metabolic pathways, cell membrane structurH RU WKH ERG\¶V LPPXQH V\VWHP WKXV 
processes that have been implicated in cancer and its proliferation.  
From table 2.1, Gene 4 was specified to be involved in nucleic acid metabolism, 
carbohydrate metabolism as well as the biosynthesis of vitamins that may signal the 
stimulation of cell proliferation as well as partake in reorganization of metabolic 
activities. The onset of cell proliferation through the cell cycle has been reported to 
require doubling of total biomass (proteins, lipids and nucleic acids) a phenomenon 
that poses a great metabolic challenge to cells and which must be overcome for cells 
to respond to proliferative stimuli (DeBerardinis et al., 2008). Thus deregulation of 
these pathways should enhance tumour growth, hence the probable role of this gene 
and/ or is protein product in cancer onset or progression.   
Metabolism in cancer cells differ from the normal dormant cells in high rates of 
glycolysis leading to an increase in lactate production, increase production of lipids 
and other macromolecules.  Proliferating cells often take up nutrients in excess of 
energy flow required and link metabolites into pathways that support a platform for 
biosynthesis for achieving the three basic needs of dividing cells which are rapid ATP 
generation to maintain energy status, increased biosynthesis of macromolecules and 
tightened maintenance of the appropriate cellular redox status (DeBerardinis et al., 
2008).  
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Table 2.1: Pathways linked to the different identified putative biomarker genes using 
KEGG 
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Gene 4 was also linked to carbohydrate metabolism (table 2.1), which suggests a role 
for it in sustaining cancer cells. The best studied metabolic process observed in tumour 
cells is the Warburg effect. This is a process of ATP generation through glycolysis by 
converting glucose to lactate even in the presence of oxygen, a shift from the normal 
ATP generation through oxidative phosphorylation (Cairns et al., 2011). 
The seven candidate genes also included Gene 1 a member of the integrin family that 
are involved in extracellular matrix receptor interaction activity (table 2.1). The 
integrin family of adhesion receptors transduces signals from the extracellular matrix 
that regulate growth, gene expression and differentiation, cell shape, motility and 
cytoskeletal architecture. It is reported that integrin in conjunction with other classes 
of adhesion receptors or growth factor receptors help to transduce signals (Damsky 
and Werb, 1993). Fisher et al. (2004), reported that, different members of the small 
integrin binding ligand N-linked glycoprotein (SIBLING) gene family, have been 
reported to modulate the activities of the cell surface proteins known as the matrix 
metallo-proteinases (MMPs). MMPs was shown to be differentially expressed in 
different cancer types including breast cancer. The study concluded that SIBLINGs 
are potential markers of early disease progression in a number of different cancer 
types, some of which lack vigorous clinical markers (Fisher et al., 2004). This suggest 
that Gene 1, being in the same class as the SIBLINGs could also serve as a biomarker 
for breast cancer.  
Gene 7 is a member of the protein family that binds to natural killer cells to initiate 
their activities. The pathway analysis result confirmed this by associating this gene to 
natural killer (NK) cell mediated cytotoxicity (table 2.1).  NK cells are important 
components of the innate immune system, which is regulated by a complex balance 
resulting from signals received via inhibitory and activating receptors (Rölle et al., 
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2003). NKG2D is an activating receptor found on natural killer cells. They serve as 
immune-receptor of cytotoxic lymphocyte. Tumours can escape immune surveillance 
by shedding off ligands that binds NKG2D receptors for NK cell stimulation. These 
VROXEOHOLJDQGVWKXVDUHSUHVHQWLQFDQFHUSDWLHQWV¶VHUDDQGFRXOGVHUYHDVELRPDUNHUV
(Paschen et al., 2009).  Ligands of the NK receptors have strongly been suggested as 
biomarkers for monitoring cancer initiation, progression and therapeutics (Neagu et 
al., 2010). Since Gene 7 is a NKG2D ligand family member and was annotated as a 
secreted protein (Figure 2.1), it could thus be shed into bodily fluids of breast cancer 
patients and could serve as a useful biological marker for the disease.    
2.4.3 Protein Interaction Analysis 
Protein-protein interactions are very important in understanding biological processes, 
in that it provide insights into protein function(s). It may also help to uncover the 
generic organization principles of functional cellular networks, when both spatial and 
temporal aspects of interactions are considered (Stelzl et al., 2005). The protein 
composition in a cell is very dynamic and changes during development, disease 
condition and in response to external stimuli, and these proteins form large interaction 
networks, in which they regulate and support each other (Von Mering et al., 2002).  
Using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 
database, the interaction among the seven candidate genes was analyzed. For the 
purpose of this thesis, the protein products of Gene 1-7 will be referred to as BRG 1-
7 respectively.  
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F igure 2.2: Protein interaction analysis of candidate genes using STRING. The figure 
showed the interaction between the gene products (BRG 1-7) and their link to 
Apoptosis (Circle A) and Autophagy (Circle B) 
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The seven proteins showed no direct interaction or linked with each other (Figure 2.2). 
This implies that these genes might not directly interact with each other, but may 
present an expression pattern for breast cancer onset or progression. Based on the 
criteria used by STRING to establish the interactions, the database might also not hold 
enough information to confirm the link between these proteins. However, it has been 
reported that sets of genes used as biomarkers for disease does not necessarily directly 
interact with each other (Barabási et al., 2011). 
To determine if these proteins modulate the processes of apoptosis, cell cycle and 
autophagy (three major hallmarks of cancer), the STRING software was used to query 
the interaction of the seven candidate genes and major proteins in the above mentioned 
processes. The result (Figure 2.2) suggest that most of the protein products of the 
candidate genes might not directly modulate these processes as no direct interaction 
was shown to well-known proteins linked to these processes. However, this does not 
imply that they are not involved in these pathways, but may be linked through 
interaction with intermediary proteins, which has not be reported or predicted to date 
by the STRING database. Most proteins functional linkages are not necessarily stable 
physical interaction. They may interact by catalyzing subsequent reactions in a 
metabolic pathway, regulate each other transcriptionally or post-transcriptionally, or 
jointly contribute to larger, structural assemblies without ever making direct contact 
(Franceschini et al., 2013).   
Figure 2.2 also showed that BRG 2 is directly linked to a protein (BECN1) involved 
with the biochemical process of autophagy and this protein directly linked apoptosis 
to autophagy. An interesting part of this result was that this protein was also indicated 
to be involved with most of the cancer processes examined in the functional annotation 
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analysis (Figure 2.1), but was not shown to be differentially expressed in the qRT-
PCR analysis (Ngcoza, 2012).  
2.4.4 T ranscription Factors Associated with genes 
Complete knowledge of all proteins that directly and/or indirectly interacts with a 
protein in a given cell type or condition would present an important milestone towards 
a comprehensive description of cellular mechanisms and functions (Franceschini et 
al., 2013). These proteins could also be regulated by the same transcription factors.  
The transcription factors (TF) were annotated to the putative genes using the Qiagen 
and/or regulatory elements and epigenetics data from the Genecards database (Safran 
et al., 2010). Identifying genes to whose promoters either non-oncogenic or oncogenic 
transcription factors binds could provide insight into the transcriptional regulation of 
such genes and thus their role in the control of normal cell growth, differentiation as 
well as in cancer development.  
The transcription factors that were predicted to target the promoter region of the 
candidate genes have been reported to be involve in cancer initiation, repression or 
progression (table 2.3). For example, p53 is a tumour suppressor protein that plays a 
critical role in most cancer types. Though this gene was initially thought to be an 
oncogene, it was later discovered that the mutation of the gene is involved in many 
common human malignancy (Hollstein et al., 1991). This TF was annotated to 
regulate three of the candidate genes, all of which that did not show differential 
expression in breast cancer versus a normal breast cell line in the qRT-PCR analysis 
(Ngcoza, 2012).  
 
 
 
 
 
   69     
     
Table 2.2: Transcription Factors associated with the seven putative breast cancer 
genes. 
Gene Regulatory T ranscription Factor 
Gene 1 CREB, p53,  deltaCREB,   MyoD, STAT3 
Gene 2 AP-1, p53,   ATF-2,   CUTL1,   Nkx2-5, c-Jun 
Gene 3 AhR, Sox5, Pax-5, RREB-1, GATA-1, Arnt, 
ZID, NF-Y, CBF(2) 
Gene 4 E2F-3a, E2F-4, E2F-5, FOXF2,  Pax-2, Pax-2a 
CUTL1, E2F-2, E2F-1,E2F 
Gene 5 Bach1, Pbx1a, GATA-3, AML1a, MEF-2, 
Nkx2-5, XBP-1, C/EBPalpha, MEF-2A, aMEF-2 
Gene 6 c-Fos, p53, AP-1, GR-beta, ATF-2, STAT3, c-
Jun 
Gene 7 AP-2alpha isoform 3, AP-2alpha isoform 4, AP-
2alpha isoform 2, AP-2alpha, AP-2alphaA 
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CREB has been shown to be over-expressed in leukemic blast cells from patients with 
acute myeloid leukemia (AML) and its over-expression was associated with poor 
prognosis in AML patients. However the over-expression of the CREB protein did not 
correlate closely with CREB mRNA levels, suggesting that post-transcriptional 
mechanisms may contribute to the elevated expression (Sakamoto and Frank, 2009). 
This TF showed association with one of the seven putative genes (Gene 1) as shown 
in table 2.2. 
Table 2.2 showed three of the seven genes (Gene 2, Gene 6 and Gene 7) to be 
associated with a family of genes that encodes the AP transcription factors. The 
mammalian AP-1 protein is a dimer protein made up of a group of DNA binding 
protein comprising of the Jun, Fos and ATF subgroups of transcription factors. They 
have been found to regulate cell proliferation, neoplastic transformation and apoptosis 
(Shaulian and Karin, 2001).  There is evidence that AP-1 proteins, mostly those that 
belong to the Jun group, control cell life and death through their ability to regulate the 
expression and function of cell cycle regulators such as Cyclin D1, p53, p21cip1/waf1, 
p19ARF and p16 (Shaulian and Karin, 2001).  
The Stat-3 transcription factors has been reported to be an oncogenic signaling 
pathway component whose expression suppresses tumour expression of pro-
inflammatory mediators and whose block in expression increases expression of pro-
inflammatory cytokines and chemokines that activate the innate and the adaptive 
immune systems (Wang et al., 2004). E2A-Pbx1 is a fusion onco-protein found in 
about 10 % of acute leukemia in humans (Thorsteinsdottir et al., 1999). This TF 
showed association to Gene 6 (table 2.2). 
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Table 2.2, also showed a list of transcription factors that have been directly linked to 
different types of breast cancer. Gene 2 and Gene 4 are two of the seven genes that 
were associated with CUTL1. CUTL1, is a known transcription factor that acts as a 
major regulator of cell motility and invasion and an important downstream effector of 
7*)ȕ, a key factor modulating cell migration, invasion and tumour progression. It 
was highly expressed in high-grade carcinomas and its expression is inversely 
correlated with survival in breast cancer (Michl et al., 2005).  
Over-expression of c-Jun (a transcription factor associated with Gene 6) in MCF-7 
cells was reported to lead to an increased aggressiveness in cancer cell growth, as a 
result of an increased in cellular motility, and increased expression of a matrix-
degrading enzyme (MMP-9). Breast cancer cell lines that over-expressed c-Jun were 
also reported to be unresponsive to estrogen and tamoxifen (Smith et al., 1999). There 
is an indication that the over-expression of c-Jun represents an estrogen-independent 
phenotype of breast cancer. The observed phenotype for MCF-7 cells with c-Jun over-
expression is similar to that observed clinically in advanced breast cancer, which do 
not respond to hormonal treatment (Smith et al., 1999).  
A germline mutation of the tumour suppressor gene BRCA1 is an indicator of an 
increased lifetime risk of breast and/or ovarian cancer (Cantor et al., 2001). BACH1 
is a nuclear protein that helps in DNA repairs by direct interaction with the highly 
conserved, C-terminal BRCT repeats of BRCA1. A disruption in this interaction as a 
result of mutation in the BRCA1 or BACH1 genes may lead to defects in DNA repairs, 
which eventually results to breast and/or ovarian cancers (Cantor et al., 2003).  There 
are reports on some women with early-onset breast cancer with no defects in either 
BRCA1 or BRCA2 possessing a mutated germline BACH1 coding sequence, 
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suggesting that a dysfunction in BACH1 contribute to the tumour induction in breast 
cancer (Cantor et al., 2003). BACH1 was linked to Gene 5 (table 2.2). 
The transcription factor GATA-3 was also linked to Gene 5 (table 2.2). This TF is 
majorly responsible for maintaining luminal epithelial differentiation in adult 
mammary gland, which raises important implications for the pathogenesis of breast 
cancer. It was shown that a deletion of GATA-3 in mice lead to severe defects in 
mammary development as a result of failure in terminal end buds formation during 
puberty. This resulted in an undifferentiated luminal cell expansion with basement-
membrane detachment, which led to caspase mediated cell death (Kouros-Mehr et al., 
2006). 
Table 2.2 also showed the AP-2 family of transcription factors to be linked to Gene 7. 
This AP-2 family of transcription factors has also strongly been implicated in different 
subtypes of breast cancer and modulations of genes associated with this transcription 
factor, based on their characteristics in these different types of breast cancer, could 
serve as good biomarkers (Vogel et al., 2003).  
Perissi et al. (2000), reported that the AP-2 transcription factors are implicated in the 
estrogenic regulation of the ERBB2 gene expression. The ERBB2 is an oncogene 
repressed by estrogen in human breast cancer (Perissi et al., 2000). Also, the level of 
AP-2alpha and AP-2gamma were shown to be highly expressed in the majority of 
breast cancer cell lines over-expressing c-erbB-2 (Bosher et al., 1996). Gene 7, the 
candidate gene associated with this transcription factor, was the most highly 
differentially expressed gene from the qRT-PCR result (Ngcoza, 2012). Taken 
together the association of these various TFs to the putative breast cancer biomarkers, 
 
 
 
 
   73     
     
suggest that these genes could be good prognostic markers as well as markers for 
monitoring therapeutic outcomes in various types of breast cancers.  
2.4.5 Expression pattern of the candidate biomarkers in different cancer types 
The expression pattern of the candidate genes was monitored in different cancer types 
to determine their specificity using the gene expression atlas database (Kapushesky et 
al., 2012). Only cancer types that showed expression result for four or more 
experiments for at least one of the candidate genes was considered. The result obtained 
showed the expression level of the seven putative genes has been monitored in breast, 
colon lung and prostate cancer (figure 2.3).  
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F igure 2.3: Gene expression pattern in breast, colon, lung and prostate cancer types. 
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Figure 2.3 shows that Gene 1 and Gene 5 in addition to the three genes (Gene 3. 4 and 
7) that showed high expression levels from the qRT-PCR analysis (Ngoza, 2012) were 
highly differentially expressed in breast cancer based on this in silico analysis. The 
result obtained for Gene 1 and Gene 5 that were not shown to be differentially 
expressed based on qRT-PCR analysis, might be as a result of the methods used to 
determine their expression levels as reported in this database.  
The Gene Expression Atlas is a representation of gene expression across tissues, cell 
types and cell lines under different biological conditions, including development 
stages, physiological states, disease state and phenotypes in different organism curated 
directly from array express Archive of Functional Genomics Experiments and the 
European Nucleotide Archive (Kapushesky et al., 2012). Identifying these genes to be 
differentially expressed in breast cancer types further validate them as valuable 
biomarker prospects for breast cancer diagnosis, prognosis or predictive purposes.  
The seven putative genes were differentially expressed in other cancer types as well, 
which bring into concern the specificity of these genes as breast cancer biomarkers. 
However, the expression pattern of these genes in the different cancer types differs. 
For example, Gene 7 was differentially expressed in breast, lung and prostate cancer 
but not expressed in colon cancer from this in silico analysis (Figure 2.3). Gene 2 was 
highly expressed in prostate cancer but was differentially expressed in breast cancer 
as shown by the GEA output. However, Gene 2 was linked to most of the processes 
associated with cancer in the earlier sections (Figure 2.1 and 2.2), an indication that 
the expression of this gene could probably be repressed in breast cancer. These 
differential expression signatures serve as a suggestion that a combination of this set 
of genes used in combination will serve the purpose of biomarkers for breast cancer 
detection or monitoring.  
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Cancer cells are known to display a broad spectrum of genetic alterations that include 
gene rearrangements, point mutations and gene amplifications, leading to disturbances 
in molecular pathways. These alterations generates a pattern of secreted varying 
protein signatures in surrounding cells or at more distal and easily sampled sites of the 
body and could serve as biomarkers for better management of cancer (Bhatt et al., 
2010). The expression signature of these different candidate genes could be more 
appropriate as a biomarker panel for either breast cancer diagnosis or prognosis. 
It has been reported that multiple proteins will be more appropriate as biomarkers for 
cancer detection and monitoring. Although single biomarker may serve in selected 
cases, there is growing consensus that multiple (e.g., three to five) markers used 
individually or as part of an integrated panel will be required for most applications, 
and the performance advantages of panels have been confirmed in several publications 
(Rifai et al., 2006; Hanash et al., 2008; Hu et al., 2008). 
2.4.6 Protein interaction analysis of BR G 7 
To further determine the biochemical role of BRG 7, proteins that physically interact 
with this protein were assessed using the STRING database (figure 2.4). 
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F igure 2.4: Protein interaction analysis of Gene 7 using STRING 
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Figure 2.4 shows the protein-protein interaction network of the protein product of 
Gene 7 (BRG 7). BRG 7 is a member of an immune-receptor ligand family expressed 
on tumour cells and it has been reported that cancer cells could escape from immune-
surveillance by shedding off this protein (Paschen et al., 2009). Most proteins that 
have direct physical interaction with BRG 7 are members of the immune-receptor 
ligands and their receptor proteins (figure 2.4). Apart from this group of proteins that 
interacted directly with BRG 7, another membrane bound protein (BRG 8) also 
interact with this protein. BRG 8 also showed a direct physical interaction with 
estrogen receptor protein (ESR1). This protein (whose gene and protein product will 
be referred to as Gene 8 and BRG 8 respectively in the subsequent chapters of this 
thesis) was also considered a very good putative breast cancer biomarker based on its 
direct interaction with BRG 7 and ESR1 as shown by STRING analysis (Figure 2.4).    
BRG 8 has been reported to act as a mediator of transcriptional repression of an 
estrogen receptor (ER)-selective co-regulator that potentiates the inhibitory activities 
of anti-estrogens and represses the activity of estrogens (Manavathi et al., 2014).  
Estrogen receptor (ER) status of invasive carcinoma has been reported to be a useful 
prognostic and predictive factor and has become a common practice in the 
management of breast carcinomas. ER positivity predicts for response to endocrine 
therapy such as anti-estrogen (tamoxifen) administration or ovarian suppression 
(Bauer et al., 2007).   
Five different morphological subtypes of invasive breast cancer were recently 
reported from microarray profiling analysis. They include: luminal A, luminal B, 
normal breast-like, HER2-overexpressing, and basal-like. The basal-like subtype is 
the most aggressive histologically and is normally characterized by negativity to 
estrogen receptor, progesterone receptor and HER2 expression. It accounts for about 
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15 % of breast cancer cases and it is associated with poor prognosis, unresponsiveness 
to the usual endocrine therapies, shorter survival, and BRCA1-related breast cancer 
(Bauer et al., 2007). A direct link of this protein using STRING analysis, gives more 
credence to BRG 7 as a probable biomarker for breast cancer management. 
Steroid hormone receptors (SHRs), utilize different tissue-VSHFL¿FFR-regulators for 
their activity in a continuum manner. Co-regulators act as a bridging or helper 
molecules forming large protein complexes to modulate the activity on target gene 
chromatin. These co-UHJXODWRUVPD\SRVLWLYHO\RUQHJDWLYHO\LQÀXHQFHWKHUHFHSWRU¶V
transcriptional activity by modifying the target gene chromatin. The co-regulators that 
enhance the transcriptional activity of SHRs are called co-activators, and those that 
decrease its activity are called co-repressors (Manavathi et al., 2014). BRG 8 is a co-
repressor of the estrogen receptor and could serve in conjunction with BRG 7, as good 
biomarker to distinguish different types of breast cancer from each other, however, 
more in silico and molecular analysis is required to validate this. 
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2.6 Conclusion 
Good biomarkers are urgently required to improve diagnosis, prognosis, guide-
targeted therapy, and monitor therapeutic responses across the various types of breast 
cancer. Currently thousands of proteins curated from genomic analyses and gene 
expression data have been predicted and published either as individual or a group of 
proteins as candidate cancer biomarkers (Kulasingam and Diamandis, 2008). Interest 
in proteins as biomarkers is based on their record as biomarkers for other disease states 
as a result of their function or family relation (Hanash et al., 2008).  
Understanding the molecular basis of cancer should provide means for early detection 
as well as better diagnosis, prognosis and staging of disease and aid in the evaluation 
of response to therapy, prevention and establishing novel treatment strategies (Seth 
and Watson, 2005). 
The candidate genes from an earlier study (Ngcoza, 2012) were primarily identified 
from DNA microarray experiments that were published or stored in different 
databanks. DNA microarrays allows for simultaneous determination of the expression 
levels of thousands of genes based on certain treatments, diseases, or at the 
developmental stages of such diseases, and it has been widely applied in cancer 
research for better diagnosis and prediction of the disease states (Huang et al., 2010). 
Functional analyses done in this chapter using an in silico approach, confirmed these 
genes as having good prospects as potential biomarkers for breast cancer based on 
their involvement in different cancer processes.  
In addition to the three genes (Gene 3, Gene 4 and Gene 7) identified to be 
differentially expressed from the qRT-PCR result (Ngcoza, 2012), the protein 
products of two other genes were also hypothesized to be good candidates as breast 
 
 
 
 
   81     
     
cancer biomarkers based on the in silico analysis performed in this chapter. One of the 
two genes (Gene 2) was part of the seven genes identified in the previous study but 
was not shown to be differentially expressed in a breast cancer versus normal cell line 
based on qRT-PCR analysis. This gene was found to be involved in most of the 
processes linked to breast cancer and cancer in general based on the GO, TF and 
protein interaction analysis. We postulate that the protein expression pattern of this 
protein could serve as an additional means for monitoring breast cancer onset, 
progression as well as monitor therapy.   
The specific differential expression signatures of the candidate genes in different 
cancer types, suggest that a single candidate gene or protein may not be very specific 
as a breast cancer biomarker, but combining these genes/proteins may be more 
appropriate.  
An additional candidate biomarker (BRG 8) was identified as it showed direct 
interaction with BRG 7 through STRING analysis. This protein is also reported to 
modulate the expression of estrogen receptor (ESR), a prognostic factor in a large 
group of breast cancer types.  
Based on the result from this chapter, it was concluded that the protein products of 
these genes or at least some of them could serve as a panel of biomarkers for diagnosis, 
prognosis or predictive markers for breast cancer management. To further validate 
these genes as biomarkers, their prognostic value was analysed using different 
bioinformatics tools in the subsequent chapter. 
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Chapter 3: Prognostic and Predictive validation of Genes using an in silico 
approach   
3.1: Background 
After the introduction of markers such as the estrogen receptor and HER2 for the 
evaluation of the clinical course of breast cancer, the search for breast cancer 
biomarker is now shifting towards the identification of gene or protein expression 
levels capable of predicting the outcome or prognosis of breast cancer (Györffy et al., 
2010). Clinician used these signatures when examining early stage cancers, which aid 
in evaluating the type of therapy best, suited or if adjuvant therapy is required after 
surgical resection (Khaleel et al., 2014). Identifying cell surface genes whose 
expression signatures and protein products could serve as biomarkers for breast cancer 
outcomes, would be a useful addition to current methods used in breast cancer 
management. 
Breast cancer still remains one of the leading causes of cancer deaths despite the 
increase in the availability of effective adjuvant medical treatment. Although regular 
mammography screening programs provides a means of detecting early stage (<2cm), 
node-negative breast cancer and bring about better prognosis, which also contribute 
to improved outcomes, there is still a need to avoid overtreatment in patients who 
hardly benefit, whilst suffering from toxic side effects. On the other hand, under 
treatment or incorrect treatment also have to be avoided (Weigel and Dowset, 2010).  
Thus, the need for identifying breast cancer biomarkers that could serve as prognostic 
or predictive indicators of the disease.  
Prognostic biomarkers aims to predict objectively and independently patient clinical 
outcome before treatment. These biomarkers must have the capacity to define 
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outcome in patient cohorts that did not undergo adjuvant treatment. Whilst the 
predictive biomarkers tends to foretell the response of a patient to a specific 
therapeutic intervention and are associated with tumour sensitivity or resistance to a 
type of therapy (Weigel and Dowset. 2010). 
Classical clinical features used for cancer prognosis are mostly pathological practices, 
which include tumour size, histological subtype and grade, lymph node metastases, 
and lymphovascular invasion. The TNM (tumour, nodes, and metastasis) system 
integrates these into tumour staging, which have major prognostic value by careful 
histological examination of a primary breast cancer sample (Weigel and Dowset. 
2010). However, the advent of high-throughput methods, have provided large data on 
genes and protein candidates that can serve as prognostic and predictive biomarkers 
(Hayes et al., 2007) for a more effective and less laborious means of evaluating the 
prognosis of a breast cancer patient as suppose to the pathological methods.  
Gene-expression profiling of tumourigenic breast-cancer cells has been used as a 
prognostic tool in assessing survival in patient with breast cancer (Sotiriou, et al., 
2003). Liu et al., (2007) identified 187 genes that are differentially expressed in 
tumourigenic breast cancer cells compared to normal breast epithelium and reported 
a distinct gene signature for the disease that differs from an earlier reported gene 
signature in breast cancer. They concluded that this signature is an indication that a 
EUHDVWWXPRXUZRXOGOLNHO\PHWDVWDVL]HDQGWKHLUVWXG\UHIHUUHGWRLWDV³LQYDVLYHQHVV´
gene signature (IGS). The IGS was also reported to be associated with the risk of death 
and metastasis not only in breast cancer but also in lung cancer, prostate cancer, and 
medulloblastoma, suggesting that the IGS could be a general biological feature shared 
by several different types of tumours (Liu et al., 2007). 
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With the advent of high throughput technologies, like microarray analysis and qRT-
PCR for gene expression profiling, many candidate genes have been identified and 
suggested to be good biomarkers for monitoring outcomes in breast cancer treatment, 
however most of these candidate biomarkers have not been validated either in 
multivariate analyses nor was their discriminative power validated in large clinical 
cohorts (*\ĘUII\et al., 2012).  
The discovery of biomarkers must be followed up with validation studies. Before 
drawing conclusion about the expression of candidate genes, independent 
experimental validation using several techniques such as reverse transcriptase-PCR, 
Northern blot analysis, or tissue microarrays on human samples that generates large 
number of datasets, should be carried out (Rhodes, et al., 2002). Uniting several 
datasets from different studies, employing several statistical methods can enhance and 
provide more accurate estimates of biomarkers for cancer diagnosis and prognosis 
(Gyorffy, et al., 2013). With the increasing number of publicly available datasets, a 
meta-analysis of multiple datasets that address similar hypotheses can be used to 
validate and statistically assess all the valuable candidate biomarkers simultaneously, 
potentially yielding significant, differentially expressed genes, void of inadequacies 
from individual studies (Rhodes, et al., 2002).   
For the analysis of candidate biomarkers for their prognostic value, several tools such 
as ITTACA, KMPlot, RecurrenceOnline, bc- GeneExMiner, GOBO, PrognoScan, and 
many others have been proposed (Aguirre-Gamboa, et al., 2013). Some of these 
survival analysis data tools were employed to validate the eight candidate biomarkers 
in this study. 
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3.2: K aplan Meier plot 
The relative gene expression level using the microarray technology is regarded as an 
effective preliminary test tool to evaluate prognostic biomarkers (Fan, et al., 2006). A 
prudent means of exploiting these biomarkers is by looking into already existing 
clinical microarray cohorts generated (Györffy et al., 2010). Validating candidate 
genes as prognostic or predictive biomarkers in well researched breast cancer cohorts 
is of utmost interest in monitoring treatment and predicting the correct treatment 
(Weigel and Dowsett, 2010).  
The Kaplan±Meier estimator (also known as the product limit estimator) is one of the 
best statistical options used in estimating the fraction of subjects living for a certain 
number of years after treatment. The effect of an intervention in clinical trials or 
community trials is assessed by measuring the number of subjects that survived after 
an intervention over a period of time (Goel et al., 2010).  
It is one of the simplest statistical tool that can be used to compute and estimate the 
survival of human subjects over time in spite of all the difficulties associated with 
subjects or situations. For example, it takes into account losses from the cohort, if a 
patient withdraws from a study, by computing the probabilities of occurrence of the 
event at the point of exit and multiplying this successive probabilities by any earlier 
computed probabilities to get the final estimate. The association between a clinical 
parameter (or biomarker) and survival can be visualized by drawing a Kaplan±Meier 
plot in which patients are split into groups according to the parameter (Györffy et al., 
2010).  
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3.1.2: K aplan Meier plotter® 
The Kaplan Meier plotter is an online statistical tool used to draw survival plots, to 
determine the clinical relevance of the expression levels of various genes on the 
outcome of both treated and untreated cancer patients (Györffy et al., 2010).  The tool 
can assess the effect of 22,277 genes from 10,188 cancer samples, which include 4,142 
breast, 1,648 ovarian, 2,437 lung, and 765 gastric cancer patients. The background 
database is manually curated and handled by a MySQL server, which simultaneously 
curate gene expression and clinical data of different cancer patients. The data is 
analysed using the R statistical tool for calculations (Györffy et al., 2010). The 
package calculates WKH µµVXUYLYDO¶¶ OHYHO DJDLQst input gene and the Kaplan±Meier 
survival curves is plotted, indicating the number of patient at risk below the main plot. 
The hazard ratio with 95 FRQ¿GHQFH LQWHUYDOV DQG ORJUDQN3DUH FDOFXODWHG DQG
displayed on the plot. The feedback is received on the webpage. The Kaplan±Meier 
plotter is set up using a central server, which can be accessed over the Internet with a 
primary purpose of meta-analysis based in silico biomarker assessment (*\ĘUII\et 
al., 2013). 
3.2: SurvExpress® 
The SurvExpress (http://bioinformatica.mty.itesm.mx/SurvExpress) is a cancer-wide 
gene expression database with clinical outcomes and a web based tool that provides 
survival analysis and risk assessment of cancer datasets. It is a bioinformatics tool 
used to look at the performance, validates survival and prognostic biomarkers for 
cancer outcomes. The tool is a cancer dataset that comprises 20,000 samples and 130 
GDWDVHWVZLWKFHQVRUV¶FOLQLFDOLQIRUPDWLRQFRYHULQJRYHUGLIIHUHQWW\SHVRIWLVVXHV
The web interface can easily be used to perform in silico biomarker validation, and 
compare genes within the database. The Input page accepts gene list based on NCBI 
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compatible gene identifiers (official symbol, Entrez, Ensembl, HGNC, or others) and 
dataset of interest can be selected from the list. Users can also choose how to treat 
genes detected using different experimental methods (Aguirre-Gamboa et al., 2013). 
Compared to most tools for analysing the validity of biomarkers for cancer outcomes, 
SurvExpress is the largest and the most versatile free tool for analysing differentially 
expressed multi-gene biomarkers in human cancers at the same time (Aguirre-
Gamboa et al., 2013). The SurvExpress results include a Kaplan-Meier curve for risk 
groups, clinical information available related to risk group, heat map representation 
of the gene expression values, a box plot across risk groups, and tables with the 
summary of the Cox fitting and the prognostic indexes (Aguirre-Gamboa et al., 2013).  
3.3: Gene Expression-Based Outcome for Breast Cancer Online (G O B O) 
Various databases provide large repertoire of prognostic and/or treatment predictive 
gene expression studies on breast cancer e.g. Gene Expression Omnibus (Hess et al., 
2006). The major aim of the Gene Expression-Based Outcome for Breast Cancer 
Online (GOBO) an online bioinformatics tool (http://co.bmc.lu.se/gobo) is to provide 
a means to examine the differential expression level of various genes in an 1881 
sample breast tumour dataset and a 51 breast cancer cell lines dataset, generated on 
Affymetrix U133A microarrays. The 1881-sample breast tumour set comprises 11 
public datasets analysed using Affymetrix U133A arrays. GOBO allows the 
assessment of precompiled datasets to be interrogated for three main classes which 
are: gene set analysis (GSA) in different subgroups of breast tumours and breast 
cancer cell lines, identification of co-expressed genes (CG), and sample prediction 
(SP) which is an expression levels of single genes, sets of genes, or gene signatures in 
multiple subgroups of the 1881-sample breast cancer data set.  GSA analysis using the 
GOBO web interface is further divided into outcome analysis in breast tumours (GSA-
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Tumour) and expression patterns in breast cancer cell lines (GSA-Cell line) (Ringnér 
et al., 2011). 
3.4: A im of study 
The aim of this chapter was to evaluate the prognostic and predictive values of the 
identified putative gene as biomarkers using different bioinformatics tools. 
3.4.1 Objectives 
x Prognostic/ predictive validation of candidate genes using two datasets from 
SurvExpress 
x Predictive analysis of individual biomarker candidate genes using the Kaplan 
Meier plotter 
x Prognosis/ Predictive analysis of candidate genes for different breast cancer types  
using GOBO      
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3.5: Materials and methods 
3.5.1: SurvExpress 
The online biomarker validation tool SurvExpress was assessed online at 
http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp. The eight 
candidate gene symbols were used as input in the space provided for gene list and 
³EUHDVW´RSWLRQZDVVHOHFWHGDV WLVVXHW\SHDQGWKHGHIDXOWVHWWLQJZDVXVHGIRU WKH
RSWLRQ³GXSOLFDWHGJHQHV´7KHJHQHVZHUHWKHQDQDO\]HGWZLFHXVLQJWZRdifferent 
broad datasets; (1) a dataset comprising 9 datasets from the same platform compiled 
by seven authors using 1574 samples (for this study termed DATA 1) and (2) 
metabases constructed by performing a quantile normalization compiled by 
SurvExpress with 1901 samples (termed DATA 2). Both databases are recurrence, 
meta-analysis clinical data (Aguirre-Gamboa et al., 2013). The analysed button was 
FOLFNHGDQGRQWKHQH[WSDJH³5HFXUUHQFH)UHH6XUYLYDO<HDUV´ZDVVHOHFWHGDQG
the output was downloaded in pdf. Format. 
3.5.2: K aplan-Meier Plotter 
Kaplan Meier plotter an online cancer survival analysis tool was used to assessed the 
effect of each candidate gene on breast cancer outcome at 
http://kmplot.com/analysis/index.php?p=service&cancer=breast ³%UHDVW´ ZDV
chosen as cancer type and each gene symbol for the candidate genes were used as 
input into the gene space provided. All other default setting was used after which the 
³draw Kaplan-Meier plot´ option was selected. The output results were downloaded 
in pdf. Format. 
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3.5.3: G O B O databases gene analysis 
GOBO (Gene Expression-Based Outcome for Breast Cancer Online) database 
(http://co.bmc.lu.se/gobo) was used to validate the prognostic value of the candidate 
genes. The gene sets were queried in the Gene Set Analysis-outcome in the breast 
tumours (GSA-Tumours) application. The gene symbols was used as input and the 
option, ³GLIIHUHQWtumour W\SHV´ZHUHVHOHFWHGDQGDQDO\]HGRQHDWDWLPHXVLQJWKH
JURXSVTXDQWLOHVDQG³IXOO\HDUVFHQVRULQJ´RQWKHGHIDXOWVHWWLQJVRingnér, et al., 
2011).  
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3.6: Results and Discussion 
To validate the prognostic and/or predictive value of the identified candidate genes as 
a set of biomarkers, several prognostic software and databases were used.  
3.6.1: SurvExpress 
Using the SurvExpress tool, the prognostic ability of this set of candidate biomarkers 
was determined using two broad datasets; (1) One comprising 9 datasets from the 
same platform/methods compiled by seven authors comprising 1574 samples (DATA 
1) and (2) meta-bases constructed by performing a quantile normalization compiled 
by SurvExpress comprising 1901 samples (DATA 2). From the results, three genes 
out of the eight showed promise as good distinguishable prognostic markers based on 
their p-value (p < 0.05) in DATA 1, while two genes were indicated as significant 
genes in DATA 2 (table 3.1).
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Table 3.1: Result summaries of gene expression analysis showing significant genes based on p-YDOXHVSRILQGLYLGXDOJHQHVIURP
two datasets; (a) DATA 2 and (b) DATA 1 using SurvExpress  
 
A   B  
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From table 3.1, DATA 1 shows 2 genes (Gene 6 and Gene 8) were significantly 
expressed whilst DATA 2 shows 3 genes (Gene 3, Gene 6 and Gene 7) to be 
significantly expressed. Gene 6 was common in the output from both datasets. 
Interestingly this gene was highly differentially expressed in a breast cancer versus 
normal cell line from the qRT-PCR result (Ngcoza, 2012). Two of the three significant 
genes from DATA 2 (table 3.1) were also found to be highly differentially expressed 
in the qRT-PCR experiment using a breast cancer cell line versus a non-cancer breast 
cell line (Ngcoza, 2012), while the second significant gene from DATA 2 was Gene 
8, the additional candidate gene identified from the earlier in silico work (Chapter 2).  
Figure 3.1 shows the Kaplan-Meier plots by risk group, the log-rank test of differences 
between risk groups, the hazard-ratio estimate, and the concordance indeces, which 
estimate the probability that subjects with a higher risk (red) will experience relapse 
after subjects with a lower risk (green) for both databases. Unlike the variance in 
significant genes in both datasets, these figures suggest that the genes when combined 
as biomarkers could significantly predict the prognostic outcome of breast cancer 
patient based on the difference in outcome between the higher and the lower risk 
groups. The difference in output from these two datasets showed different individual 
biomarkers of significance, might be as a result of different approaches used in 
identifying and compiling these databases. This can be corroborated by a study that 
showed that the performance of biomarkers may differ in different populations, based 
on clinical information, probes per gene, the gene expression technology and the 
conditions used (Aguirre-Gamboa, et al., 2013).  
However the significant output shown by the Kaplan-Meier plots of the combine 
genes from the two datasets suggest that our candidate gene list might serve as good 
prognostic biomarkers for breast cancer. Although a database with the highest 
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population of patients was selected for this analysis, the gene expression technology 
and clinical information of individual patient in the datasets may have affected the 
performance output of the individual candidate genes.  
In accordance with our approach of validating these candidate genes using the 
SurvExpress analytical tool, Cronin, et al., (2007) used this software to analyse 16 
biomarker genes to predict the likelihood of breast cancer recurring in early-stage, 
node-negative, estrogen receptor±positive breast cancer patients. These genes are 
currently used in a multigene commercial test kit known as Oncotype DXTM, a 
clinically validated, high-complexity, multianalyte reverse transcription±PCR 
genomic test tool (Cronin et al., 2007).  
This kit was used to analyzed four different breast cancer patients datasets, and the 
result showed that though some of the individual genes may not adequately separate 
the low and high risk groups, the Kaplan-Meier plots based on the concordance 
indexes confirmed that the Oncotype DXTM could significantly separate low and high-
risk groups in the four datasets tested (Aguirre-Gamboa, et al., 2013). This result is 
similar to results obtained from this chapter, using the seven candidate genes to 
monitored breast cancer treatment outcome in the two largest dataset sets using the 
SurvExpress analytic tool.  
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F igure 3.1: Kaplan±Meier analysis for all candidate genes for breast cancer outcomes. 
By class: treatment/ pre-surgery (overall betas) concordance index = 61.25, log-rank 
equal curves p=0.02728, r^2=0.043/0.921 risk groups hazard ratio = 1.88 (conf. int. 
1.06 ~ 3.32), p=0.02987. a) DATA 1. b) DATA 2. 
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Two other result output types from SurvExpress analysis were a box plot graph and 
heat map showing the expression level of each of the candidate genes (Fig, 3.3 and 
3.4). The gene expression of each gene is plotted along risk groups obtained in the 
analysis for the box plot. The box plot indicates whether gene expression levels are 
different between risk groups based on visual difference (high risk group are 
represented with red and low risk groups in green) and also the p-value S. 
Whilst the heat map shows the expression level (by colour) of each candidate genes 
against samples ranked by their prognostic index.  
Box plots compare the difference of gene expression between risk groups using a t-
test. The box plots confirmed the differential expression of most of the candidate genes 
in both datasets. From DATA 1 seven of the eight candidate genes were differentially 
expressed whilst five were differentially expressed from DATA 2 (p < 0.05).  
The heat map ranked the genes based on their prognostic ability. Figure 3.3 showed 
that most of these genes are highly differentially expressed in the high-risk group (p 
< 0.05). This is an indication that high expression of these genes will present a poor 
prognosis in breast cancer patients, and the expression signature could be 
complemented with the repreessed genes in predicting treatment outcome. Figure 3.3 
showed two of the highly differentially expressed genes (Gene 4 and Gene 7) from 
the qRT-PCR analysis (Ngcoza, 2012), were among the three highly ranked genes in 
the DATA 2, while the third gene (Gene 3) and Gene 8, the gene identified from the 
earlier in silico work (chapter 2), were highly ranked in DATA 1.  
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F igure 3.2: Gene expression values across gene groups represented by box plots 
together with the p-YDOXHSRIWKHFRUUHVSRQGLQJGLIIHUHQFHFRPSDULQJULVN
groups (a) DATA 1 (b) DATA 2 
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F igure 3.3: Expression profile and gene ranking based on prognostic index. (a) 
Expression profile from the datasets compiled by SurvExpress comprising 1901 
samples. (b) Expression profile from dataset of nine databases compiled by seven 
authors comprising 1574 samples. 
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The difference in expression signature comparing the two datasets could be due to 
variance in cancer types and subtypes. Other major prognostic factors such as, age, 
tumour size, status of axillary lymph nodes, histologic type of the tumour, pathological 
grade, and hormone-receptor status could affect the expression pattern of these genes 
(Fulford, et al., 2007). Vijver et al., 2002 classified patients with primary breast 
carcinomas using a 70-gene prognosis profile, earlier identified as a gene-expression 
signature associated with either poor or good prognosis and concluded that the gene-
expression profile studied was a more powerful predictor of the outcome of disease in 
young patients irrespective of the lymph node status. Fan et al., 2006 concluded in 
their work, that the lack of similarities in performance of different gene expression 
signatures for breast cancer prognosis, derived from almost similar studies, are not 
completely known, but may include differences in the patient cohorts, microarray 
platforms, and mathematical methods of analysis. 
3.6.2: K aplan-Meier plotter 
To further determine the prognostic value of the individual biomarker candidates in 
recurrence of breast cancer, the Kaplan-Meier plotter was used (www.kmplot.com). 
This software uses gene expression microarray data and survival information of 2,324 
patients with breast cancer downloaded from GEO (Affymettrix HGU133A and 
HGU133+2) to present the expression of an individual gene in patient survival 
outcome (Romagnoli et al., 2012). High expression level of some of these genes was 
significantly correlated with poor outcome of breast cancer, while the expression of 
others did not show a significant distinguishing outcome (p  0.05). Genes of major 
interest were the three genes that were differentially expressed in the qRT-PCR 
analysis (Ngcoza, 2012).  
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F igure 3.4: Survival risk curves for Gene 2, 3, 7 and 8. Low and high risks are drawn 
in black and red respectively. The p-value was shown in the right hand corner of each 
FXUYHSLVVLJQLILFDQW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F igure 3.5: Survival risk curves for genes 1, 4, 5 and 6. Low and high risks are drawn 
in black and respectively. The p-value was shown in the right hand corner of each 
FXUYHSLVVLJQLILFDQW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Figures 3.4 and 3.5 showed difference in the survival rate of risk groups, based on the 
expression of the individual genes. From the survival curves, Gene 3, Gene 4 and 
Gene 7 have a significant p-value in predicting the prognostic outcome based on the 
differential value of the biomarkers in breast cancer patients (Figure 3.4), however, 
Gene 8 did not show significant distinguishing value in predicting the disease outcome 
(fig 3.5). Also in addition to the three genes that showed significant p value, the 
Kaplan-Meier plots showed Gene 1, potentially have a good prognostic value based 
on its p-value from this analysis (Figure 3.5). However, this gene was not highly 
differentially expressed in the qRT-PCR analysis (Ngcoza, 2012) and interestingly, 
this gene was not listed among the genes of significance in the SurvExpress analysis 
report from both datasets used (Section, 3.6.1).  
The variations observed using different bioinformatics tools might be as a result of the 
different sample types used in assessing the value of these biomarkers in the various 
databases. Variation in gene expression has been reported in human mammary 
epithelial cells and breast cancer tissues, which are two different sample types. A 
publication suggested that different clusters of genes with coherent expression 
patterns in cultured cells are different from breast tumour samples and the difference 
were due to specific features of biological variation among the samples (Buess et al., 
2007). Also, the Kaplan-Meier plotter is known to access a database of breast cancer 
patients, undergoing different types of treatment, whilst the expression analysis using 
qRT-PCR, involved the use of only two types of breast cell lines (MCF-7 and MCF-
12) which are not total representation of the heterogeneous nature of a breast tumour 
and a normal breast tissue.    
Holliday and Speirs (2011) reported that there is a limitation to the extent to which a 
single cell line will mirror the clinical samples, covering specialised histopathological 
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types and maintaining the phenotype of a cell line in cell culture just like the breast 
tumour in vivo. However, the tremendous advances in the understanding of the 
biology of breast cancer were made and still rely on the use of cell lines (Holliday and 
Speirs 2011). 
The approach used in this study to validate the candidate genes as breast cancer 
biomarkers was similar to that of Romagnoli, et al., (2012). Using the Kaplan Meier 
plotter, they identified and analyzed the expression pattern of BMP-5 in different 
cancer types and concluded that the low expression of this gene significantly 
FRUUHODWHG ZLWK EUHDVW FDQFHU VXUYLYDO HVSHFLDOO\ LQ (5Į-negative breast tumours 
(Romagnoli, et al., 2012).  
3.6.3: Gene Expression-Based Outcome for Breast Cancer Online (G O B O) 
The effective prognostic ability of this set of candidate biomarkers was determined in 
different subtypes of breast cancer, using the Gene Expression-Based Outcome for 
Breast Cancer Online (GOBO) and the results represented with survival curves 
(Kaplan-Meier plots). Five major subtypes of morphologically similar breast cancer 
types namely: luminal A, luminal B, normal breast-like, HER2-overexpressing, and 
basal-like have been identified based on microarray profiling of invasive breast 
carcinoma (Turashvili, et al., 2011). The basal-like subtype is generally characterized 
by non-expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 
(Bauer et al., 2007).  
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F igure 3.6:  Survival curve for different breast cancer subtypes  (a) ER+ all tumour subtype (b) ER+ luminal B tumour subtype (c) ER- 
all tumour subtype (d) ER- ERBB2 tumour subtype (e) ER- luminal negative tumourVVXEW\SHS
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Figures 3.6 represent the survival outcomes in low-risk, intermediate-risk and high-
risk patients based on the candidate genes expression pattern in different cancer types.  
The Kaplan-Meier analysis is performed on different stratified groups based on gene 
expression in different subtypes and presented as percentage distant metastasis-free 
survival (DMFS) against time in years. The output from this analysis indicated that 
this set of candidate biomarkers may not predict effectively all estrogen receptor 
positive (ER+) breast cancer subtype based on the Kaplan-Meier plot (p = 0.26799), 
however the candidate biomarkers were effective in predicting the outcome of luminal 
B ER+ breast cancer subtype based on the Kaplan-Meier plot p-value S  
(Figure 3.6).  
Also, the GOBO output showed this set of genes could be accurately used to predict 
the survival outcome of ERBB2 subtype of estrogen receptor negative (ER-) tumours, 
and lymph node negative subtype of ER- tumours, but not all subtype of ER- tumours 
based on the individual survival curves outcome for these diseases (Figure 3.6). The 
percentage DMFS difference between survival groups for a ten year period in ER- 
tumour patients based on the expression of these genes/proteins was not statistically 
significant (p = 0.43041), while the difference between the risk groups in the ER- 
human ERBB2 tumour patients (p = 0.00781) and the ER- luminal negative patients 
S ZHUHVWDWLFDOO\VLJQLILFDQWS 
The luminal types of breast cancer exhibit distinct characteristics, features, and 
difference in response to different drugs. Luminal B breast cancer has been reported 
to exhibits worse prognosis as compared to luminal A. The luminal B cancer types 
expresses lower hormone receptors, higher expression of proliferating markers and 
possess higher histological grade than luminal A (Ades, et al., 2014). The ability of 
predicting the outcome in luminal B cancer type patients, present a promising set of 
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biomarkers that could assist in identifying patients with this subtype of breast cancer, 
monitor their treatments, and predict their treatment outcome, thereby, providing 
better prognosis for this type of breast cancer patients. 
 Matboli et al., (2014), used GOBO analytical tool to identify high expression of 
Histidine-rich glycoprotein RNA (HRG) in breast cancer with relative higher 
expression in basal and grade 2 subtypes. This was further validated using reverse 
transciptase PCR (RT-PCR) to monitor the RNA expression level; they concluded that 
the expression pattern for biomarker purposes was 71.7 % sensitive and 93.3 % 
specific. Also the HRG serum protein was analysed using ELISA and an outcome with 
86.7 % sensitivity and 80 % specificity was reported. It was concluded that HRG tissue 
RNA and serum protein could serve as markers for breast cancer prediction (Matboli, 
et al., 2014). Paolicchi et al., (2012) used the GOBO database to analyse the 
expression of different KDM genes as prognostic biomarker for breast cancer in 
several datasets after identifying them from Oncomine.  The output showed KDM5A 
expression to be low in different types of breast cancer and correlated its expression 
pattern to the worse clinical outcome for breast cancer (Paolicchi, et al., 2012).  
These approaches used to identified and validate KDM5A protein is similar to the 
approach used for the search for these candidate genes as breast cancer biomarkers, 
which also included the identification of these candidate genes from the Oncomine 
dataset in the earlier study (Ngoza, 2012). This suggest, that this approach is effective 
in validating biomarkers and the eight candidate genes would probably predict 
correctly the outcome of breast cancer treatment atleast in the luminal B ER+, ERBB2 
ER- and lymph node negative subtype of ER- tumours breast cancer types.  
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3.7: Conclusion 
In recent times, numerous genes that could serve as biomarkers have been identified 
for various cancer types. Several gene expression studies using high-throughput 
technologies have identified expression profiles of sets of genes that showed promise 
as prognostic, predictive biomarkers or both for patients with breast cancer (Fan et al., 
2006). One of the most important processes in the discovery of multiple genes/proteins 
for cancer prognosis is validation of the genes/proteins in clinical outcomes. Often, 
from these list of identified biomarkers, multiple gene products have been linked to a 
specific cancer tissue and their subtypes. However, validating the role of these 
biomarkers in different populations or evaluating competing biomarkers has been a 
herculean task, even though lots of data for these genes are available (Aguirre-
Gamboa, et al., 2013).  
Validating these prognostic or predictive candidate genes in different breast cancer 
cohorts is of great interest (Gyorffy et al., 2009). In silico approach to biomarker 
validation could be a more cost-effective strategy for biomarker development, which 
is typically a fast and cost effective process compared to the traditional methods of 
biomarker validation (Chen et al., 2014).  
From this study, some significant genes that could independently serve as effective 
breast cancer diagnosis, prognosis, or predictive biomarkers were identified using the 
SurvExpress biomarker validation tool. However, the variance in significant genes 
identified from two different datasets from the SurvExpress biomarker analytical tool, 
suggest that a panel of multiple genes will be more appropriate as candidate 
biomarkers for breast cancer than the individual genes. The result confirmed that most 
of the identified genes are differentially expressed in breast cancer and the expression 
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signature of these set of genes could serve as prognostic or predictive indicators in 
breast cancer.  
The outcome of this results also suggest that the expression signature(s) of the 
candidate genes as biomarkers could be specific for different breast cancer types and 
subtype, and indicated effectiveness in accurately predicting the outcome of estrogen 
positive luminal B subtype of breast cancer as well as estrogen negative human 
epidermal growth factor receptor 2 (ERBB2) and the lymph node negative subtypes. 
The current prevailing view is that the most powerful single biomarker of tumours 
have already been discovered, thus, multiple markers will serve a more effective 
purpose as breast cancer markers  (Diamandis, 2004). The differential expression and 
presence of the protein products of these genes in body fluids could provide an easy 
means of monitoring breast cancer, therefore we proceeded to monitor the expression 
of these proteins in cancer and non-cancer cell lines using a molecular approach in the 
subsequent chapter. 
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Chapter 4: Protein expression analysis of identified candidate genes in a breast 
cancer cell line 
4.1 Introduction 
Biomarkers are becoming increasingly important in cancer management because they 
could serve as effective molecular indicators that can be monitored non-invasively in 
readily available bodily fluids from humans. These biomarkers will surely benefit 
cancer patients and clinicians by providing an easy to use point of care device for 
identifying cancer risk, early detection, prognosis, and monitoring SDWLHQWV¶ responses 
to therapeutics (Aebersold et al., 2005). An ideal tumour marker should be easily 
measurable, and presentable in a reliable, cost-effective and easy to use assay format 
with high analytical sensitivity and specificity (Kulasingam and Diamandis, 2008). 
Well characterized biomarkers such as the estrogen receptor (ER), progesterone 
receptor (PR), and the c-erbB2/ HER-2/neu oncogene are used in clinical analysis of 
breast cancer by immunohistochemistry and fluorescence in situ hybridization (FISH), 
using formalin-fixed, paraffin-embedded tumour tissue as samples (FFPE) (Zhang et 
al., 2003). However, these procedures are laborious and time consuming, and present 
a need for identifying biomarkers that are easily accessible as well as non-invasive for 
breast cancer monitoring. 
Proteins are believed to be a better molecule as biomarkers because they are more 
diverse than DNA or RNA and therefore carry more information than the nucleic acids 
(Greenbaum et al., 2003). The gene that produces these proteins could undergo 
alternative splicing and different post-translational modifications, which may result in 
multiple forms of a protein product of a gene in a species. Also proteins are dynamic 
and more reflective of many physiological changes most of which, occur at post-
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transcriptional level and may not be revealed at the nucleic acid level. Proteins are 
also more dynamic and reflective of cellular physiology (Aebersold et al., 2005).  
Cancer as well as many other diseases is caused by pathway perturbations that occur 
as a result of genetic and/ or environmental changes and the effect may manifest in 
altered expression of mRNA transcripts, microRNA, and subsequently the cellular 
protein profile. The alterations in microRNA expression ultimately modulates the 
translation of mRNA transcripts, which subsequently alter the quantity of specific 
proteins shed into the tissue/organ microenvironment, and ultimately end up in the 
bodily fluids (Ahn and Simpson. 2007).  
The expression of altered proteins either in molecular structure or concentration 
produced by either diseased tissues or normal adjacent tissues in response to disease 
stimulus, may get to the peripheral blood circulation for easy sampling through 
processes as simple as venipuncture (Ralhan et al., 2008). Disease-related proteins 
may also be present in other bodily fluids such as urine, saliva, cerebrospinal fluid, 
sweat, cystic fluid, and effusions, most of which can be easily accessed as sample for 
subsequent analyses in the laboratory (Schrohl et al., 2008). The exciting challenge of 
modern proteomics seek to identify such protein signature in diseases, with strong 
believe that if this is met, bodily fluids will become potential bio-specimen sources 
and windows into health and disease. It is hypothesized that the concentration of these 
disease signatures will correlate with the extent or type of cancer that influenced their 
expression and could serve as biomarkers for the early detection of cancer, monitoring 
of cancer progression, and the check of effect and efficacy of drugs (Ahn and Simpson. 
2007). 
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Though high-throughput technologies like microarray and next generation sequencing 
analysis provides a means of identifying differentially expressed genes, it is a known 
fact that not all genes are translated to their protein products (Celis et al., 2000). The 
basic understanding is that, changes in the synthesis of specific transcripts will lead to 
alterations in the expression level of protein products of such genes, but the multitude 
of steps between transcription and translation which provide many different regulatory 
opportunities have proven otherwise (Taylor et al., 2013). Common practice has been 
to equate the expression level of mRNA to the concentrations and activities of the 
corresponding proteins, thereby limiting the analysis of the protein abundance to gene 
expression analysis. However, advances in proteomic techniques have shown this is 
not always the case (Vogel and Marcotte, 2012).  
Different linked processes which include transcription of mRNA, processing, 
degradation of mRNA, translation, localization, protein modification and 
programmed destruction of protein products are involved in the production and 
maintenance of cellular proteins and protein abundance. These processes are 
modulated by various factors (Vogel and Marcotte, 2012). Several recent studies have 
looked at the relationship between gene expression and protein levels. In general, 
these studies have suggested that there are varied reason for lack of correlation 
between the absolute levels of transcripts and their protein products. Differences in 
translational efficiency between transcripts and variations in protein turnover are 
believed to play prominent roles (Taylor et al., 2013; Ning et al., 2012; 
Schwanhäusser et al., 2011).  
Change in cell growth rates, as well as cellular stress are known to directly affect the 
translational efficiency and these changes have been shown to change the relationship 
between mRNA and their corresponding protein abundance in cells (Firczuk et al., 
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2013). In some cases, translational efficiency was strongly linked to alterations by 
environmental factors. For example, environmental alterations was reported to change 
the translation of some mRNA transcripts in yeast, though it was not clear if the 
changes in translational efficiency or protein turnover were at the level of individual 
transcripts or general cellular response to alteration in environmental conditions 
(Taylor et al., 2013).  
In human cancer cell lines and tissue samples, there are varying reports correlating 
protein expression of highly differentially expressed genes to their protein products. 
Shankavaram et al. (2007), reported variations in the level of gene expressed in NCI-
60 cell line and their corresponding protein products, reporting that genes involved in 
maintenance of cellular processes and structural properties showed a stronger 
correlation than other genes in the cell line. It was also stated that genes with 
characteristics such as high codon adaptation indices (CAI), and/ or ribosomal 
occupancy showed higher correlations with the expression of their corresponding 
proteins than the main population of gene products (Shankavaram et al., 2007). 
Assessing the correlation of microarray RNA profiles and their corresponding protein 
products, using immunohistochemistry techniques, of 1066 genes in 23 human cell 
lines, Gry et al. (2009), concluded that only one third of the RNA molecules showed 
significant correlation with their protein (Gry et al., 2009).  
Although gene expression analysis provides an alternative in identifying candidate 
protein biomarkers from identified genes as protein expression is often known or 
predicted from gene expression data, differentially highly expressed genes are not 
always correlated with protein abundance. More so, some proteins are known to 
undergo modification based on influence of cancer development and cannot be 
predicted from genomic data (Zhang and Chan 2007). It is therefore necessary to 
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validate the expression of candidate protein products of putative biomarker genes 
identified from gene expression data. 
Generally protein biomarkers for cancer monitoring are broadly classified into four 
groups as human tumour antigens. Two groups are majorly patient-specific antigens 
arising from either somatic mutations in normal gene products (e.g., BRCA1 and 
BRCA2 gene) or antigens that are generated as a result of mutations related to 
oncogenic processes. These two groups are reported not suitable for general use in 
many patients. A third group is an antigen produced in normal tissue but the levels 
increase in tumours (e.g., PSA in prostate cancer). This class of proteins is common 
in many patients, but is not necessarily tumour specific, but rather tissue specific. The 
fourth and most appropriate group is tumour specific, relates to the general oncogenic 
process and thus is expressed in a wide range of human tumours (Onda et al., 2001). 
Based on reports in literature regarding variation between gene and protein expression 
levels in cancer samples, it is important to analyse the protein expression levels of 
these identified genes. Thus, the protein expression levels of three of the seven 
putative biomarkers identified to be highly differentially expressed when these genes 
were analysed using qRT-PCR in the previous study (Ngcoza, 2012) will be analysed. 
Furthermore, protein expression of Gene 2 (a member of the seven putative gene) and 
Gene 8 an additional putative biomarker for breast cancer identified from this study 
using in silico methods (Chapter 2) will also be monitored in different cell lines. Thus 
the aim of this chapter was to analyse the protein expression levels of these five 
putative biomarkers.     
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4.2 Materials and methods 
4.2.1 Materials	  	  
Table 4.1: List of reagents used and suppliers 
Materials Suppliers 
Acetone Merck 
40% acrylamide Bis solution 37:5:1 Serva 
Beta Actin antibody-HPR conjugated Cell Signalling 
Ammonium persulphate (APS) Merck 
Bacteriological agar Merck 
Bovine Serum Albumin (BSA) Roche 
Bromophenol blue Merck 
Coomassie Brilliant Blue R-250 (CBB) Bio-Rad 
Cytobuster Protein Extraction Reagent Novagen 
Detection Solution Bio-Rad 
Dithiothreitol (DTT) Fermentas 
Donkey Anti-Mouse antibody Santa Cruz 
'XOEHFFR¶V 0RGLILHG (DJOH¶V 0HGLXP
(DMEM) 
LONZA 
Ethylene Diamine Tetra-acetic acid (EDTA) Merck 
Ethanol Merck 
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Fetal Bovine Serum (FBS) Invitrogen 
Geneticin (G418) Sigma 
6X Gel Loading Buffer Fermentas 
Glycerol Merck 
Hydrochloric Acid Merck 
Isopropanol Merck 
Metafectene Transfection Reagent Biontex Laboratories 
Methanol Merck 
Nuclease free water Fermentas 
Penicillin-Streptomycin Invitrogen 
Phosphate Buffered Saline (PBS) Invitrogen 
Potassium Acetate Merck 
Sodium Chloride (NaCl) Merck 
Sodium Dodecyl Sulphate (SDS) Merck 
Sodium Hydroxide (NaOH) Merck 
111¶1¶-Tetramethylethylenediamine 
(TEMED) 
Sigma Aldrich 
Tryptone Merck 
Trypsin Merck 
Tween 20 Merck 
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4.2.2 Solutions and buffers 
Coomasie B rilliant Blue (C BB) staining solution: 0.1 % CBB R-250 in 40 % 
methanol and 10 % acetic acid made up in distilled water. 
Destain Solution: 40 % methanol and 10 % acetic acid made up in distilled water. 
D T T buffer: 2 % (w/v) DTT in SDS equilibration buffer. 
2X Sample buffer: 100 mM Tris-HCL, pH 6.8, 20 % Glycerol, 0.025 % bromophenol 
blue, 4 % (w/v) SDS, and DTT added just before use to a final concentration of 200 
mM. 
10X SDS electrophoresis buffer: 10 g SDS, 30.3 g Tris, 144.1 g Glycine make up to 
1.0 Liter in distilled water, pH 8.4 
10X T BS-Tween: 24.23 g Tris, 87.66 g NaCl, make up in distilled water, pH 7.4 (0.1 
% Tween 20 was added when preparing a 1X solution) solution stored at -200 C 
10X T ransfer Buffer: 30.28 g Tris, 144 g Glycine, in distilled water (20 % methanol 
was added when making 1X solution) solution stored at -200 C 
4 % Paraformaldehyde: 16 g Paraformaldehyde was dissolved in 80 ml of distilled 
water by stirring in fume cupboard on a hot plate, 1 M sodium hydroxide was added 
dropwise till the solution became clear. The solution was allowed to cool down and 
the pH was adjusted to 7. 0. The solution was made up to 100 ml and an equal volume 
of 2X PBS was added. 
4.3 Cell culture 
All cell lines used for this study were from the American Type Culture Collection 
(ATCC). All the cells were cultured in filter-FDSFXOWXUHÀDVNVZLWKWKHLUUHVSHFWLYH
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recommended media and supplements. The cells were incubated at 37 °C in a 90 % 
KXPLGL¿HGDWPRVSKHUHRI&22 till cells reached confluence. 
  Table 4.2: Summary of cell lines used and their respective media composition 
Cell 
lines 
T issue G rowth medium 
A2780 Cervix RPMI, 10 % FBS, and Penstrep 
CaCo2 Colon DEMEM, 10 % FBS, and Penstrep  
HeLa Cervix DEMEM, 10 % FBS, and Penstrep 
HepG2 Liver DEMEM, 10 % FBS, and Penstrep 
HT29 Colorectal DEMEM, 10 % FBS, and Penstrep 
Kmst-1 Normal 
Fibroblast 
DMEM, 10 % FBS and Penstrep 
MCF7 Breast±
pleural 
effusion 
EMEM, 10 % FBS, Penstrep, and 
insulin 
MCF-
12A 
Normal 
Breast 
DMEM-F12, 10 % FBS, Penstrep, 
EGF, Hydrocortisone and Insulin 
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4.3.1 Sub-culturing of cells 
 Cells were monitored every two to three days and media changed before the cells 
reached confluency. To split cells, media were poured off, and cells were rinsed with 
sterile PBS (LONZA) to remove excess media. The cells were subsequently treated 
with 1X sterile trypsin (LONZA) and incubated for a period of 1-3 minutes for cells 
to detach from flasks. Trypsin was de-activated by adding fresh complete medium and 
the cells were pelleted by centrifugation at 3000 X g for 3 min.  The pelleted cells 
were re-suspended in fresh growth medium, split into different flasks at varying 
densities and incubated under the recommended conditions.  
Excess cells were frozen down for storage by suspending cell pellets in 10 % DMSO 
in complete medium, aliquots of about 1.0-1.5 mL were placed in cryotubes and stored 
in a bio-freezer at -150o C.  
4.4 Protein extraction and quantification 
Protein were extracted from cells using the CytoBusterTM Protein Extraction Reagent 
(Novagen) according to the manufacturer instructions. Cells were cultured to 
confluency, after which media was removed from the flask and the flask was rinsed 
with 1X PBS. The recommended volume of CytoBusterTM extraction solution was 
added and the cells were incubated on a shaker (Belly dancer, Stovall Life Science 
Inc., USA) for 5 minutes. After incubation, the cells were scraped from the flask using 
a cell scraper and collected into a 1.5 ml tube. The tubes were centrifuged at 16,000 
X g at 40 C for 5 minutes. The supernatant containing the total protein was collected 
into fresh 1.5 ml tubes and stored at -200 C until required. 
 
 
 
 
   119     
     
4.4.1 Protein quantification 
The concentration of total protein extracted from each of the cell lines was determined 
XVLQJWKH4XELW3URWHLQ$VVD\.LWVIROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
ml tubes were labelled for each protein samples plus extra tubes for the standards. 
Working solutions was made by adding Quant-iT reagent (1 x n) µL with Quant-iT 
buffer (199 x n) µL (n = number of sample tubes + 3 standards) and vortexed for about 
3-5 seconds, while preventing formation of bubbles. The standards were prepared by 
combining 10 µL of standards 1, 2, 3, provided in the kit with 190 µL of working 
solution. The protein samples were prepared by adding 5 µL of the individual protein 
extracts into their labelled tubes combined with 195 µL working solution. Tubes were 
gently vortexed for 3-5 seconds and incubated for 15 minutes at room temperature. 
7KH4XELW ,QYLWURJHQZDV XVHG WR UHDG FRQFHQWUDWLRQ RI the samples after 
taking the readings of the standards. 
4.5 1D SDS-Polyacrylamide Gel E lectrophoresis 
4.5.1 Gel preparation 
One dimensional (1D) polyacrylamide gel electrophoresis was used to separate the 
total protein extracted from each cell line. Glass plates and apparatus (Bio-Rad) used, 
were first cleaned with 70 % ethanol to ensure it was free of acrylamide. A 12 % 
separating gel was prepared with the constituents and volumes as stipulated in table 
4.3. The solution was poured between the gel plates, overlaid with 1 ml isopropanol, 
and allowed to solidify. 
The stacking gel was prepared as stipulated in table 4.4. Once the separating solution 
had solidified, the isopropanol was poured off and the gel rinsed with distilled water. 
TEMED and APS were added to the other components of the stacking gel, a 10 well 
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Bio-Rad comb was inserted and the gel was allowed to solidify. After the gel 
solidified, the comb was removed and the gel was set up in a gel electrophoresis tank 
(Bio-Rad). The tank was filled with 1X SDS running buffer and was pre-run at 100 V 
for 10 minutes to remove any SDS or liquid acrylamide from the wells of the gel. 
 
Table 4.3: Stock solutions for 12 % separating gel solution  
Reagent Volumes 
1.875 M Tris-HCl separating buffer pH 
8.8 
2 mL 
40 % Acrylamide-Bis 3 mL 
10 % SDS 100 µL 
10 % APS 50 µL 
Distilled water 4.84 mL 
TEMED 10 µL 
Total Volume for two plates 10 mL 
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Table 4.4: Stock solutions for 4 % stacking gel solution 
Reagent Volumes 
0.625 M Tris-HCl stacking buffer pH 
6.8 
500 µL 
40 % Acrylamide-Bis 500 µL 
10 % SDS 50 µL 
10 % APS 38 µL 
Distilled water 4 mL 
TEMED 10 µL 
Total volume for two plates 5 mL 
 
4.5.2 E lectrophoresis 
The protein samples were removed from -200 C and left to thaw on ice. Equal volume 
of protein sample with 2X sample buffer was mixed in new tubes and boiled at 950 C 
in a block heater (Stuart Scientific) for 5 minutes. Samples were removed from heater 
and immediately placed on ice, the samples were centrifuged for about 1 minute using 
a benchtop Eppendorf centrifuge at 16,000 X g. Approximate concentrations of each 
sample were loaded onto the polyacrylamide gel and electrophoresed at 110 V for 60-
90 minutes. 
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4.5.3 Gel staining  
After electrophoresis, gels were carefully removed from the plates and stained with 
coomasie staining solution by placing gel in a tray containing the coomasie stain and 
placed on a shaker (Belly dancer, Stovall Life Science Inc., USA) for 45-90 minutes. 
The staining solution was then removed, and the gel destained by placing in destaining 
solution on a shaker for 10-16 hours. Distained gels were viewed and captured with a 
UVP imager (UVP LLC, Biospectrum). 
4.6 Monitoring protein expression using Western blot analysis 
4.6.1 Blot transfer of Proteins onto PV D F membrane 
The protein samples were electrophoresed with the use of the 1D SDS polyacrylamide 
gel electrophoresis as described in section 4.5.2. The protein separated on the 
electrophoresed gels were transferred onto a PVDF membrane (BioTraceTM) using a 
Trans-Blot Turbo transfer system (Bio-Rad), at 7.0 Amp, for 15 minutes. After blot 
transfer, the gel was stained in coomasie blue as described in section 4.5.3, to monitor 
how well the proteins were transferred, while the membrane was further analysed. 
4.6.2 Analysis of individual protein 
The membrane was blocked in 1 % casein in TBS-Tween for 1 hour at room 
temperature. After 1 hour, the membrane was washed three times in TBS-Tween for 
5 minutes on a shaker. After the third wash, individual membranes were incubated in 
their respective primary antibodies diluted as stipulated in their different product data 
sheets, with 1 % casein in TBS-Tween. Membranes were incubated with primary 
antibodies overnight on a shaker at 40 C. The following day, the primary antibody was 
removed and the membrane washed in TBS-Tween three times for 5 minutes for each 
wash. The respective membranes were then incubated with their specified secondary 
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antibodies (diluted 1:500 TBS-Tween) as stipulated in the different product datasheets 
and incubated on a shaker for 1 hour at room temperature. Following incubation, the 
membranes were washed with TBS-Tween thrice for 5 minutes at room temperature 
using a shaker. The membranes were then individually transfered to the UVP-
Biospectrum imaging system (USA), incubated in 2 ml ClarityTM western ECL 
substrate (Bio-Rad), for viewing and the image captured with a UVP-Bospectrum 
imaging system built in camera. 
4.7 Immunofluorescence expression analysis of protein product of the candidate 
genes 
About 1 x 105 MCF7 and MCF-12A cells were seeded in six well plates on a sterile 
cover slip for 24 hours. After 24 hours, the cells on cover slips were wash twice with 
1X PBS. Cells were then fixed in 1 ml 4 % paraformaldehyde for 15 minutes. Cells 
were washed three times for 5 minutes for each wash with 1X PBS, adding 100 mM 
glycine in the second wash. The cells were permeabilized by incubation in 0.1 % triton 
X100 (Sigma) in PBS for 2 minutes, after which cells were washed three times for 5 
minutes each. The cells were then incubated in blocking solution of 1 % BSA in PBS 
for 30 minutes to 1 hour. The blocking solution was removed and the cells were 
incubated for 1 hour with primary antibodies diluted (1:100) in blocking solution. 
After an hour, cells were washed with PBS three times (30 seconds for each wash) 
and then incubated with secondary antibodies diluted (1:200) in blocking solution. 
Cells were then washed three times with PBS before mounting cells with vector shield 
containing DAPI (Sigma), by placing the cover slips with the cells faced down on a 
glass slide.  The slides were left to solidify at room temperature before storage at 40 
C, pending viewing using the Axioplan 2 imaging fluorescent microscope (ZEISS).  
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4.7 Results and Discussion 
The different methods available to analyse gene expression patterns in cancer cells in 
comparison to the patterns in normal cells, such as qRT-PCR, have provided a 
powerful means of analysing total RNA expression patterns in specific cancers. 
However, these methods do not necessarily monitor the expression of the protein 
SURGXFWV RI WKHVH YDULRXV51$¶VThe emerging field of proteomics provides new 
tools for the early detection of cancer from human serum, cerebral spinal fluid, urine, 
saliva, sweat etc., by providing information about the rapid changes that occur 
UHJDUGLQJWKHSURWHRPH¶VG\QDPLFDVDUHVXOWRIGLVHDVHFRQGLWLRQV*RRGet al., 2007).  
However, the direct proteomics approach to biomarker discovery is regarded not to be 
too sensitive. For example, some authors argued that the mass spectrophotometry 
technology approach, which is a major tool in proteomics, FRXOGQ¶W reliably detect 
low-abundant cancer-specific proteins in plasma (Diamandis, 2004). Also other major 
challenges in the proteomics approach in biomarker discovery are reported that 
include the extreme complexity of the plasma proteome, variation in genomes among 
individuals in a population, the changes in the plasma proteome as a result of various 
factors such as sex, age, health status, lifestyle etc., as well as physiological and 
pathological conditions that could influence the proteomic experimental outcome 
other than the putative cancer itself (Zhang and Chan 2007). To validate the candidate 
genes identified as putative breast cancer biomarkers, protein expression of the 
differentially expressed genes from the qRT-PCR analysis (Ngcoza, 2012) and the 
additional two genes identified from further in silico validation of the candidate genes 
(Chapter 2) was monitored in different cancer and non-cancer cell lines using western 
blot analysis.  
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4.7.1: Protein profile analysis of extracted protein from different cell lines 
Figure 4.1 shows the 1D SDS polyacrylamide gel electrophoresis of total protein 
extracted from different cell lines. From the result, the protein bands are not smeared, 
thus are of good quality to be used for the western blot analysis. 
Figure 4.2 shows Western blot analysis using antibody specific for ȕ-actin to analyse 
protein expression in different cell lines. The result shows the proteins were well 
transferred and the protein concentration loaded for MCF-7 and MCF-12A, are 
approximately equal. Beta-DFWLQȕ-actin) is expressed constantly and at high levels in 
all cell types used in protein research, it is therefore used as loading control in protein 
H[SUHVVLRQDQDO\VLVVXFKDV:HVWHUQEORWȕ-actin as the control shows that the proteins 
of interest was loaded equally on a gel, that it is being transferred as well as showing 
that the reagents are functioning normally (Liao, 2000).  
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 F igure 4.2: 1D SDS PAGE of isolated protein from different 
cell lines. 
 
F igure 4.1ȕ-actin expression analysis in different cell lines suing 
western blot 
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4.7.3: Protein expression analysis of Gene 7 (BR G 7) 
Figure 4.3 shows the expression of protein product of Gene 7 (BRG 7). Although the 
protein band was not well pronounced, the result from the western blot analyses 
confirmed expression of this protein in a breast cancer cell line (MCF-7) was higher 
when compared to MCF-12A. The expected molecular weight of this protein is 38 
KDa (shown by the orange box) although it is known to undergo various post-
translational modifications. The result also showed a protein band of higher molecular 
weight common to both the breast cancer and non-cancer cell lines (Figure 4.3). 
Another reported member of the NKG2D ligand family of proteins have been 
described to encode an extra domain whose amino acid sequence is similar to the 
amino acid sequence of the candidate protein of interest (BRG 7), we postulate that 
the higher molecular weight band represent that protein. These two proteins have been 
reported to be co-expressed in cell lines, and are induced by the same stimuli (Ohashi 
et al., 2010). 
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F igure 4.3: Western blot result showing the expression of BRG 7 in different cell lines 
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Gene 7 was annotated using KEGG (see Section 2.4.2) to be associated with pathways 
involving natural killer cells. Natural killer (NK) cells serves as the first line of 
defence against pathogens, cancerous or stressed cells. They expressed specific 
surface receptors that receive signals from the environment and in response, produce 
effector molecules that suppresses tumour growth as well as convey information to 
the immune system for total clearance (Smyth et al., 2002). In disease conditions, the 
active receptor Natural killer (NK) group 2, member D (NKG2D) is expressed on the 
cell surface of NK cells but naive cells do not express this NKG2D protein (Skov et 
al., 2005). The NKG2D receptor recognises some classes of protein ligands that are 
constitutively expressed on some tumour cells as well as viral/bacterial infected cells 
(Skov et al., 2005). 
Also, members of this protein family are known to undergo different post translation 
modification. For example, an ortholog of a member of the protein family in mice was 
reported to undergo post-translation regulation, by ubiquitination on lysine residue 
(Nice et al., 2009). The protein family has also been reported to undergo N-
glycosylation as to get to the membrane surface, and the inhibitor of glycolysis and 
N-linked glycosylation, 2-deoxy-d-glucose (2DG), potently inhibits surface 
expression of their ligands. These are alternate mechanisms used by cancer cells to 
evade immune-detection (Andresen et al., 2012).  
The immunofluorescence analysis of this protein in a breast cancer cell line versus a 
non-cancer breast cell line indicated that this protein is synthesized in the cytoplasm 
and expected to be translocated to the membrane. Based on fluorescent intensity, the 
expression of this protein appears less on the membrane of the cancer cell line as 
compared to the non-cancer cell line (Figure 4.8). The band that is common to both 
cell lines in Figure 4.3 is also suspected to be the protein of interest (BRG 7) that have 
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undergone post-translational modification The post-translational forms of this protein 
could also account for the higher molecular weight band seen in the western blot result 
(Figure 4.3) as well as the seemingly lower membrane expression level in a breast 
cancer cell line. 
Analyzing the expression of the protein products of Gene 3 and Gene 4 using Western 
blot analysis was not successful after several trials (result not shown). It was 
hypothesized that the commercial primary antibodies for these proteins might bind the 
proteins better in their native forms, thus, leading to analyzing the expression of these 
proteins using immunofluorescence. It has been reported that, the interaction between 
a protein and its corresponding antibody may be disrupted by competition with high 
concentrations of the pure epitope itself, as well as high salt concentrations, extremes 
pH, and detergents (Janeway et al., 2001). 
Furthermore, although use of immunoassays in a clinical setting is believed to provide 
a cost effective approach to cancer management, the development and production of 
effective antibodies against identified proteins is known to be a major challenge 
(Zhang and Chan, 2007). Faça and Hanash, (2009), reported that the analysis of the 
proteome of ovarian cancer cell lines indicated that some proteins were predominantly 
in the cell surface fraction, compared with the cell culture medium or to whole cell 
lysates. This is an indication that these proteins of interest may not necessarily be 
abundant in the cell lysate that were used for the western blot analysis and may also 
account for the low intensity of BRG 7 (Figure 4.3) and a need for immunofluorescent 
analysis.  
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4.7.4 Immunofluorescence analysis of the protein products of Gene 3, 4 and 7 
The expression and localization of the protein products of the three highly 
differentially expressed genes (Gene 3, Gene 4 and Gene 7) were analyzed using the 
immunofluorescence analysis. The nuclei of breast cancer and non-cancer cell lines 
were stained with '$3, ƍ -diamidino-2-phenylindole), while the secondary 
antibodies against the primary antibodies had a green fluorophore (Alexa Fluor®448 
from Life Technology) attached to them.  
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F igure 4. 4: Immunofluorescence analysis of BRG 3 in breast cell lines. (a) MCF-7 
(b) MCF-12A (40x magnification) 
 
 
B 
A 
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F igure 4. 5: Immunofluorescence analysis of BRG 4 in breast cell lines. (a) MCF-7. 
(b) MCF-12A (40x magnification). 
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B 
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Figures 4.4 and 4.5, showed proteins BRG 3 and 4 are expressed in both cancer and 
non-cancer cell lines, it would appear the protein expression are more in the breast 
cancer cell lines than the non-cancer breast cell lines, validating the qRT-PCR analysis 
result (Ngcoza, 2012). The protein products of Gene 4 (BRG 4), appears to be more 
localised to the cell membrane of the breast cancer cell line (MCF 7) as compared to 
the breast non-cancer cell line (MCF-12A) (Figure, 4.5 a, b). Also, BRG 3 appears to 
be more on the cell membrane of the breast cancer cell line when compared to the 
non-cancer breast cell line (Figure 4.4 a, b), although a number of the MCF-12A cell 
population shows an increase concentration of the protein localised to the cell 
membrane.  
The localization of the protein product of Gene 7 was also monitored using the 
immunofluorescence assay. Figure 4.8 showed the expression and localisation of the 
protein BRG 7, from the figure, it seems the protein is almost equally expressed in 
both breast cancer and non-cancer breast cell line, but more are localised on the cell 
surface of the breast cancer cell line (MCF 7). However, more analysis needs to be 
done to confirm this. 
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F igure 4.6: Immunofluorescence analysis of BRG 7 in breast cell lines. (a) MCF-7 
(b) MCF-12A (40x magnification) 
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B 
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The protein product of the candidate Gene 7 observed with the Western blot analysis 
(Figure 4.6) is a member of one of the NKG2D groups of ligand found on the 
membrane of disease cells. Membrane bound proteins are attractive biomarker 
candidates because of their potential use in cancer imaging, targeted therapeutic 
strategies, and also they are often shed into the bloodstream, which makes them useful 
FDQGLGDWH¶V IRU HDUO\ GHWHFWLRQ +DUVKD et al., 2009). BRG 7 is known to be an 
anchored protein just like most of the NKG2D ligands family memeber. They serve 
as immune signals in some disease conditions (González et al., 2008).  
In evading detection by the immune system, cancer cells are known to shed off some 
membrane proteins especially immune signaling proteins (Hanahan and Weinberg). 
Some of the NKG2D ligands have also been reported to be shed off the surface of 
cancer cells for the cells to evade the immune system. Wang and Sun (2014), reported 
that, the NK cells stimulates the shedding of some of these ligand proteins in response 
to cancer treatment (Wang and Sun, 2014) which further validates that a member of 
this group of protein would be a good candidate biomarker for cancer progression and 
effective therapeutics monitoring.  
4.7.5: Protein expression analysis of Gene 8 (BR G 8) 
Figure 4.7 showed the expression level of BRG 8, the protein that was reported to 
interact with BRG 7 and annotated to regulate ESR (see Section 2.4.6), using an in 
silico method (Chapter 2). Interestingly, the protein was not expressed in the breast 
and colon cancer cell lines but found to be expressed in a non-cancer breast cell line 
(Figure 4.7). Annotation of this protein showed it could also be a membrane protein 
that modulates the expression of estrogen receptors. Estrogen receptor (5Į-positive 
primary breast tumours account for more than 70 % of all cancer cases and this protein 
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is inhibited in breast tumours resistance to hormone therapy drugs and tumour cells 
involved in breast cancer progression (Kim et al., 2013). 
The reason for the breast and colon cancer cell lines not expressing this protein is not 
known as it is expected to be expressed in breast cancer, however, the differential 
expression of this protein could be a good candidate biomarker for tamoxifen 
resistance breast cancer patients. The protein has been reported to be in blood 
circulation and higher in cancer patient than non-cancer patients (Sievers et al., 2006). 
Tamoxifen is a synthetic anti-estrogen drug used as standard treatment for patients 
with ERĮ-positive breast cancer. The drug serve as a selective ER modulator by 
directly inhibiting the interactions of estrogen (E2) and the ERĮUHFHSWRUKRZHYHU
tumours often develop resistance to this drug. Although, the mechanisms by which 
tumours develop resistance is yet to be defined. The mechanism could include ERĮ
modulating proteins that are co-regulated and the link between the ERĮSDWKZD\DQG
other growth factors and kinase networks (Yoshimaru et al., 2013).  
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F igure 4.7: BRG 8 expression analysis in different cell lines using western blot analysis
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4.7.6 Protein expression analysis of Gene 2 (BR G 2)  
Figure 4.8 shows the expression of BRG 2, the protein product of Gene 2, the gene of 
this protein was amongst the seven candidate genes identified from the earlier work 
(Ngcoza, 2012). This gene though not highly differentially expressed from the qRT-
PCR analysis (Ngcoza, 2012), was found using in silico functional analysis (Chapter 
2) to be involved in different processes linked to breast cancer in particular and cancer 
in general.  
The protein was expressed in all cancer types used for the western blot analysis. This 
could be the reason why the gene did not show differential expression in the qRT-
PCR analysis (Ngcoza, 2012), however it seems the protein is cleaved in the non-
cancerous breast cell line as it is presented as an extra band in the Western blot 
analysis.  This protein is a multifunctional endoplasmic reticulum protein that has been 
reported to play a major role in intracellular calcium storage and transfer as well as 
other functions like chaperoning and adhesion (Lwin et al., 2010).  
This protein is reported to interact with ERĮWRSUHYHQWFDQFHUFHOOLQYDVLRQLQEUHDVW
cancer and also reported as a contributing factor in the role of thrombospondin-1 in 
invasion (Platet et al., 2000). It is also reported in literature, that molecular chaperones 
(a function family of protein which BRG 2 belongs), may also induce a humoral 
immune response and generate autoantibodies that could serve as cancer biomarkers 
for screening, diagnosis, as well as in immunotherapy (Kabbage et al., 2013). Thus, 
this protein is expected not to be highly expressed in cancer cells or modulated to 
prevent it from carrying out its anti-cancer functions. However, the expression pattern 
needs to be further investigated to validate it for use as a breast cancer biomarker. 
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F igure 4. 8: BRG 2-protein expression analysis in different cell lines using western blot analysis. 
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4.9: Conclusion 
From the protein expression analysis using the Western blot procedure, it was 
demonstrated that the protein products of the genes of interest are expressed and there 
was an indication that certain proteins may be differentially expressed. BRG 3 and 
BRG 4 were not successfully demonstrated to be expressed using the Western blot 
analysis, however the proteins are shown to be expressed using immunofluorescence 
analysis. The immunofluorescence analysis confirms BRG 3, BRG 4 and BRG 7, the 
protein products of the three highly differentially expressed genes in the previous 
study (Ngcoza, 2012) as membrane bound and would probably be shed into the bodily 
fluids. BRG 8, which was identified from the in silico validation study (Chapter 2), 
was shown to be expressed in other cell lines except the breast and colon cancer cell 
lines.  
It was exciting to observe that this protein which was identified to directly interact 
with BRG 7 seem not to be highly expressed in the breast cancer cell line. The 
presence of these proteins however, would have to be looked at in the culture media 
of these cell lines, this will serve as a strong indication that they are shed off by breast 
cancer cells at some point of progression and could be present in the serum of breast 
cancer patients. The detection of cancer biomarkers in plasma and other bodily fluids 
using immunoassays provides a cost effective approach to cancer diagnosis (Zhang 
and Chan 2007). Antibodies that target these specific biomarker proteins can be used 
to develop easy to use point of care devices for early detection as well as tools to 
complement existing methods for effective management of breast cancer. However, 
further molecular validation needs to be done to validate these proteins and how well 
they can serve as breast cancer biomarkers.  
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Chapter 5: Establishing stable transfected breast cell lines for over-expression 
and silencing of BR G 7  
5.1 Background 
The innate immune system LVWKHILUVWOLQHRIWKHERG\¶VSK\VLRORJLFDOGHIHQVHDJDLQVW
cancer and the natural killer (NK) cells, are central to mediating this type of immune 
system which can impede tumour growth through the process of immune surveillance, 
identifying tumour cells and destroying them (Crane et al., 2014). The NK cell is 
activated when a specific surface receptor such as the Natural killer group 2, member 
D (NKG2D) receptor identifies and binds its ligand expressed by tumour cells. This 
ligation results in the production of cytokines and the release of cytotoxic granules 
that cause tumour lysis (Orr and Lanier, 2010; Crane et al., 2014). Therefore tumour 
cells expressing ligands for the NKG2D receptor are susceptible to NK killing 
The NKG2D ligands include MHC class I polypeptide-related sequence A (MICA), 
MHC class I polypeptide-related sequence B (MICB), and UL16-binding proteins 1±
6 (ULBP1-6). They are known to be highly expressed by any type of cell under stress 
as well as cancer cells (Critchley-Thorne et al., 2009). There are various studies and 
reports highlighting the mechanisms by which NKG2D ligands could be involved in 
immune evasion in different tumour types and whether the detection of these ligands 
on circulating monocytes in cancer patients could provide useful biomarkers to either 
monitor cancer at different stages or monitor relapse (Crane et al., 2014).  
Mice that lack the MIC genes but express retinoic acid early inducible-1 (RAE-1) 
protein, a homologous protein of ULBP, H60 and murine ULBP-like transcript 1, have 
been used to demonstrate that sufficient high levels of expression of the NKG2D 
receptors could stimulate cell death. Suggesting that related NKG2D ligands 
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expression could be expressed even when the expression of the MHC class I is normal 
(Skov et al., 2005). RAE-1 transfected cancer cells were eliminated in vivo by NK cell 
compared to parent cells that were not expressing RAE- DOVR Ȗį 7-cells were 
reported to kill skin cancer cell by the NKG2D (Skov et al., 2005). These reports 
strongly suggest a role for NKG2D/NKG2D ligand interaction in tumour rejection and 
surveillance (Skov et al., 2005). 
Soluble NKG2D ligands are believed to be release by tumour cells and some have 
been identified to serve as markers for tumour prognosis (Wang and Sun, 2014). For 
example, Kaiser et al., (2007), reported that most epithelial cancer cells express large 
amounts of MICA on the cell surface, although the late-stage human tumours sustain 
the surface expression but shed off this NKG2D ligand, which negatively impact on 
the systemic immune response, thereby promoting tumour immune evasion (Kaiser et 
al., 2007).  
The presence of the soluble MICA could thus serve as biomarker for cancer diagnosis 
and prognosis. Also, it was reported that pharmacological inhibition of thioreductase 
and the modulation of endoplasmic reticulum protein (ERp5), a protein that associates 
with MICA could regulate MICA shedding and ERp5 could serve as a marker and 
target for therapeutic intervention (Kaiser et al., 2007). Also activation of heat-shock 
transcription elements in the promoters of corresponding genes is believed to lead to 
upregulated expression of MICA and MICB in many tumour-cell lines and primary 
tumours of epithelial origin (Raulet, 2003).  
NKG2D ligands are also reported to be involved in modulating the NKG2D-related 
effector functions. Groh et al., (2002), reported a 60-70 % reduction in expression of 
NKG2D on CD8+ T cells from MIC positive tumour infiltrating lymphocytes, 
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extracted from epithelial tumours. Whereas none of the 13 MIC-negative tumour 
specimens that were examined, had their NKG2D expression altered when compared 
to normal control peripheral blood monoclonal cells.  
Also cisplatin and interleukin 2 (IL-2) have also been demonstrated to enhanced 
apoptosis and growth inhibition when used as combined therapy in head and neck 
cancer. The combined therapy showed a synergistic interaction between cisplatin and 
IL-2, which resulted in NKG2D-based cytotoxicity increasing tumour specific lysis 
from CTLs and NK cells (Li et al., 2002). Wang and Sun, (2014), showed that NK 
cell/ apoptosis induced cell surface shedding of ULPB protein ligands through the 
action of metalloproteinase and concluded that compounds inhibiting NKG2D ligand 
shedding may offer therapeutic means by reducing excessive pathogenic NK cell 
activities. 
Considering the important role of NKG2D ligands in modulating the effect of NKG2D 
related effector functions and the great possibility of them being in bodily fluid as a 
result of cancer cells shedding them to evade detection, it is worthwhile to look at the 
effect of modulated expression of Gene 7 and its protein product in breast cell lines. 
From the early study, Gene 7 a NKG2D ligand was detected to be the most highly 
differentially expressed gene in a breast cancer cell line (Ngcoza, 2012). Also, earlier 
in silico analysis (Chapters 2 and 3) suggest that this protein shows a great promise as 
a biomarker for monitoring breast cancer.  
The success in gene sequencing and the ability to identify, predict and characterize 
their expression pattern in disease conditions has led to the need to study their role in 
tissue functions. Major approaches used to study gene function, such as gene knockout 
in murine subjects, are expensive, time consuming and cannot be applied to human 
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tissues (Rubinson et al., 2003).  The advent of the RNA interference technology 
(RNAi), have provided the means of analysing gene functions in primary mammalian 
cells. This approach used to silence a gene of interest, is fast, more cost effective, and 
can be easily adapted to study homologous gene function in a wide variety of 
organisms (Stewart et al., 2003).  
Three mediating methods that are used to achieve an RNAi effect in mammalian cell 
lines include; small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-
functional shRNA (Rao et al., 2009). The siRNA is the easiest construct to produce 
and it provides an effective easy means for transient monitoring of silenced genes. 
However, using optimized shRNA constructs that will be processed by endogenous 
RNAi processing machinery, allow for high potency, sustainable effects using low 
concentration, and less off-target effects. The Bi-function shRNA constructs may 
provide a more enhanced potency of gene silencing, but poses the challenges of 
tumour selective delivery vehicles and a means for off-target effect evaluation (Rao 
et al., 2009).    
Vector based shRNA delivery has also been reported to provide in vivo RNAi 
effectiveness in mammalian cells (Tong et al., 2005). In vivo studies make use of many 
delivery methods, however lentiviral vectors are increasingly becoming the method 
of choice for shRNA delivery in mammalian cell transfection. This is because, the 
virus has the ability to stably integrate into the host cell genome (Cooray et al., 2012). 
Another advantageous feature of lentivirus vectors is the ability to mediate potent 
transduction in stable transfected cells in dividing and non-dividing cells both in vitro 
and in vivo (Castanotto and Rossi, 2009). 
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Several studies have shown successful use of lentiviral vectors for the delivery of 
shRNA constructs in different mammalian systems some of which include: the down-
regulation of an activated Ras oncogene, which was achieved using a lentiviral-
delivered shRNA (Brummelkamp et al., 2002), expression of superoxide dismutase 1 
(SOD1) was down-regulated in mouse models of amyotrophic lateral sclerosis using 
shRNA delivered using a lentirus (Raoul et al., 2005), also a lentiviral vector was used 
to deliver a shRNA that targets smad3 protein for regeneration of satellite cells and 
repair of old and injured muscle (Carlson et al., 2008). 
Another important approach to study a protein function is to express it in its actual 
post-translational modified forms, as these contribute to its biological activity 
(Panavas et al., 2011). Although mammalian proteins have been successfully over-
expressed in bacteria, yeast, or insect cells, mammalian cell culture system still remain 
the system of choice because it allows for specific protein post-translation 
modification (Varakala 2008; Panavas et al., 2011). Most mammalian secreted and 
membrane bound receptor proteins often possessed compulsory post-translational 
modifications that may include disulphide bonds and glycosylation that aid protein 
proper folding as well as biological activity (Dalton and Barton, 2014). 
Generally mammalian cells over-expressing a protein of interest can be constructed to 
be transient or stable expression system. Transient expression systems allows protein 
production within a few days after the mammalian cell line have been transfected with 
expression plasmid, whereas stable cell lines takes a longer time to develop (Andréll 
and Tate, 2013). However, stable over-expressing mammalian cell lines, provides a 
source that can be stored and reused over a long period, providing a source for multiple 
analysis and a medium to study the effect of a specific protein over-expression (Dalton 
and Barton, 2014)  
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F igure 5. 1: SF'1$9-His TOPO® cloning vector map (Invitrogen) 
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Table 5.1: TOPO® cloning reaction setup 
Reagent Quantity added 
Fresh PCR product (10ng/ml) 2 µl 
Salt solution 1 µl 
Sterile water 2 µl 
SF'1$7232YHFWRU 1 µl 
Total 6 µl 
 
5.3.7.3: T ransformation of ligated product 
The One Shot® TOP10 chemically competent E . coli cells provided in the cloning kit 
(Invitrogen) as well as freshly prepared LB plates containing 100 µg/ml of ampicillin 
were used for this step of the cloning process according WR WKH PDQXIDFWXUHU¶V
instructions. A vial of the One Shot® TOP10 was thawed on ice, 2 µl of the cloned 
reaction solution from the previous step was added and mixed gently. This reaction 
was incubated for 30 minutes on ice, after which, the cells were heat shocked for 30 
seconds at 420 C without shaking, and the tube was immediately transferred to ice. 
250 µl of room temperature SOC medium (Invitrogen) was added, and the tube was 
incubated while shaking horizontally at 370 C for one hour. 100 and 200 µl of the 
transformation solution was plated onto two different freshly prepared LB plates 
containing ampicillin, and the plates were incubated overnight at 370 C. Different 
colonies were picked from each plates for further analysis. 
5.3.7.4: Colony PC R 
The colonies were screened for the presence of the insert with the use of colony PCR. 
Ten different colonies were randomly picked from the transformed plates and 
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suspended in 5 µl of nuclease free, double distilled sterile water and this was used as 
a template for the PCR reaction. The parameters for the PCR were the same as 
previously described in section 5.3.4, using the 2X KAPA Taq Extra Hotstart 
ReadyMix with dye. Two positive clones were sent to Inqaba Biotec for sequence 
analysis. 
5.3.8: Gene K nock down analysis 
5.3.8.1: shRN A constructs	  
Short hairpin or small hairpin RNA (shRNA) were used for the knock down study. 
Glycerol stocks of five constructs of different shRNA sequences that target different 
parts of Gene 7 was purchased from Sigma Aldrich (MISSION shRNA). Each shRNA 
is cloned into the pLKO.1 lentivirus puro vector (Figure 5.2). 
 
F igure 5.2: TRC1 and TRC1.5 Lentiviral Plasmid Vector pLKO.1-puro (Sigma 
Aldrich) 
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5.3.8.2: Isolation and culture of shRN A plasmid from glycerol stocks 
The vials of glycerol stock representing the individual shRNA constructs, were gently 
spin down, and ice splinters of the frozen bacterial glycerol stock was removed from 
the vials using a sterile loop. The ice splinters was placed into a sterile culture tube 
containing 0.5 ml of LB without antibiotics, and the culture incubated at 370 C on a 
shaker for 30 minutes. 35 ml of the incubated culture was plated onto freshly prepared 
Luria broth (LB) plates containing 100 mg/ml ampicillin, and the plates were 
incubated over night at 370 C. Single colonies were picked from the plates and 
inoculated into a LB containing 100 µg/ml of ampicillin. The plasmid DNA were 
isolated from the overnight cultures broth. 
5.3.8.3: Restr iction endonuclease analysis 
A double restriction enzyme digestion was used to confirm the isolated plasmid 
shRNA from the glycerol stocks. An in silico digestion was first carried out using 
Biolabs NEBcutter V2.0 (Vincze, et al., 2003) to predict the number of expected bands 
and sizes from the digestion. The vector sequence (pLKO. 1-puro) was downloaded 
from the manufactural site (Sigma Aldrich) https://www.sigmaaldrich.com/ and the 
shRNA sequences were inserted into the vector sequence. The combined sequence 
were pasted in the box provided at the software site http://nc2.neb.com/NEBcutter2/, 
two restriction enzymes (BamH1 and EcoR1) that do not have restriction sequence for 
the shRNA were selected, DQG ³VXEPLW´ to carry out the analysis. The output was 
IXUWKHU DQDO\VHG E\ VHOHFWLQJ WKH ³YLUWXDO LPDJH´ WR JHW D YLUWXDO LPDJH RI
electrophoresed digest, webpage was snapshot and image stored (result not shown). 
Restriction enzyme digestion was then carried out in the laboratory using the BamH1 
and EcoR1 fast digest from Fermenters according to manufDFWXUHU¶VLQVWUXFWLRQ7KH
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reaction solutions were set as described in table 5.3.8. The solution was gently mixed, 
and incubated at 370 C and incubated for 60 minutes. The enzymes were deactivated 
by heating the solution at 800 C for 5 minutes. 
 
Table 5.2: Double digestion set up of shRNA plasmid DNA 
Reagents Volume 
Nuclease free water 31 µl 
10X Fast digest buffer 5 µl 
Plasmid DNA (up to 1µg) 10 µl 
Fast digest enzyme1 
(BamH1) 
2 µl 
Fast digest enzyme2 
(EcoR1) 
2 µl 
Total  50 µl 
 
5.3.9: Plasmid DN A isolation (pcDN A and shRN A containing plasmid) 
The plasmid for both cloned pcDNA and the shRNA glycerol stocks were isolated 
using the Wizard® Plus SV Minipreps DNA purification system (Promega), according 
WRWKHPDQXIDFWXUHU¶VLQVWUuctions. Colonies from the pcDNA clone for expression and 
shRNA plates were inoculated in 50 ml LB containing 100 µg/ml ampicillin, and 
cultured overnight at 370 C with shaking. The bacterial cultures were harvested by 
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centrifuging 10 ml of LB culture for 10 minutes at 3500 X g. The supernatants were 
removed and the tubes were blotted on paper towels. The pelleted cells were re-
suspended in 250 µl resuspension solution by gentle pipetting after which, 250 µl of 
cell lysis solution was added and the solution gently mixed by inverting the tubes four 
times and the tubes incubated for 5 minutes. 10 µl alkaline protease solution was added 
to the solution and gently mixed by inverting the tubes four times before incubating 
for 5 minutes at room temperature.  
The action of the alkaline protease was stopped by adding 350 µl neutralization 
solution and immediately mixed by inverting the tubes 4 times. The bacterial lysate 
was centrifuge at 14000 X g for 10 minutes at room temperature. A column provided 
in the extraction kit was placed in a collection tubes and the cleared lysate transferred 
into the column. The tubes containing the columns were centrifuged for 1 minute at 
maximum speed, the flow through was discarded, the column re-inserted into the tubes 
and 750 µl of column wash was added. The tubes were centrifuge at maximum speed 
for 1 minute, the flow through discarded and the wash repeated with a 250 µl of 
column wash buffer and centrifuged for 2 minutes at maximum speed. The columns 
were transferred into  new, sterile 1.5 ml micro centrifuge tubes, and the plasmids 
were eluted with 100 µl nuclease free water, by adding the water to the column and 
centrifuge the tubes at maximum speed for 2 minutes. The isolated plasmid were 
electrophoresed on 1 % agarose gel as described in section 5.3.5 and the remaining 
stored at -200 C until required for further analysis.      
5.3.10: T ransfection of isolated plasmids 
The pcDNA cloned plasmid and different constructs of shRNA of the gene of interest 
were transfected into a breast cancer cell line (MCF-7) and non-cancer breast cell line 
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(MCF-12A) using the Metafectene® Transfection Reagent for Mammalian Cells 
%LRQWH[DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
About 2 x 105 cells were seeded into six well plates and left to grow to about 70 % 
confluency. Two separate solutions comprising the plasmid DNA and the metafectene 
transfection reagent were made in serum free media. Solution A comprises 1 µg of 
DNA in 50 µl of serum and antibiotic-free medium and solution B comprises, 3 µl of 
mectafectene in 50 µl of serum and antibiotic-free medium. The solutions were mixed 
gently separately by pipetting and combined without any mixing. The mixture was 
incubated at room temperature for 25 minutes. After the incubation, the mixture was 
added drop wise to the cells, with gentle swirling, and returned into the incubator for 
4 hours, after which complete media was added and the cells incubated for 24 hours.  
5.3.11: Selection of stable transfected cells 
Media with transfection reagent and plasmid DNA was removed after 24 hours of 
incubation of the cells, cells were rinse with sterile PBS, and fresh complete media 
containing antibiotics G418 and puromycin, expressed by the respective vectors. The 
pcDNA clones were treated with 800 µg/ml G418 (Roche), while the shRNA 
constructs were treated with 2 µg/ml Puromycin (Gibco®). Media containing these 
antibiotics were added to the respective transfected cells and the media changed 
regularly every 48 hours until all the cells in the control wells (cells not transfected 
with plasmid) were all confirmed dead. The selective media were then replaced with 
complete media into all wells including control wells, and media were changed every 
48 hours until transfected cells grow to 70-90 % confluence and no cell growth was 
seen in the control wells. Once wells were confluent, the cells were trypsinized and 
sub-cultured in a 25 cm2 flask for further analysis. Transfected cells were monitored 
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using a light microscope (Nikkon TMS) and images captured using a Leica EC3 
camera (Leica Microsystem Switzerland). The total protein was extracted and western 
blot analysis of BRG 7 was carried out as described earlier in section 4.6, to confirm 
over-expression and ³knock down´. 
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5.4: Results and Discussion 
5.4.1: Polymerase Chain Reaction (PC R) of cDN A using the two sets of primers 
Figure 5.3 shows the PCR products of the two sets of primers (A and B) used to 
DPSOLI\F'1$¶VIURPGLIIHUHQWEUHDVWFHOOOLQHV7KHILJXUHVKRZHGWKHH[SHFWHGVL]H
of the gene (741bp). PCR amplification was then repeated using primer A and cDNA 
from MCF-12A, the PCR product was electrophoresed (result not shown). The DNA 
(PCR product) was extracted from the gel and cloned into the pcDNA3.5 TOPO 
vector. The ligated products was used to transformed TOP10 bacterial competent cells 
(invitrogen).  
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F igure 5.3: PCR amplification of Gene 7 with cDNA from different breast cell lines using two sets of primers.
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5.4.2: Colony PC R 
Transformed bacterial cells, following cloning, were streaked onto two LB plates 
containing ampicillin antibiotics. The plates were incubated for 24 hours at 370 C and 
five individual colonies from each plate were selected and used for colony PCR. 
Figure 5.4 showed the electrophoresed PCR products of the five different colonies 
taken from the respective LB plates. Columns represent PCR products of five colonies 
taken from two different plates representing transformed bacteria cells of clones of 
Gene 7. 
Plasmids that express the BRG 7 protein were successfully cloned and confirmed 
using the colony PCR (Figure 5.4). Colonies that were successfully transformed with 
the gene of interest were screened using the gene specific primers thus expecting a 
PCR product of 714 bp. First column represents the negative control without any 
template (bacterial cells) but water. The columns that showed specific bands of the 
expected product size of Gene 7. Colonies 6, 7, 8 and 10 were sent for sequencing at 
Inqaba Biotec to confirm that the gene of interest was successfully cloned into the 
vector. Products of colony 7 and 8 showed 99 % similarity in sequence to the gene of 
interest using the NCBI nucleotide blast tool (BLASTn). The DNA sequence result 
received from Inqaba Biotec was translated into the protein sequence using the 
ExPASy nucleotide-translating tool (www.expasy.org) and was confirmed to be the 
protein of interest by blasting the protein sequence against sequences in the NCBI 
database using BLASTp tool and colony 8 were used for further analysis after 
isolating plasmid DNA. 
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F igure 5.4: Colony PCR products of transformed bacteria cells electrophoresed on a 1 % agarose gel
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5.4.3: Isolation of plasmid DN A from shRN A glycerol stocks 
Figure 5.5 shows the isolated plasmid DNA carrying shRNA constructs against the 
gene of interest. The plasmids were isolated from glycerol stocks of the PLKO.1 
lentivirus clones of three different shRNAs that target different regions of Gene 7 
(Sigma Aldrich). Lentivirus vectors have been reported to be an efficient delivery tool 
of short hairpin RNAs (shRNAs) in transformed and primary cells for effective 
silencing of target genes (Rubinson, et al., 2003).  
The figure confirmed plasmids were successfully isolated from the glycerol stock and 
the plasmid DNA are of the expected molecular weight according to the manufacturer 
product sheet (Sigma Aldrich).   
To further confirm the isolated plasmids as the PLKO.1 vector with inserted shRNAs, 
endonuclease digestion was performed after an in silico digestion analysis using the 
NEBcutter software (Biolabs), using BamH1 and EcoR1 restriction endonucleases. 
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F igure 5. 5: Electrophoresed plasmid DNA of five different shRNA construct that targets Gene 7 
 
 
 
 
 
 
   161     
     
 
 
 
F igure 5.6: Endonuclease digestion of plasmid shRNA digested using BamH1 and 
EcoR1. Digested reactions electrophoresed on 1% agarose gel. 
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Figure 5.6 shows the electrophoresed products of double digestion of restriction 
endonucleases BamH1 and EcoR1 respectively. The number of bands and their 
approximate sizes of the virtual gels generated from the in silico analysis using the 
NEBcutter software (results not shown) were similar to the double digestion analysis 
using BamHI and ECORI endonucleases. This confirms the glycerol stocks contain 
samples of the pLKO.1 vector constructs with the different shRNA targets and could 
be used for further analysis. 
5.4.4: C reating stable transfected cell lines 
The breast cancer cell line MCF-7 and breast non-cancer cell line MCF-12A were 
transfected with the different constructs for protein over-expression (pcDNA clone) 
and knockdown (shRNAs constructs). Figures 5.7 and 5.8 shows transfected MCF-
12A and MCF-7 transfected cells respectively after selection with appropriate 
antibiotics. The breast non-cancer cells (MCF-12A) showed a change in cell 
morphology and inhibition in growth in cells transfected with the clone for protein 
over-expression (figure 5.7). However, the over-expression of the BRG 7 protein seem 
not to affect the morphology of the breast cancer cell line (MCF-7) (figure 5.8). This 
suggests WKHSURWHLQSOD\VDQLPSRUWDQWUROHLQFHOOJURZWKDQGLW¶VRYHUH[SUHVVLRQ
may lead to cell senescence in normal cells.
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F igure 5.7: Breast non-cancer (MCF-12A) cell lines (a) normal MCF-12A un-transfected cell line (b) stable transfected MCF-12A cell 
line over-expressing BRG 7 protein. 
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F igure 5.8: Breast cancer (MCF-7) cell lines (a) normal MCF-7 un-transfected cell line (b) stable transfected MCF-7 cell line over-
expressing BRG 7 protein  
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Increased NKG2D ligand expression is regulated by activation of DNA damage. DNA 
damage leads to cell apoptosis and a senescence-like phenotype cell in response to 
most of the chemotherapeutic agents commonly used in clinical trials (Soriani et al., 
2009). A major feature of senescent cells that distinguishes them from most quiescent 
cells, is a large flattened morphology and high expression of senescent-associDWHGȕ-
galactosidase activity. They are also known to down-regulate genes involved in 
proliferation and extracellular matrix production and up-regulate inflammatory 
cytokines as well as other molecules known to modulate the immune response 
(Krizhanovsky et al., 2008).  
The MCF-12A cells ceased growing after the first passage, and the total protein 
extracted was very low. This could be as a result premature and spontaneous aging of 
the cell due to BRG 7 over-expression.  Like most cells undergoing senescence, the 
transfected MCF-12A cells showed a striking change in morphology. They became 
flat, and multinucleated. A flat cell phenotype is commonly seen in cells undergoing 
H-ras induced senescence (Kuilman et al., 2010). 
Abnormal expression of H-ras in normal fibroblast has been shown to result in a cell 
senescence type that is very similar to replicative senescence (Mason et al., 2004). 
Cellular senescence leads to permanent cell cycle arrest that limits the uncontrolled 
proliferation and tumourigenesis of cells (Reddel, 2000). Senescence was first 
observed in replicative cultured human fibroblast cells that exhausted their replicative 
potential after a number of cell division and this was termed replicative senescence 
(Mason, et al., 2004). However, studies have shown that senescence can be triggered 
not necessarily by number of cell division or length of telomere, but also by various 
types of stress induced by various types of compounds and molecules and this type of 
senescence is referred to as premature senescence (Shay and Roninson, 2004). 
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Figures 5.9 and 5.10 VKRZVLPPXQREORWVRI%5*SURWHLQDQGȕ-actin respectively 
in stable transfected MCF-7 and MCF-12A cell lines. The ȕ-actin immunoblot result 
(figure 5.10) showed the proteins are well transferred and the protein concentration 
loaded are adequate. Figure 5.9 immunoblot showed the expression of the protein to 
be higher in pcDNA cloned transfected MCF-7 cell line compared to the MCF-12A 
cell line. Also, the blot showed the gene expression ZDVVXFFHVVIXOO\³NQRFNHGGRZQ´
in both MCF-7 and MCF-12A transfected with the shRNA constructs. 
The over-expression of the BRG 7 protein in cancer cell line and non-cancer breast 
cell line transfected with pcDNA vector clone and those transfected for gene ³knock-
down´ were confirmed using the western blot analysis. Unlike the non-cancer breast 
cell line (MCF-12A), that showed the cells becoming senescent as a result of over-
expression of the protein, the MCF-7 cells did not present any visible physiological 
change after transfecting them with both clones for over-expression as well as those 
IRU ³NQRFNGRZQ´+RZHYHU D ORQJHUSHULRGRI WLPHZDV UHTXLUHG IRU VRPHRI WKH
shRNA construct transfected cells to grow back after transfection. This suggests that, 
though the over-expression of this protein may initiates cell senescence; its basal 
expression might be needed for normal cell growth.    
One of the characteristics of cancer cells is their ability to overcome senescence, and 
one of the mechanisms suggested by which cancer cells overcome growth restriction 
posed by senescence is by overcoming the cell autonomous blockade placed to cause 
senescence in oncogenic damaged or stressed cells, though it is not so clear how 
tumour cells overcome this regulatory phenomenon (Rodier and Campisi, 2011). 
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F igure 5.9: :HVWHUQEORWDQDO\VLVRIWUDQVIHFWHGFHOOVIRUJHQH³NQRFNGRZQ´DQGSURWHLQover-expressing BRG 7 in MCF-7 and MCF-
12A cell lines. 
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F igure 5.10: ȕ-actin expression analysis in non-transfected and transfected cell lines.
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5.6: Conclusion 
Clones that express BRG 7 protein of interest was successfully generated, the plasmid 
isolated and transfected into breast cancer cell line (MCF-7), and breast non-cancer cell 
line (MCF-12A). Also plasmid DNA representing different shRNAs that target BRG 7 
were isolated from commercially available glycerol stocks from Sigma Aldrich, and were 
successfully transfected into MCF-7 and MCF-12A cell lines.  
Western blot analysis confirmed higher expression of this protein in the breast cancer cell 
line (MCF-7) and non-cancer cell line (MCF-12A). The over-expression in MCF-12A 
cell line resulted in the cell going into senescent, characterized by stop of cell growth and 
change in cell morphology. It seems the breast cancer cell line may have a way to 
overcome the senescence induced by the over-expression of BRG 7. However, further 
analysis is required to confirm this. 
Thus, further effect of over-expression of BRG 7 and its repression in enhancing 
chemotherapy induced apoptosis, was monitored in the breast cancer cell line in the next 
chapter.  
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Chapter 6: E ffect of the N K G2D ligand on apoptosis induction in breast cancer 
6.1: Background	  
Programmed cell death or apoptosis is essential for the development of metazoans and 
the development and maintenance of cellular homeostasis of the immune system in 
mammals (Henson and Hume, 2006). It is a genetic process of cell death that responds to 
both normal and pathological stimuli (Opferman and Korsmeyer, 2003). One of the 
mechanism by which apoptosis is exerted on the target cell is by exocytosis. The granules 
from the cytoplasm of the NK cell are transferred into the target cells. Also the interaction 
of the Fas ligand (FasL) or Tumour Necrosis Factor (TNF) on the Natural Killer (NK) 
cell with Fas (CD95) or TNF receptor on the tumour target cells could be employed. The 
NK cells themselves can also undergo apoptosis following the interaction of certain NK 
receptors with the target cells (Snow et al., 2010). 
The innate immune cells, which include the natural killer (NK) cells, play an important 
role in tumour regression (Textor et al., 2011). NK cells are activated by the interaction 
of receptor ligands expressed by tumour cells and the specific activating receptors 
expressed by the NK cells. These NK cell receptors include cytotoxic receptors, ADAM-
1 and NKG2D. Also the NK cells expresses the MHC class I receptor, an inhibitory 
receptor whose expression level must be low in NK cells for it to be activated (Raulet and 
Guerra, 2009).  
NKG2D ligands are distant family members of the MHC class I molecules and generally, 
they are of two major types; MICA/MICB and RAET1/ULBP (ULBP1-10). The MIC 
gene family members are mainly found in the human major histocompatibility complex, 
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whereas the ten members of the ULBP family can be found in humans and mice. In mice, 
the Raet1 genes are subdivided into Rae1, H60 and Mult1 gene subfamilies, and are 
relatively distinct in amino acid sequence to each other (Gasser and Raulet, 2006). 
The NK ligands are normally not expressed on the cell surface of healthy cells. Tumour 
cells frequently express high levels of activating NK cell receptor ligands and low levels 
of MHC class I molecules, rendering these cells highly susceptible to NK cell±mediated 
lysis (Textor et al., 2011). Soluble NKG2D ligands have been reported in various cancer 
types in humans, and many studies have suggested that the elevation of the concentration 
of these ligands in the serum of cancer patient could represent an immune escape 
mechanism that evolve in cancer cells to evade being detected in their host (Gasser and 
Raulet, 2006).     
Tumour cells are subdued by different anti-tumour effector lymphocytes. However, 
tumour cells are known to evade the immune surveillance by several means. For example, 
cytotoxic T-lymphocyte (CTL)-mediated surveillance can be escaped by tumour cells by 
the repression of the expression of the HLA class I, which will affect the recognition of 
tumour cells (Poggi et al., 2005). Various types of cancer have been linked with different 
immune cancer cells (Karin and Greten, 2005). NK cells infiltration has been found in 
human gastric and colorectal carcinoma, whilst innate immune cell types like 
macrophages are seen in human breast cancer and mast cells in human lung cancer types 
(de Visser et al., 2006).   
The NKG2D ligands have shown great importance in shaping NK cell effector function, 
as a result of cytotoxicity or cytokine production (Wang and Sun, 2014). The molecular 
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basis for the ability of NK cells to recognize stressed cells is not well understood. 
However, studies suggest that cells exposed to chemotherapeutic agents, genotoxic 
stimuli, or inhibited DNA replication cycles, upregulates the stimulatory NKG2D ligands 
(Gasser and Raulet, 2006). Different genotoxic compounds (e.g., aphidicolin, cisplatin, 
IOXRURXUDFLOȖ-irradiation, and UV radiation), response to heat shock, antigen-mediated 
activation of T cells, and dysregulation of Dicer expression, have been shown to stimulate 
upregulation of the expression of NKG2D ligands (Fine et al., 2010). 
Soluble NKG2D ligands have been reported in the sera of patients of different cancer 
types, and their increased protein concentrations correlated with poor cancer prognosis 
(Paschen et al., 2009). Wang and Sun, (2014) reported a lost in expression of ULBP2 on 
the surface of tumour cells and a shedding of this NKG2D ligand was linked to target cell 
apoptosis in contrast to spontaneous shedding, though, both the spontaneous shedding 
and shedding due to apoptosis were due to metalloproteinase activity (Wang and Sun, 
2014).  
Also tumour suppressors have been reported to modulate the expression of NKG2D 
ligands. Heinemann et al., (2012) reported that tumour suppressing miRNA suppresses 
the expression of the NKG2D ligands by binding at the 3'-untranslated region. The study 
specifically showed that the member of the miR-34 family (miR-34a and miR-34c) 
directly regulates ULBP2 by degradation and affecting its translation in a melanoma cell 
line (Heinemann et al., 2012). This class of miRNA are reported to induce cell cycle 
arrest, senescence as well as apoptosis and generally regulate cellular differentiation 
(Heinemann and Paschen, 2012).  
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Apart from the intrinsic factors and the natural features of cancer cells, the host immune 
response could serve major prognostic and predictive roles in determining the fate of 
cancer patients treated with conventional or targeted chemotherapies (Zitvogel et al., 
2011). The NK cells are reported to present the most efficient immune mechanism that 
detects and destroy tumour cells, thus, playing a significant role in host defence against 
carcinogenesis (Pende et al., 2002). The NKG2D protein is a major receptor of the NK 
cells that triggers a cytotoxic response when activated by the interaction of tumour cells 
through the NKG2D ligands (Moretta and Moretta, 2004). 
Considering the important role of NKG2D and its ligands in predicting cancer outcomes 
in different cancer types (Bui et al., 2007), there is a need to further monitor the role of 
BRG 7 (a NKG2D ligand) in the modulation of chemotherapy induce apoptosis in breast 
cancer for it to serve as a prognostic or predictive biomarker in breast cancer disease. 
Range of compounds has been reported to activate apoptosis through different pathways 
(Marks and Xu, 2009). Due to this consideration three different established apoptotic 
inducers namely: Camptothecin, Doxorubicin and DMSO were used to monitor the role 
of BRG 7 in apoptosis induction in breast cancer. 
6.1.1: Camptothecin 
Camptothecin (CPT) is a cytotoxic alkaloid reputed for its potent apoptosis inducing 
property. It was originally isolated from the Camptotheca acuminate plants native to 
China and Tibet and have been extensively used in Chinese medicine (Thomas et al., 
2004). CPT and its analogues are reported to cause cells to enter into apoptosis by 
inhibiting the function of the enzyme topoisomerase I (topo I) (Liu et al., 2000). DNA 
topo I relaxes super coiled DNA through the cleavage of the double stranded DNA and 
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the formation of a phosphoryl bond between the cleaved DNA and the active site tyrosine 
of the enzyme  (Holden, 2001). The activity of topo I is inhibited by camptothecin by 
preventing the re-ligation of the cleaved DNA strands. Camptothecin reversibly stabilizes 
the topo I-DNA complexes and the replication forks during the S-phase of the cell cycle, 
which activates stress-associated signalling that ultimately induces apoptosis (Thomas et 
al., 2004). 
6.1.2: Doxorubicin (Adriamycin) 
Doxorubicin (DOX) is an anthracycline antibiotic from the bacterium Streptomyces, 
considered to be one of the most effective agents in the treatment of breast cancer. DOX 
is used to treat early-stage or node-positive breast cancer, HER2-positive breast cancer 
and metastatic disease and resistance to it leads to an unsuccessful outcome in many breast 
cancer patients (Smith et al., 2006). Induction of apoptosis by DOX is majorly believed 
to be through its action of inhibiting topoisomerase II (topo II), thereby preventing the 
breaking-religation of this enzyme, as well as through the formation of reaction oxygen 
species (ROS) (Döhrmann et al., 2012). Free radical formation and DNA damage by 
inhibiting the action of topo II may primarily be responsible for the cytotoxic effect of 
DOX. This drug is also known to induce apoptosis by activating caspases and disruption 
of mitochondrial potential (Eom et al., 2005).   
6.1.3: Dimethyl sulfoxide 
Dimethyl sulfoxide (DMSO) is a polar solvent that readily permeates the cell membrane, 
majorly use in cell biology as solvent for chemical compounds designated for treatment 
in cell culture, for cryopreservation of many cell types and for improving primary cells 
viability in cell culture (%DQLþet al., 2011) . DMSO has been reported to be effective in 
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initiating apoptosis in disease cells by inducing the release of Cytochrome c in the 
mitochondria, collapse of the mitochondrial membrane potential, activation of caspase-9 
and -3 as well as induces apoptotic changes in a murine lymphoma cell line and down-
regulation of Bcl-2 (Santos et al., 2003). 
Stably transfected MCF-7 cell lines for BRG 7 protein over-expression was henceforth 
referred to as pcDNABRG 7, while BRG7shRNA206 and BRG7shRNA207 were used to 
UHSUHVHQWWKHVWDEO\WUDQVIHFWHGFHOOVIRU*HQH³NQRFN-GRZQ´LQWKLVVWXG\ 
6.2: A im 
The aim of this chapter was to monitor the role of the BRG 7 (a member of the NKG2D 
ligand proteins) in modulating apoptosis induced in breast cancer cell lines using three 
pro-apoptotic compounds. 
6.2.1: Objectives 
x Investigate the role of BRG 7 over-expression in camptothecin, doxorubicin and DMSO 
induced apoptosis in stably transfected breast cancer cell line (pcDNABRG7) 
x ,QYHVWLJDWHWKHUROHRI*HQH³NQRFNGRZQ´LQFDPSWRWKHFLQGR[RUXELFLQDQG'062
induced apoptosis in stably transfected breast cancer cell line (BRG7shRNA206 and 
BRG7shRNA207). 
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6.3: Materials and methods 
6.3.1: Cell culture and cell treatment 
pcDNABRG7, BRG7shRNA206 and BRG7shRNA207 were seeded into 6 well plates 
using the MEM reconstituted media comprising 1 % penicillin/streptomycin and 10 % 
fetal serum bovine (FBS) solution. The cells were cultured as described earlier in section 
4.3, at 370 C in a 5 % CO2 aerated incubator to between 70-80 % confluency. Apoptosis 
was induced in cells using camptothecin (100 µg/ml) dissolved in DMSO and diluted 
further in complete media to a final concentration of 2 µM, an effective concentration 
established by Abedin et al., (2007), 5 % v/v Dimethyl sulfoxide (DMSO) in complete 
media, and 1 µg/ml of doxorubicin (Cuvillier et al., 2001) in different plates for 24 hours. 
After 24 hours, cells were harvested and the apoptotic cells measured using the flow 
cytometer (BD accuri 6) after performing the Apo-percentage assay. 
6.3.2: Apo percentage assay  
Seeded cells were treated with various concentration of different pro-apoptotic 
compounds stated above in complete media for 24 hours. After 24 hours, the media were 
removed into 15 ml tubes. Wells were washed with 1 ml PBS and added to the individual 
15 ml tubes. Cells were trypsinized by the addition of 0.5 ml 1X trypsin to each well and 
monitored until they were about to detach and the trypsinization process stopped by 
adding 0.5 ml complete medium. The cells were gently washed off the plates and added 
to the individual 15 ml tubes. The cells were pelleted by centrifuging the tubes at 3000 
rpm for 10 minutes, and the supernatant discarded. Excess supernatant was removed as 
much as possible and the pellets re-suspended in 250 µl diluted (1:160) 3, 4, 5, 6-
tetrachloro-¶¶¶¶-tetraiodofluorescein (TCTF). Cells were incubated in dye at 370 
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C for 30 minutes, after which 4 ml of PBS was added and the tubes centrifuged for 5 
minutes at 3000 rpm, and supernatant discarded. Cells were re-suspended in 60 µl PBS 
and analyzed on a flow cytometer.  
6.3.3: F low Cytometry Analysis 
Stained apoptotic cellVZHUHDQDO\VHGXVLQJWKH)/ILOWHURQWKH%'$FFXUL&IORZ
cytometer (BD Biosciences, San Jose, CA). Acquisitions were done in linear mode and 
10,000 cells per sample were acquired for analysis.  
6.3.4: Statistical analysis 
All assays were repeated twice to ensure reproducibility and three replicates of each group 
were performed in each test. The significance of difference in apoptosis between un-
transfected cells and transfected cells induced using the different effector agents 
(camptothecin, DMSO and doxorubicin) were analyzed by one way analysis of variance 
$129$IROORZHGE\%HQIHUURQL¶VSRVW-hoc comparison using Prism 5.0 (Graph pad, 
USA). The number of cells undergoing apoptosis was represented as bar charts depicting 
the mean ± standard error percentage of triplicate samples.  
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6.4: Results and Discussion 
The effect of chemotherapy on cancer can be influenced by the hostV¶ immune system by 
either stimulating immune response to the disease or by increasing the susceptibility of 
the cancer cells to immune attack. Also, chemotherapy may directly stimulate anticancer 
immune effectors or repress immunosuppressive mechanisms (Zitvogel et al., 2011).    
Soluble NKG2D ligands of which BRG 7 is a member of, are reported to be present in 
sera of some cancer patients and are thus regarded as good predictive markers for the 
prognosis of these cancers (Wang and Sun, 2014). However, better understanding of the 
effector role BRG 7 protein play in stimulating apoptosis to repress breast cancer 
onset/progression could facilitate a point of care tool for breast cancer diagnosis, 
prognosis or use to monitor the efficacy of anti-tumour drugs. 
Most studies carried out to validate the NKG2D ligands as biomarkers, majorly focused 
on the spontaneous release of these ligands in their bid to evade NK cell tumour 
surveillance. However, better understanding of the mechanism of shedding of BRG 7 may 
facilitate the development of BRG 7 based diagnosis methods for breast cancer (Wang 
and Sun, 2014; Paschen et al., 2009; Guerra et al., 2008).  This study seek to understand 
the role of BRG 7 in modulating apoptosis induced by chemotherapeutics in a breast 
cancer cell line. 
6.4.1: The effect of BR G 7 over-expression and silencing on camptothecin induced 
apoptosis in a breast cancer cell line 
The sensitivity of cells to CPT is not only based on its action of DNA damage through 
the inhibition of topo I, but also on the ability of the cells to activate checkpoints in the S 
 
 
 
 
   179     
     
and G2 phases of the cell cycle through the action of p53 protein. Thus tumour cells that 
lack functional p53 protein lose their sensitivity to a wide range of DNA-damaging agents 
including CPT (Jones et al., 2000).   
Expression of p53 in breast cancer cell lines has been reported to be repressed in order to 
promote cell proliferation (Chang et al., 2007). A variety of molecules are known to 
override the DNA damage-dependent G2-checkpoint and enhance drug-induced 
cytotoxicity (Jones et al., 2000).  
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F igure 6.1: Quantification of apoptosis in MCF-7 cell lines using the flow cytometer (a) a representation of the MCF-7 
untreated cell line (b) a representation of camptothecin treated MCF-7 cell line (c) a representation of pcDNA transfected, CPT 
treated MCF-7 cell line 
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F igure 6. 2: Quantification of apoptosis in BRG7 silenced MCF-7 cell lines using flow cytometer (d) a representation of 
shRNA206 transfected and CPT treated MCF-7 cell line (e) a representation of shRNA207 transfected and CPT treated MCF-
7 cell line
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F igure 6.3: Percentage apoptotic cells of camptothecin treated MCF-7 cell lines; bar chart 
represents the mean and standard error of triplicate Apo-percentage values of cells after 
24 hours of incubation with- or without camptothecin. Bars with same superscript are 
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Figure 6.1 and 6.2 shows the flow cytometry percentage apoptotic cells (raw data) in a 
breast cancer cell line (MCF-7), transfected to over-express the BRG 7 (pcDNABRG7) 
protein and those transfHFWHGWR³NQRFNGRZQ´*HQHH[SUHVVLRQ%5*VK51$DQG
BRG7shRNA207) treated with camptothecin. Figure 6.3 (analysed data) showed the 
effect of camptothecin-induced apoptosis is higher in pcDNABRG7 compared to the un-
transfected MCF-7 cell lines as well as in BRG7shRNA206 and BRG7shRNA207 cell 
lines. 
Although the difference in percentage of apoptotic cells in the pcDNABRG7 cell is not 
statistically significant when compared to the un-transfected MCF-7 cell, the increase in 
apoptosis could be an indication that the NKG2D ligand, positively enhance the effect of 
CPT in stimulating apoptosis in breast cancer cells. Also, lower effect of this drug in 
MCF-7 cell lines transfected for the BRG 7 gene repression, lend more credence to the 
probability of the BRG 7 having a positive modulating effect in enhancing CPT action in 
breast cancer treatment, and the shedding and repression of this protein could be another 
means by which cancer cells resist the effect of cytotoxic drugs. 
MCF-7 is an estrogen positive, tumourigenic, non-invasive, primary human mammary 
epithelial cell line that does not express caspase-3, the stimulatory protein of the hallmark 
caspase cascade. MCF-7 responds to variety of apoptotic stimuli such as UV radiation, 
paclitaxel, tamoxifen, just to mention a few. Caspase-3 activity is characteristic of the 
apoptotic pathway, thus, the route of apoptosis induction in MCF-7 is not too clear 
(Abedin et al., 2007). Also the induction of apoptosis in MCF-7 by camptothecin is 
delayed (Abedin et al., 2007).  
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Both innate and adaptive immune systems have been reported to play crucial roles in the 
anti-tumour effects of chemotherapy and radiotherapy based cancer treatment (Schreiber 
et al., 2011). Based on the biochemical homogeneous process of apoptosis, it is generally 
assumed that pro-apoptotic chemotherapy would not elicit immunogenic cell death, thus 
cancer cells treated with mitomycin C, a drug that induces classical apoptosis, was shown 
not to stimulate an immune response when injected subcutaneously into histocompatible 
hosts in the absence of adjuvant therapy (Zitvogel et al., 2008). However, DNA-damaging 
agents such as the topoisomerase inhibitors are reported to induce the activation of 
tumour-suppressor proteins including the transcription factor p53 and the DNA-damage 
response induces the expression of NKG2D ligands on tumour cells (Gasser, et al., 2005). 
Thus, over-expression of BRG 7 a NKG2D ligand could possibly enhance the function or 
stimulation of p53 to help enhance drug-induced cytotoxicity. However p53 was not 
observed to directly interact with BRG 7 in the earlier in silico analysis study (Chapter 
2). 
Eukaryotic topoisomerase I (topo I) is an enzyme required for DNA replication to remove 
supercoils by introducing breaks and nick the DNA helical structure (Liu et al., 2000). 
Camptothecin (CPT) antitumour activity was reported to include inhibiting the action of 
topo I by preventing its activity and causing an accumulation of topo I-DNA adducts 
reported to collide with the replication fork during DNA replication, resulting in double-
strand break which leads to cell death (Staker et al., 2002). NKG2D ligands are reported 
to be upregulated in cells as a result of chemotherapeutic agents, genotoxic stimuli, or 
stalled DNA replication and the upregulation of these ligands has been reported to be as 
a result of diverse genotoxic stimuli (Gasser and Raulet, 2006), thus some of these ligands 
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may be required for the effectiveness or to enhance the potency of the drugs. This could 
probably explain, the increase in apoptosis in cells transfected to express an increase level 
of the BRG 7 protein, as compared to those whose BRG 7 gene expression is knocked 
down both compared to the breast cancer cell line (MCF-7).   
6.4.2: The effect of BR G 7 over-expression and silencing on doxorubicin induced 
apoptosis in breast cancer cell line 
DOX is reported to be very effective in a wide variety of breast cancer types including 
both metastatic and early disease, but because of its reported cardiotoxicity activity, its 
use is limited (Lao et al., 2013). Thus, the needs to identify biomarkers that can predict 
treatment response, enhance the drug efficacy, or help design therapy tailored to 
individual patients.  
Doxorubicin like most chemotherapeutics, have been reported to stimulate the immune 
system to complement their role of clearing tumour cells by preventing an 
immunosuppressive effect in the tumour microenvironment or enhance the infiltration of 
immune effector cells into tumour cells to sensitize them for immune attack (Hu et al., 
2013). Doxorubicin and interleukin-12 have been reported to increase infiltration of CD8+ 
T cells into cancer cells and also induces NKG2D expression on the CD8+ T cells which 
enhances the antitumour immune surveillance of the cells (Hu et al., 2014). The aim of 
this section was to monitor the effect of the BRG 7 protein in modulating the apoptosis 
inducing effect of DOX in a breast cancer cell line.
 
 
 
 
   186     
     
 
F igure 6.4: Quantification of apoptosis in MCF-7 cell lines using flow cytometer (a) a representation of the MCF-7 untreated 
cell line (b) a representation of DOX treated MCF-7 cell line (c) a representation of pcDNA transfected, DOX treated MCF-7 
cell line 
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F igure 6.5: Quantification of apoptosis in BRG 7 silenced MCF-7 cell lines using flow cytometer (d) a representation of 
shRNA206 transfected and DOX treated MCF-7 cell line (e) a representation of shRNA207 transfected and DOX treated MCF-
7 cell line. 
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F igure 6.6: Doxorubicin treated MCF-7 cell lines; bar chart represents the mean and 
standard error of triplicate apo-percentage values of cells after 24 hours of incubation 
with/without Doxorubicin. Bars with same superscript are statically not significant (p 
0.05). 
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Figure 6.6, shows the difference in the level of apoptosis in an epithelial cancer cell line 
(MCF-7), MCF-7 transfected to over-express BRG 7 protein, a ligand to the NKG2D 
receptor and MCF-7 cells transfected to repress the expression of the protein by two 
shRNA constructs that targets two different parts of Gene 7 after 24 hrs treatment with 
DOX. The result showed the pcDNABRG7 cell lines are undergoing more apoptosis than 
the MCF-7, BRG7shRNA206 and BRG7shRNA cell lines. The percentage apoptosis 
difference when the three categories of cell lines were compared were statically 
VLJQLILFDQW S   7KHUH ZDV DQ LQGLFDWLRQ WKDW %5*VK51$ DQG
BRG7shrNA207 were undergoing apoptosis faster than the un-transfected MCF-7 cell 
line.  
Having more apoptotic cells in MCF-7 with knocked down NKG2D ligand gene than the 
un-transfected MCF-7 cell line cannot be readily explained. However, this may suggest 
WKDWDOWKRXJKWKH1.*'OLJDQGPD\HQKDQFHWKHHIILFDF\RI'2;FRPSOHWH³NQRFN-
GRZQ´RIWKHJHQHPDy also be detrimental to the cell. Knocking down this gene could 
stress the cell and stimulate the expression of other NKG2D ligands or other immune 
signals, which can enhance the effect of the cytotoxic drug.  
The engagement between NKG2D and its ligands enhances cell-mediated cytotoxicity 
and cytokine production against transformed cells. Some of these ligands have been 
described as stress-related proteins that can be induced by heat shock and are regulated 
by heat shock transcription elements, which are activated during cell transformation 
(Okita et al., 2012). The result suggest that either the over-expression of BRG 7 or its 
repression could assist breast cancer treatment using DOX. Also the over-expression or 
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repression could probably be used to determine the effective concentration of DOX, thus, 
the potential of this ligand protein serving as biomarker for therapeutic outcome of DOX.  
Breast cancer cells developing resistance to DOX remain a major obstacle in the 
successful treatment of breast cancer patients. Biomarkers that enhances and correlates 
with treatment response, would allow treatment to be tailored to an individual on the basis 
of biomarker expression (Smith et al., 2006).  Although breast tumours are regarded as 
one of the most chemo-sensitive solid tumours, there are reports that the initially 
responsive tumours could relapse and develop resistance to a wide spectrum of drugs 
making them refractory to cytotoxic drugs which is typically incurable (Harris et al., 
2012).  
The most frequently identified molecular changes observed in DOX resistance breast 
tumours are reduced intracellular concentration of the drug as a result of lots of membrane 
efflux pumps, increase in enzymes involve in drug metabolism and failure of the apoptotic 
pathways (AbuHammad and Zihlif, 2013). Result from this study suggest that increase in 
the level of BRG 7 protein could be used to enhance the efficacy of DOX in treating breast 
cancer, as well as serve as a biomarker to determine the appropriate drug dose, however 
the actual concentration of this NKG2D ligand that correlates to the effective dose of 
drug, needs to be determined. 
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6.4.3: The effect of BR G 7 over-expression and silencing on D MSO induced 
apoptosis in breast cancer cell line 
DMSO has been reported to stimulate apoptosis in different cancer cells (Wang et al., 
2012). The apoptotic initiating effect of DMSO was reported to vary based on the cell 
types (Aita et al., 2005). Deng et al., (2014) reported a DMSO dose dependent tumour 
growth inhibition in mouse 4T1 breast cancer cell line that lasted for at least three days 
in breast cancer mice (Deng et al., 2014). Also 2 % DMSO was reported to increase the 
expression levels of MDR-I gene and protein and increase the chemo sensitivity of MCF-
7 after 48 hours of incubation (Zhang, 2001). A MTT chemosensitivity analysis for 
DMSO was carried out to determine the IC50 in an earlier study, and it was observed that 
about 50 % of the cells died when cells were incubated with 5 % DMSO for 24 hours 
(result not shown). 
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F igure 6.7: Quantification of apoptosis in MCF-7 cell lines using flow cytometer (a) a representation of the MCF-7 untreated 
cell line (b) a representation of DMSO treated MCF-7 cell line (c) a representation of pcDNA transfected, DMSO treated MCF-
7 cell line 
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F igure 6.8: Quantification of apoptosis in BRG 7 silenced MCF-7 cell lines using flow cytometer (d) a representation of 
shRNA206 transfected and DMSO treated MCF-7 cell line (e) a representation of shRNA207 transfected and DMSO treated 
MCF-7 cell line. 
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F igure 6.9: DMSO treated MCF-7 cell lines; bar chart represents the mean and 
standard error of triplicate apo-percentage values of cells after 24 hours of incubation 
with- RUZLWKRXW'062%DUVZLWKVDPHVXSHUVFULSWDUHVWDWLFDOO\QRWVLJQLILFDQWS
0.05). 
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Figure 6.9, shows the difference in the level of apoptosis in an epithelial cancer cell 
line (MCF-7), transfected to over-express (pcDNABRG7) or repress BRG 7 
(BRG7shRNA206 and BRG7shRNA207) treated with DMSO for 24 hours. The result 
just like the CPT and DOX treated cells showed that the pcDNABRG7 cell line 
responded more positively to the cytotoxic effect of the DMSO as compared to MCF-
7, BRG7shRNA206 and BRG7shRNA207. Also the BRG7shRNA cells showed more 
resistance to the cytotoxic effect of DMSO when compared to MCF-7, although the 
difference was not statistically significant. 
DMSO has been reported to be effective as an anticancer drug against many types of 
cancer. Wang et al., (2012), showed the prospect of DMSO as an anticancer drug for 
lung adenocarcinoma by stimulating tumour suppressor proteins. DMSO was reported 
to present a synergistic effect when used in combination with antineoplastic agents 
against ovarian cancer (Pommler et al., 1988). Its anti-tumour activity has also been 
linked to the induction of the tumour necrosis factor of the p-53 mitochondrial 
pathway (Koiri and Trigun, 2011). DMSO has also been used to treat refractory cancer 
pain (Hoang et al., 2011). 
DMSO is regarded generally as an inert compound, with little or no physiological 
effect in biological system. However, studies have shown the amphipathic compound 
could stimulate the immune system. DMSO have been shown to activate Natural 
Killer T-cells and NK cells in vivo in hepatic tissue, increasing the intracellular levels 
of the cytotoxic effector molecules, interferon (IFN)-Ȗ DQG JUDQ]\PH % SURWHLQ
(Masson et al., 2008). The increased level of the NK cells as a result of the stimulating 
effect of the DMSO could increase apoptosis in the transfected cells expressing more 
of the BRG 7, a protein ligand of NKG2D receptor on the NK cells.  
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Lower expression of the ligand in the BRG7shRNA206 and BRG7shRNA207 cell 
lines could be the reason for the reduction in apoptosis in these cells. However, DMSO 
also possesses an anti-oxidative property, which could be used to selectively induced 
cell death of tumour cells and extending the half-life of the NKT cells (Masson et al., 
2008). BRG 7 was modulated by AP-2 a member of the activator protein (AP) 
transcription factor family (Chapter, 2) and the effect of DMSO in stimulating 
apoptosis could also be, its influence on the AP transcription factor families. DMSO 
was reported to modulate the activity of AP-1, a member of the activator protein 
transcription factor family and the effect suppresses the expression of ICAM-1 
(Intercellular Adhesion Molecule 1) also known as CD54 in the respiratory syncytial 
virus (RSV)-induced production of IL-8 to promote tumour suppression in A549 
epithelial cells (Wang et al., 2012).  
6.4.4: E ffect of different shRN A targets on Gene 7 ³knock-down´ on apoptosis 
induction 
The BRG7shRNA206 and BRG7shRNA207 are both stable constructs of MCF-7 cell 
OLQHVZLWK*HQH³NQRFNGRZQ´XVLQJGLIIHUHQWVK51$FRQVWUXFWV7KHHIIHFWVRIWKH
various pro-apoptotic compounds on these stably transfected cell lines varied, 
although BRG 7 expression was repressed in both cell line (Chapter 5). Apoptosis was 
more induced in the BRG7shRNA206 compared to the BRG7shRNA207 when the 
cells were treated with camptothecin, although the difference was not significant 
(figure, 6.2), also more cells were apoptotic in the BRG7shRNA206 cells when 
DMSO was used (figure, 6.6). Comparing percentage of apoptotic cells in 
BRG7shRNA207 and the MCF-7 untreated cells in DMSO treated study; the 
difference was not statistically significant. However, apoptosis was more induced in 
the BRG7shRNA207 cell lines compared to the BRG7shRNA206 when cells were 
 
 
 
 
   197     
     
treated with DOX (figure, 6.4). This variance of drug effect in shRNA Gene 7 
³NQRFNHGGRZQ´FHOOVLVSUREDEO\GXHWRWKHVK51$WDUJHWLQJGLIIHUHQWUegions of the 
gene, thereby modulating the expression of protein and effect of drugs differently. 
Several studies have reported variance to pro-apoptotic drug in cells using different 
short RNA constructs to target different region of a candidate gene for JHQH³NQRFN
GRZQ´+ROHQet al., (2002), showed that siRNA synthesized against different region 
of a particular mRNA demonstrated difference in silencing. They carried out limited 
tiling of different siRNA across a region of the human coagulation trigger factor gene 
(TF) and reported that by shifting the siRNA target site by only three nucleotides at a 
time resulted in different degree of silencing. Also Pretorius at al., (2013), showed 
difference in the level of RBBP6 gene knock down using two different siRNA 
constructs that targets different region of the gene. They also showed that the level of 
resistance of the two different siRNA stably transfected NIH 3T3 cells treated with 
FDPSWRWKHFLQWRLQGXFHDSRSWRVLVGLIIHUHGDVFHOOWKDWVKRZHGKLJKHU³NQRFNGRZQ´
of RBBP6 presented more resistance to apoptosis (Pretorius et al., 2013). 
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6.5	   Conclusion	  
MCF-7 is an estrogen receptor positive breast cancer cell line, which accounts for 
about 65 % of all detectable breast cancer cases in human (Keen, 2011). Estrogen 
receptor positive cancers present the most favourable prognosis of all subtypes and 
are usually believed to respond normally to hormone therapy (Speirs and Kerin, 2000). 
Based on the numerous biological and clinical findings that ER positive patients GRQ¶W
derive equal benefit from chemotherapy and hormonal based treatment, Paik et al., 
(2006), suggested the use of chemotherapy as well as hormone based treatments and 
their outcomes, should not only be based on baseline prognostic information but also 
prediction of degree of benefit from chemotherapy (Paik et al., 2006). Identifying 
BRG 7 as a prime candidate in a set of identified candidate genes as breast cancer 
biomarkers suggest a high prospect for this gene and it protein product in particular 
and the others in general in breast cancer management. The findings from this chapter 
confirmed that cancer cells over-expressing the BRG 7 protein responded faster and 
better to the three apoptotic inducing drugs. 
ER positive breast cancer patients have been reported to have a slow response to 
camptothecin (Abedin et al., 2007). A Study carried out to determine the underlying 
mechanisms for the delayed death response of a breast cancer cell line to 
camptothecin, showed that the slow response of MCF-7 to cytotoxic apoptosis 
stimulatory compounds may be due to lack of caspase-3 activity, and possible defects 
in the formation of apoptosome/ caspase-9 activation  (Abedin et al., 2007). The effect 
of CPT was reduced and probably delayed in breast cancer cell lines not expressing 
the BRG 7 protein compared with the un-transfected cells, whereas the effect of CPT 
was enhanced in cells transfected for expression of BRG 7, suggesting that this protein 
could serve as a biomarker for predicting how a specific breast cancer type would 
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respond to CPT treatment. The result also suggest that BRG 7 could serve as a 
biomarker in determining the appropriate concentration and drug combination in 
designing drug specific individual treatment for breast cancer patients. There was an 
indication from this result that, apart from BRG 7 enhancing the apoptotic stimulating 
effect of CPT, it could probably serve as a biomarker to monitor the prognosis and 
therapeutic outcome of CPT and other related apoptotic chemo-therapeutics.  
Doxorubicin is regarded as one of the most effective substances for the effective 
treatment of breast cancer patients. However, resistance to this drug is reported to be 
common and present a major challenge in breast cancer management (Smith et al., 
2006). From the result, there is an indication that the NKG2D ligand (BRG 7) could 
probably be used to modulate the outcome of doxorubicin treatment in breast cancer 
patients. Designing treatment tailored on an individual patient basis, patients 
expressing a  high level of the BRG 7 protein would indicate a good outcome when 
treated with DOX. Also, the result showed that a complete repression of BRG 7 could 
enhances apoptosis in DOX treated breast cancer cell line.      
Dimethyl sulfoxide (DMSO) is used as a reagent in the field of bioscience as a 
universal water solvent of insoluble compounds, as a protectant in the process of 
cryopreservation of cells, as well as used as an apoptosis regulator. However, the mode 
of action of the substance is not well established (Aita et al., 2005). The trend the 
DMSO treated transfected cells showed, was better defined as compared to 
camptothecin and doxorubicin treated transfected cells for BRG 7 over-expression and 
repression. The result suggest that breast cancer cells over-expressing BRG 7 will 
better respond to DMSO induced apoptosis whilst cells having this protein repressed, 
have apoptosis induction reduced in them. The mode of DMSO induction of apoptosis 
in cells in not well defined (Hanslick et al., 2009), however the result observed in the 
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DMSO treated transfected cells is similar to the CPT treated transfected cells. This 
suggests that DMSO could probably induce apoptosis following the same route as 
CPT.  
The difference in the response of BRG7shRNA206 and BRG7shRNA207 induction 
of apoptosis by different pro-apoptotic compounds, further proves that BRG 7 could 
play a significant role in the treatment and management of breast cancer using pro-
apoptotic compounds. The variance in the effect of the pro-apoptotic compounds on 
BRG7shRNA206 and BRG7shRNA207 suggest targeting the gene at different 
regions, for gene knock down will present different outcome when pro-apoptotic 
compounds are used for treatment. Hence, BRG 7 could probably serve as a good 
biomarker for the effective management of ER positive breast cancer, however more 
studies is required to confirm this.  
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Chapter 7: General Discussion and Conclusion 
7.1 General discussion 
Breast cancer remains the major type of cancer amongst women and a global health 
problem (AbuHammad and Zihlif, 2013). Based on the challenges posed by breast 
cancer, there is an urgent need for biomarkers to improve the diagnosis, prognosis, 
guided therapy and management, as well as monitor patient response to therapeutics. 
The advent of high throughput analysis technology have provided a fast means of 
genomic analysis which have provided differential expression level of gene in disease 
condition and whose protein products have been predicted and published as candidate 
cancer biomarkers (Kulasingam and Diamandis, 2008). Using different bioinformatics 
tools and processes, Ngcoza, (2012) identified seven genes, whose protein products 
are membrane bound, from different databases e.g. Oncomine. Most of the 
differentially expressed genes, identified from these various databases were obtained 
from microarray analysis (Ngcoza, 2012).  
Differential expression analysis of these seven genes in different cancer cell lines and 
non-cancerous cell lines including breast cell lines was carried out using semi-
quantitative PCR and qRT-PCR. The results showed that three of these genes; Gene 
3, Gene 4 and Gene 7 were highly expressed in a breast cancer cell line as compared 
to the non-cancerous breast cell line and other cancer cell lines (Ngcoza, 2012). 
Although finding a single biomarker has been the target for most biomarker discovery 
research, and some have been identified in some disease types, there is growing 
consensus that multiple (e.g., three to five) markers used individually or as part of an 
integrated panel will be more appropriate for cancer management. The performance 
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and advantages of a panel of biomarkers in cancer management have been confirmed 
in several publications (Rifai et al., 2006; Hanash et al., 2008; Hu et al., 2008).  
One of the most important processes in the discovery of multiple genes/proteins for 
cancer biomarkers is validation of the genes/proteins in clinical outcomes. In recent 
times, numerous genes have been identified as biomarkers for various cancer types 
based on gene expression analysis, using high throughput techniques such as 
microarray profiling and more recently the RNA-Seq technologies and qRT-PCR. 
Often, from these list of identified biomarkers multiple gene products have been 
linked to a specific cancer tissue and their subtypes. However, validating the role of 
these biomarkers in different populations or evaluating competing biomarkers has 
been a herculean task, even though lots of data for these genes are available (Aguirre-
Gamboa et al., 2013).  
In silico approach to biomarker validation could be a more effective strategy for 
biomarker development, which is typically a fast and cost effective process compared 
to the traditional methods of biomarker validation (Chen et al., 2014). To validate the 
diagnostic, prognostic and/or predictive value of the identified candidate genes as a 
set of biomarkers, several software and databases were used. Most of the genes were 
confirmed as having good prospects as a biomarker, based on their association with 
different cancer related processes using the in silico validation procedure. 
Two additional genes were hypothesized as having a good prospect as breast cancer 
biomarkers after several in silico functional analysis. These genes included another 
member of the seven putative breast cancer biomarker gene list (Gene 2), and Gene 8, 
whose protein product was observed to have a direct interaction with the protein 
product of the most highly expressed Gene 7 from the qRT-PCR study (Ngcoza, 
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2012). Gene 2 was not shown to be highly expressed from the qRT-PCR analysis, 
however the gene was found to be functionally involved in many cancer processes in 
general, using in silico annotation tools, and could potentially be differentially 
expressed in breast cancer. The protein product of Gene 8 was also annotated as a 
modulator of expression of the estrogen receptor protein (ESR). ESR is a prognostic 
factor in a large group of breast cancer multiple cohorts (Hartman et al., 2009). Also 
the in silico functional analysis (Chapter 2) showed some of the other candidate genes 
were linked to at least one process linked to cancer progression. It was postulated that 
this set of candidate biomarkers could complement one another as breast cancer 
prognosis or predictive biomarkers, thus, an in silico validation of these candidate 
genes was carried out (Chapter 3) to determine their prognostic and predictive values.  
Several genes have been identified as candidate biomarkers especially as prognostic, 
predictive or both for patients with breast cancer (Fan et al., 2006). Validating these 
prognostic or predictive candidate genes in different breast cancer cohorts is now of 
great interest in cancer management (Gyorffy et al., 2009). These candidate genes are 
usually validated using several molecular techniques, which could be cumbersome 
and time consuming. To validate the prognostics and/or predictive values of the 
identified candidate genes as a set of biomarkers, some prognostics software and 
databases were used.  
Using the SurvExpress tool, the prognostic ability of this set of candidate biomarkers 
were analysed in two datasets namely DATA 1 and DATA 2. DATA 1 is a dataset 
comprising 9 datasets from the same platform compiled by seven authors using 1574 
samples, while DATA 2 is a meta-bases constructed by performing a quantile 
normalization compiled by SurvExpress with 1901 samples. The two datasets showed 
variance in number and the genes that are relevant in predicting breast cancer 
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treatment outcome based on their differential e[SUHVVLRQS$OWKRXJKRQHRI
the seven genes was common to both datasets, three genes were listed as being 
significant in DATA 1 and two listed in DATA 2, with one of the genes common to 
both. The variance in the significance of the set of genes listed as being significant, 
suggest this set of genes will be more effective when combined than used as individual 
biomarkers for breast cancer. The effective differentiation of risk groups, based on 
combined gene expression, add credence to this suggestion. The combined set of 
genes showed positive prognostic and predictive value using the two different datasets 
from SurvExpress. 
The Kaplan Meier plotter was used to analyze the prognostic ability of the individual 
candidate biomarkers based on them differentiating between the low and the high risk 
patients groups based on their expression levels. From the survival curves, Gene 3, 
Gene 4 and Gene 7 showed significant P-value in predicting the prognostic outcome 
of breast cancer based on the differential value of the biomarkers. These genes were 
also highly expressed in the qRT-PCR analysis (Ngcoza, 2012), validating their 
significance as putative breast cancer biomarkers. In addition to these genes, Gene 1 
also showed significance in differentiating the two risk groups based on its expression. 
However, this gene was not differentially expressed in the qRT-PCR analysis 
(Ngcoza, 2012).  
The difference in outcomes of the different bioinformatics tools was postulated to be 
as a result of different cancer types and techniques used in analyzing the differential 
gene expression. The ability of this bioinformatics tool to confirm the same genes 
from the qRT-PCR study as having value as potential biomarkers is an indication that 
the tool is effective for in silico analysis of prospective biomarkers. The corroboration 
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of the Kaplan Meier plotter with previously observed results (Ngcoza, 2012) also give 
more credence to further analyse these genes as breast cancer biomarkers.  
The effective prognostic ability of this set of candidate biomarkers was determined in 
different subtypes of breast cancer, using the Gene Expression-Based Outcome for 
Breast Cancer Online (GOBO). GOBO present Kaplan-Meier plots performed on 
different stratified groups based on gene expression in different subtypes and 
presented as percentage distant metastasis-free survival (DMFS) against time in years. 
The output from this analysis indicated that, this set of candidate biomarkers may not 
predict effectively all estrogen receptor positive (ER+) breast cancer subtypes, 
however the candidate biomarkers were effective in predicting the outcome of luminal 
B ER+ breast cancer subtype. The GOBO results also showed the candidate genes 
could probably be used to predict the survival outcome of ERBB2 subtype of estrogen 
receptor negative (ER-) tumours, and lymph node negative subtype of ER- tumours, 
but not all subtype of ER- tumours based on the individual survival curves outcome 
for these diseases (Chapter 3).  
The specific differential expression signature of the candidate genes in different 
cancer types, suggest that a single candidate gene or protein may not be very specific 
as breast cancer biomarker, but combining these genes/proteins base on their 
expression pattern could be more appropriate. The current prevailing view is that the 
most powerful single biomarker of tumours have already been discovered, thus, 
multiple markers will serve a more effective purpose as breast cancer markers  
(Diamandis, 2004). However some genes within the list of putative biomarkers 
showed more promise as effective biomarkers and needed to be further analyzed for 
their effective use as breast cancer biomarkers.  
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Based on the Kaplan Meier plotter results, box plots and the GEA analysis, Gene 3, 
Gene 4 and Gene 7 were validated to be differentially expressed in breast cancer. 
These three genes were the genes differentially expressed in the qRT-PCR (Ngcoza, 
2012). In addition to these genes, Gene 2, one of the seven genes that was shown to 
be involved in almost all the biochemical processes associated to cancer initiation and 
progression from the GO and protein interaction analysis (Chapter 2) was also 
considered a likely candidate biomarker. Although, this gene was not observed to be 
differentially expressed in breast cancer from the in silico analysis (GEA analysis) in 
chapter 2 and the qRT-PCR analysis (Ngcoza, 2012). Gene 8 was also postulated to 
be a good biomarker for breast cancer management based on its direct association with 
the most differentially expressed gene from the qRT-PCR analysis Gene 7 (Ncogza, 
2012). BRG 8 was also directly linked to estrogen receptor (ESR) protein (Chapter 2).   
Estrogen receptor (ER) status of invasive carcinoma has been reported to be a useful 
prognostic and predictive factor and has become a common practice in the 
management of breast carcinomas. ER positivity predicts for response to endocrine 
therapy such as anti-estrogen (tamoxifen) administration (Manavathi et al., 2014).  
The protein expressions of these five candidate genes were monitored in different 
cancer cell lines using Western blot analysis. Western blot analysis confirms the 
expression of three of the five protein products of these genes and also there was an 
indication from the Western blot analysis that certain proteins may be differentially 
expressed when the expression level of these proteins in MCF-7 was compared with 
expression in other cell lines. However, BRG 3 and BRG 4 were not successfully 
demonstrated to be expressed using Western blot analysis. This was thought to be as 
a result of the commercial primary antibody to these proteins unable to bind the 
proteins in their native forms. It has been reported that, the interaction between a 
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protein and its corresponding antibody may be disrupted by competition with high 
concentrations of the pure epitope itself, as well as high salt concentrations, extreme 
pH, and detergents (Janeway et al., 2001). Thus, immunofluorescence analysis was 
used to analyze the expression of BRG 3, BRG 4 and BRG 7 in whole cell lines, 
comparing the expression in MCF-7 (a breast cancer line) to MCF-12A (a breast non-
cancerous cell line). 
From the immunofluorescence analysis results, the proteins were shown to be 
expressed in both cell lines. The results also suggest these proteins were more 
expressed in the breast cancer cell line as compared to the non-cancerous breast cancer 
cell line, however, a quantitative immunofluorescence analysis needs to be done to 
confirm this. The immunofluorescence protein expression analysis also validated 
BRG 3, BRG 4 and BRG 7 to be membrane bound, thus, would probably be shed into 
the bodily fluids. Membrane bound proteins are attractive biomarker candidates 
because of their potential use in cancer imaging, targeted therapeutic strategies, and 
also they are often shed into thHEORRGVWUHDPZKLFKPDNHVWKHPXVHIXOFDQGLGDWH¶V
for early disease detection (Harsha et al., 2009). 
The expression analysis of BRG 8 using Western blot analysis showed this protein 
was not expressed in breast cancer as well as the colon cancer cell lines. Gene 8 was 
shown to directly interact with BRG 7 (Chapter 2) and its differential expression in 
breast cancer compared to breast non-cancerous cell line was concluded, could serve 
or complement BRG 7 as breast cancer biomarker. Also the expression of these 
proteins could modulate chemotherapeutics effect in treating cancer and hence can be 
use as biomarker to monitor the prognosis and therapeutic outcome in breast cancer 
based on its direct association with an estrogen receptor protein, a prognostic and 
predictive factor in breast cancer types. 
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BRG 7 was consistently shown through the in silico and the protein expression 
analysis as a probable effective biomarker for breast cancer management. BRG 7 is a 
member of the NKG2D ligand family, reported to be anchored on the cell surface of 
diseased cells to serve as immune signal, that signal the NK cells against cancer cells 
and/or virus infection cells (González et al., 2008). Some of the NKG2D ligands have 
also been reported to be shed off the surface of cancer cells for these cells to evade the 
immune system.  
Wang and Sun (2014), reported that, most studies looked at the spontaneous shedding 
of NKG2D ligands in order to evade the immune system and thus reported that, NK 
cells stimulates the shedding of some of these ligand proteins in response to pro-
apoptotic cancer treatment (Wang and Sun, 2014). We postulated that, BRG 7, a 
NKG2D ligand will enhance the effectiveness of pro-apoptotic compounds in breast 
cancer treatment, and the expression level could be use as biomarker to monitor the 
therapeutic outcome of pro-apoptotic drugs.   
In recent times, discovery of biomarkers for cancer management for therapeutics has 
been of great interest (Kuppusamy et al., 2014), thus, the effect of over-expression of 
this proWHLQDQGWKH³NQRFNGRZQ´RILWVJHQHLQHQKDQFLQJDSRSWRVLVDPDMRUKDOOPDUN
of cancer progression was monitored in breast cancer cell line (Chapters 5 and 6).  
To confirm the effect of the over-expression of BRG 7 in enhancing the initiation of 
apoptosis in breast cancer, MCF-7 (an estrogen positive cancer cell line) and MCF-
12A (a non-cancerous breast cell line), were stably transfected to over-express BRG 
7 using a cloned plasmid and repressed by ³knocking GRZQ´ the gene using three 
commercial shRNA constructs. The cloned plasmid and the commercial shRNA 
constructs were confirmed using colony PCR and endonuclease digestion respectively 
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(Chapter 5). Also, the isolated plasmid was sent for sequencing and the result confirms 
the plasmid insert having 99 % homology to Gene 7 using the NCBI nucleotide blast 
tool (BLASTn).   
The over-expression of BRG 7 in non-cancerous cell line (MCF-12A) lead the cell to 
undergo senescence as the cell presented a changed in morphology to flattened, 
elongated and nucleated cells characteristic of senescence. However, the over-
expression of the BRG 7 protein seems not to affect the morphology of the breast 
cancer cell line (MCF-7) (Chapter 5). A major feature of senescent cells that 
distinguishes them from most quiescent cells is a large flattened morphology. They 
are also known to down-regulate genes involved extracellular matrix production and 
upregulate inflammatory cytokines as well as other molecules known to modulate the 
immune response (Krizhanovsky et al., 2008). Increased NKG2D ligand expression 
is regulated by activation of DNA damage. DNA damage leads to cell apoptosis and 
a senescence-like phenotype cell in response to most of the chemotherapeutic agents 
commonly used in clinical trials (Soriani et al., 2009). This result suggest that the 
over-expression of this protein in breast cells might be a defense mechanism against 
cancer, while it seems the breast cancer cells, have a mechanism to overcome the 
induced senescence by over-expression of the protein.   
Stably transfected MCF-7 cell lines for BRG 7 protein over-expression was referred 
to as pcDNABRG 7, whilst BRG7shRNA206 and BRG7shRNA207 were used to 
UHSUHVHQWWKHVWDEO\WUDQVIHFWHGFHOOVIRU*HQH³NQRFN-GRZQ´LQWKLVVWXG\ 
The effect of BRG 7 in modulating camptothecin, doxorubicin and DMSO in MCF-
7, an ER positive cell line was invstigated (Chapter 6). Estrogen receptor positive 
breast cancer accounts for about 65 % of all detectable breast cancer cases in human 
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(Keen, 2011). However, ER positive breast cancer patients have been reported to have 
a slow response to Campotethecin (Abedin et al., 2007). Doxorubicin is regarded as 
one of the most effective substances for the effective treatment of breast cancer 
patients. However, resistance to this drug is reported to be common and present a 
major challenge in breast cancer management (Smith et al., 2006). DMSO has been 
reported to stimulate apoptosis in different cancer cells (Wang et al., 2012).  
The result from this study showed that BRG 7 enhances the effect of CPT by 
increasing the level of apoptosis in pcDNABRG 7, whilst the effect of CPT in 
inducing apoptosis in MCF-7, BRG7shRNA206 and BRG7shRNA207 seems delayed 
and reduced, although, the difference in percentage apoptotic cells between 
pcDNABRG 7 and MCF-7 was not statistically significant. Camptothecin antitumour 
activity is majorly by preventing DNA replication through the inhibition of topo I 
activity (Staker et al., 2002). NKG2D ligands are reported to be upregulated in cells 
as a result of chemotherapeutics, which stall DNA replication, and the upregulation of 
these ligands has been reported to be as a result of diverse genotoxic stimuli (Gasser 
and Raulet, 2006). This suggest that NKG2D ligands might be required for effective 
genotoxic effect of CPT in inducing apoptosis and the over-expression of the BRG 7 
could help in improving the delayed response of ER positive tumours to CPT. 
Also pcDNABRG 7 cells showed a more effective response to apoptosis induced by 
DOX. Also there was an indication that BRG7shRNA206 and BRG7shrNA207 were 
undergoing apoptosis faster than the un-transfected MCF-7 cell line. Having more 
apoptotic cells in MCF-7 with knocked down NKG2D ligand gene expression than 
the un-transfected MCF-7 cell line, cannot be readily explained, however, this suggest 
that, although the NKG2D ligand may enhance the efficacy of DOX, complete 
³NQRFNGRZQ´RIWKHJHQHPD\DOVREHGHWULPHQWDOWRWKHFHOO 
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Although breast tumours are regarded as one of the most chemo-sensitive solid 
tumours, there are reports that the initially responsive tumours could relapse and 
develop resistance to a wide spectrum of drugs making them refractory to cytotoxic 
drugs which is typically incurable (Harris et al., 2012). These results suggest that the 
mode of BRG 7 expression in breast cancer could aid the design of treatment tailored 
on an individual basis. Patients expressing high level of the BRG 7 protein would 
indicate a good outcome when treated with DOX, while those not expressing or whose 
expression is below an established baseline could indicate the breast cancer patient 
may not respond well to DOX. Also combined therapy that repressed BRG 7 could be 
employed with DOX to get a more effective cancer treatment therapy strategy using 
DOX.  
BRG 7 showed an effective enhancement of apoptosis induction by DMSO. 
pcDNABRG 7 cells were shown to experience more apoptosis when treated with 
DMSO as compared to MCF-7, BRG7shRNA206 and BRG7shrNA207 and the 
differences when compared were statistically significant. Although the mode of action 
of DMSO in initiation apoptosis in cancer cells is not well established (Aita, et al., 
2005). The trend in apoptosis undergone by DMSO treated transfected and un-
transfected cells showed some similarities to that seen with the camptothecin treated 
cells. This suggest that mode of action of DMSO inducing apoptosis in breast cancer 
cells expressing high levels of BRG 7 protein is similar to that of CPT.  
Studies have reported variance to pro-apoptotic drug in cells using different short 
RNA constructs to tDUJHWGLIIHUHQWUHJLRQRIDFDQGLGDWHJHQHIRUJHQH³NQRFNGRZQ´
Holen et al7KHHIIHFWRI³NQRFNHGGRZQ´RI%5*LQPRGXODWLQJHIIHFWRI
the three pro-apoptotic drugs varied comparing BRG7shRNA206 to 
BRG7shRNA207. This could be as result of these shRNA transfected constructs 
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binding the gene at different region, thereby generating different effects. The level of 
resistance of the two different siRNA stably transfected NIH 3T3 cells treated with 
camptothecin to induce apoptosis were shown to differ as cell showed variation in 
gene ³knock down´ DQGFHOOWKDWVKRZHGKLJKHU³NQRFNGRZQ´RI5%%3SUHVHQWHG
more resistance to apoptosis (Pretorius et al., 2013). 
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7.2: Conclusion 
The outcome of the functional analysis of the seven candidate genes using an in silico 
techniques;  
x The three genes (Gene 3, Gene 4 and Gene 7) that were differentially expressed 
from the qRT-PCR analysis were confirmed to be highly expressed in breast 
cancer, as shown by the in silico analysis in chapter 2.  
x An additional gene (Gene 2) from the seven candidate genes was found to be 
involved in most of the cancer processes, however not differentially expressed 
in the qRT-PCR analysis (Ngcoza, 2012), was considered to be a good 
biomarker candidate for breast cancer for further investigation. 
x Also another protein candidate (BRG 8) was discovered from the protein 
interaction analysis based on its direct interaction with ESR protein and BRG 
7 (Chapter 2).  
x The individual genes were shown to be involved in one cancer process or the 
other and we concluded these genes will serve well as a panel of biomarkers 
for breast cancer management based on the in silico functional analysis 
(Chapter 2).  
x The prognostic/predictive validation of these individual genes also showed 
variations as effective individual breast cancer biomarkers. 
x A panel of these biomarkers were shown to be more effective in predicting the 
outcomes of breast cancer patients based on the analysis using two different 
databases from SurvExpress. 
x Gene 3, Gene 4 and Gene 7 showed consistency as breast cancer biomarkers 
in predicting breast cancer treatment outcome, based on their individual 
survival analysis (Kaplan Meier plotter), also Gene 1 was also shown to be 
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significant as a predictive biomarker based on the Kaplan Meier plotter result 
(Chapeter 3). 
x The in silico prognosis analysis of these genes also suggest that the expression 
signature of the candidate genes as biomarkers could be specific for different 
breast cancer types and subtype, and indicated effectiveness in accurately 
predicting the outcome of estrogen positive luminal B subtype of breast 
cancer, estrogen negative human epidermal growth factor receptor 2 (ERBB2) 
and the lymph node negative subtypes. 
The protein expression of five of the candidate genes were monitored in breast cancer 
cell line compared to non-cancerous breast cell line and other cancer cell lines. These 
genes are: Gene 3, Gene 4 and Gene 7, the genes that showed differential expression 
based on the qRT-PCR analysis and based on their consistency as effective biomarker 
from the in silico analysis. In addition Gene 2; the gene that was found to be involved 
with most cancer processes based on the in silico analysis, although not differentially 
expressed in the qRT-PCR analysis and Gene 8; the gene whose protein product 
directly interact with BRG 7 and ESR from the STRING analysis. 
x Western blot analysis was used to show BRG 7 is expressed in breast cancer 
cell lysate, although the expression was not well pronounced. It was concluded 
the protein might have been shed off the cell membrane. 
x BRG 3, BRG 4 and BRG 7 were successfully shown to be differentially highly 
expressed in MCF-7 (breast cancer cell line) as compared to MCF-12A (non-
cancerous breast cell line) using immunoassay analysis and may serve as 
breast cancer biomarkers. 
 
 
 
 
   215     
     
x BRG 8 was not expressed in MCF-7 but expressed in MCF-12A and was 
concluded could be an effective biomarker.  
x BRG 2 was expressed in all cancer cell lines analyzed but not differentially 
expressed. It was concluded this gene will not effectively serve as an 
individual breast cancer biomarker. 
The modulating effect of BRG 7 in apoptosis induction was monitored in breast cancer 
cell lines stably transfected for BRG 7 overe-expression and repression: 
x The findings of the modulating role of BRG 7 in drug induced apoptosis, 
suggest it could probably play an important role in personalised medicine and 
could serve as a biomarker to monitor the prognosis and/or therapeutic 
outcome of camptothecin, doxorubicin and DMSO treated breast cancer 
patients. 
x There was an indication that targeting the gene at different region for 
repression resulted to variance modulating effect on pro-apoptotic compounds. 
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7.3: Future work 
Over-expression of BRG 7 in non-cancerous breast cell line resulted in the cell 
changing morphology to flat nucleated cell, which is a major feature of cell in 
VHQHVFHQFH+RZHYHUWKLVQHHGVWREHIXUWKHUYDOLGDWHGE\PRQLWRULQJWKHOHYHORIȕ-
galactosidase. Also the effect of over-expression on the p53 protein a major 
modulating protein of cell senescence, apoptosis and a tumour suppressor protein need 
to be evaluated as well as other apoptotic proteins. In addition to the modulating effect 
of BRG 7 on apoptosis, the effect of over-expression and knock down on cell cycle 
needs to be monitored in breast cancer and non-cancerous cell lines. Also, the 
modulating effect of the protein needs to be monitor in other breast cancer cell line 
types.    
Some of the proteins were qualitatively shown to be differentially expressed in breast 
cancer cell line using the immunofluorescence assay, however the expression level of 
the protein needs to be quantified using quantitative immunofluorescence analysis or 
enzyme linked immunosorbent assay (ELISA).  As these candidate proteins are 
annotated to be cell surface proteins and are expected to be shed into bodily fluids, the 
presence of these proteins need to be validated in various bodily fluids and tissue 
samples of breast cancer patients.  
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